{"meta":{"query_hash":"7c55eea1011c","filters":{"venue":"Cancer Chemotherapy and Pharmacology"},"cohort_total":186,"direct_labels_cover":0,"predictions_cover":186,"exported":186,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/7c55eea1011c","api":"https://metacan.xera.ac/api/v1/cohort?venue=Cancer+Chemotherapy+and+Pharmacology"},"results":[{"id":"W1269875034","doi":"10.1007/s00280-015-2859-8","title":"Inhibition of sodium-independent and sodium-dependent nucleobase transport activities by tyrosine kinase inhibitors","year":2015,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Alberta Innovates - Health Solutions","keywords":"Gefitinib; Erlotinib; Lapatinib; Pharmacology; Tyrosine-kinase inhibitor; Chemistry; Sunitinib; Dasatinib; Tyrosine kinase; Sorafenib; IC50; Vandetanib; Imatinib; Biochemistry; Medicine; Internal medicine; Cancer; In vitro; Epidermal growth factor receptor; Receptor","score_opus":0.012817044680818861,"score_gpt":0.2725603903060015,"score_spread":0.25974334562518264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1269875034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809434,0.00768849,0.0029403106,0.00020496814,0.00007427582,0.000055998204,0.00028022905,0.00010505954,0.0077072103],"genre_scores_gemma":[0.9928853,0.0035735718,0.0008516648,0.00003364223,0.000015596062,0.000028153481,0.00020074857,0.0000108663135,0.0024003887],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989283,0.000016884424,0.000011272611,0.00001432237,0.000027822847,0.00003684923],"domain_scores_gemma":[0.99993324,0.000016515653,0.000020034797,0.0000071582954,0.000009481891,0.000013480634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016878259,0.00027032962,0.00023257882,0.00020104481,0.00015222435,0.00027596287,0.00028426253,0.00018317942,0.0013675186],"category_scores_gemma":[0.0001742093,0.00009720305,0.00016504561,0.0001867293,0.00012561641,0.00027244902,0.00013393511,0.00050533056,0.00024489925],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008563354,0.00016322809,0.00032504095,0.000106495296,0.000028526905,0.00010480984,0.000031968368,0.00044509833,0.9774778,0.0012968711,0.0002679626,0.018895853],"study_design_scores_gemma":[0.000082690196,0.0007284375,0.0023305553,0.000009314516,0.00003250785,0.00019755715,0.000020200872,0.0013054125,0.990387,0.00014778198,0.004750922,0.000007757886],"about_ca_topic_score_codex":0.0008917659,"about_ca_topic_score_gemma":0.0028622784,"teacher_disagreement_score":0.0013675186,"about_ca_system_score_codex":0.0004689732,"about_ca_system_score_gemma":0.00031613567,"threshold_uncertainty_score":0.0045747757},"labels":[],"label_agreement":null},{"id":"W1485463859","doi":"10.1007/s00280-003-0600-5","title":"Ketotifen reverses MDR1-mediated multidrug resistance in human breast cancer cells in vitro and alleviates cardiotoxicity induced by doxorubicin in vivo","year":2003,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Drug Transport and Resistance Mechanisms","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Erasmus+","keywords":"Ketotifen; Doxorubicin; Pharmacology; Cardiotoxicity; In vivo; Medicine; P-glycoprotein; Multiple drug resistance; Toxicity; Biology; Chemotherapy; Drug resistance; Internal medicine","score_opus":0.011156783804032152,"score_gpt":0.28719737719788846,"score_spread":0.2760405933938563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1485463859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913755,0.0044208546,0.0009523695,0.0002876392,0.00009445255,0.000042752283,0.0005821809,0.00019849499,0.0020457143],"genre_scores_gemma":[0.9919601,0.0031359696,0.00069874345,0.00006941447,0.00003654991,0.000025681666,0.0009180589,0.000026334703,0.0031290778],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988437,0.000034364795,0.000010056464,0.000010969557,0.000018505594,0.00004175557],"domain_scores_gemma":[0.99988997,0.000025307298,0.00002146641,0.000022722013,0.000013703488,0.00002677231],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016181066,0.00038456786,0.00065248436,0.0003632606,0.00036780792,0.0003069326,0.0002559703,0.00022674416,0.002551439],"category_scores_gemma":[0.00017836515,0.00019535534,0.00024912847,0.00029134535,0.0002343576,0.00027282853,0.00017446264,0.000700054,0.00041123136],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027640276,0.0003383318,0.00078791275,0.000218067,0.000044562326,0.0002120343,0.00012515299,0.00025908175,0.979189,0.00030318627,0.0007525496,0.015006184],"study_design_scores_gemma":[0.00032770782,0.0031016963,0.010206964,0.000015072172,0.00008189509,0.0009877506,0.00012539266,0.0006527708,0.97723275,0.00007973764,0.0071696946,0.000018601233],"about_ca_topic_score_codex":0.003215104,"about_ca_topic_score_gemma":0.006438087,"teacher_disagreement_score":0.003215104,"about_ca_system_score_codex":0.0003273489,"about_ca_system_score_gemma":0.00041971673,"threshold_uncertainty_score":0.008535385},"labels":[],"label_agreement":null},{"id":"W1549234286","doi":"10.1007/s00280-003-0609-9","title":"Sanguinarine-induced apoptosis is associated with an early and severe cellular glutathione depletion","year":2003,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Berberine and alkaloids research","field":"Medicine","cited_by":121,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal","funders":"","keywords":"Sanguinarine; Cytotoxicity; Glutathione; Apoptosis; Programmed cell death; Cancer cell; Cell culture; DNA fragmentation; Molecular biology; Biology; Biochemistry; Chemistry; Pharmacology; In vitro; Alkaloid; Cancer; Enzyme","score_opus":0.028932101287650988,"score_gpt":0.33180703909973247,"score_spread":0.30287493781208147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1549234286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98407656,0.00807378,0.003945939,0.00022066884,0.00007472905,0.00008134104,0.0004515065,0.00025092726,0.0028246497],"genre_scores_gemma":[0.9959971,0.0010763981,0.0007176897,0.000073188356,0.000016068458,0.000032697164,0.00036505592,0.000010882172,0.001711097],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998325,0.00003973828,0.000018712517,0.000020857906,0.000044578544,0.000043561293],"domain_scores_gemma":[0.999808,0.00003196599,0.00004903908,0.000049052273,0.000030037601,0.0000319634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001709533,0.00049010606,0.0006874281,0.00043543376,0.00019598333,0.00021929691,0.00018569772,0.00047991532,0.0014308991],"category_scores_gemma":[0.00017991732,0.00022729613,0.00040419647,0.0002878288,0.0002900585,0.00029078036,0.00030408957,0.00066963665,0.0003733065],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006690235,0.00005058065,0.00074752746,0.00008215571,0.000028169721,0.00043178315,0.000030205218,0.000036502926,0.99522275,0.0001404509,0.000068751186,0.0024921305],"study_design_scores_gemma":[0.000045096862,0.0010536106,0.031709623,0.000010225474,0.00004565631,0.0017455989,0.00006193863,0.00029245001,0.9622217,0.00019975014,0.002605925,0.000008491991],"about_ca_topic_score_codex":0.00044092536,"about_ca_topic_score_gemma":0.0008589939,"teacher_disagreement_score":0.0014308991,"about_ca_system_score_codex":0.00029626937,"about_ca_system_score_gemma":0.00016049009,"threshold_uncertainty_score":0.004786849},"labels":[],"label_agreement":null},{"id":"W1594902063","doi":"10.1007/s00280-002-0566-8","title":"Phase I and pharmacokinetic study of anhydrovinblastine every 3 weeks in patients with refractory solid tumors","year":2003,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Air (Canada)","funders":"National Cancer Institute","keywords":"Pharmacokinetics; Refractory (planetary science); Medicine; Solid tumor; Maximum tolerated dose; Internal medicine; Oncology; Pharmacology; Cancer; Biology","score_opus":0.1627209557731493,"score_gpt":0.5160638178940202,"score_spread":0.35334286212087096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1594902063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99571604,0.0011139923,0.00059540576,0.000328909,0.00008449047,0.0007570738,0.0004202732,0.00007380313,0.0009098872],"genre_scores_gemma":[0.99419385,0.0012811368,0.0013393434,0.00026197362,0.00012242349,0.00078984944,0.0005368766,0.000035105237,0.0014394156],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9992489,0.00044035216,0.000023032022,0.000101431404,0.000064577165,0.00012172175],"domain_scores_gemma":[0.9986314,0.00038656048,0.00025336706,0.00017735589,0.00006684816,0.0004844132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012943323,0.0013696157,0.0034823555,0.0007925368,0.00055201363,0.0009858913,0.0010532737,0.0011609243,0.0021447632],"category_scores_gemma":[0.002432582,0.00074561604,0.0011559608,0.00087298447,0.0013449808,0.00078735827,0.0003225315,0.004083031,0.0005269987],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78881514,0.062551945,0.0038752349,0.00047041307,0.001157289,0.0002190173,0.00049664726,0.008622559,0.031368475,0.00075431186,0.0029449197,0.09872409],"study_design_scores_gemma":[0.3922155,0.5885736,0.008344381,0.000023189843,0.00034551218,0.0001991896,0.000091382346,0.003491222,0.0043952656,0.00027318805,0.002004522,0.000043118158],"about_ca_topic_score_codex":0.002643807,"about_ca_topic_score_gemma":0.0029691206,"teacher_disagreement_score":0.0034823555,"about_ca_system_score_codex":0.0010774132,"about_ca_system_score_gemma":0.0016984693,"threshold_uncertainty_score":0.007817209},"labels":[],"label_agreement":null},{"id":"W1935124198","doi":"10.1007/s00280-002-0561-0","title":"All-trans-retinoic acid increases cytotoxicity of 1-β-d-arabinofuranosylcytosine in NB4 cells","year":2003,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Cytotoxicity; Nucleoside; Retinoic acid; Acute promyelocytic leukemia; Pharmacology; Nucleoside transporter; MTT assay; Apoptosis; Transporter; Potency; Biology; Chemistry; In vitro; Molecular biology; Biochemistry","score_opus":0.009958186782329457,"score_gpt":0.2814055794228455,"score_spread":0.27144739264051604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1935124198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98951906,0.0034394243,0.0013262687,0.00021520257,0.00009416211,0.000042796284,0.0010406453,0.00018350482,0.004139083],"genre_scores_gemma":[0.98909307,0.0018506781,0.001386536,0.00004834878,0.000028603801,0.0000511158,0.001463854,0.000041958625,0.0060358797],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99942636,0.00017259775,0.00008714207,0.00005766538,0.000119390796,0.00013689893],"domain_scores_gemma":[0.9994665,0.00017613427,0.000067554305,0.00012411612,0.00007709934,0.000088640234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003751536,0.00069874665,0.0010204377,0.00071954087,0.0004975816,0.0005230069,0.0005673581,0.00060489785,0.0037485214],"category_scores_gemma":[0.0003642725,0.0003563438,0.00065701996,0.0006565702,0.00047703373,0.00042890685,0.00030106178,0.0013108049,0.0012120804],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013775377,0.00012331868,0.00037754633,0.00008763765,0.00002329595,0.0001638899,0.00010361692,0.00027823308,0.9957278,0.00020381785,0.00011184338,0.0014216037],"study_design_scores_gemma":[0.000028175631,0.0005086565,0.0012545633,0.000005667296,0.00001630657,0.00008687658,0.00004981428,0.00035960454,0.9968471,0.000023997813,0.0008147639,0.000004473266],"about_ca_topic_score_codex":0.008639742,"about_ca_topic_score_gemma":0.006320956,"teacher_disagreement_score":0.008639742,"about_ca_system_score_codex":0.0007816845,"about_ca_system_score_gemma":0.00085349043,"threshold_uncertainty_score":0.017178953},"labels":[],"label_agreement":null},{"id":"W1940434397","doi":"10.1007/s00280-015-2852-2","title":"Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma","year":2015,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Georgetown Hospital","funders":"Lombardi Comprehensive Cancer Center, Georgetown University; American Cancer Society","keywords":"Medicine; Sorafenib; Tolerability; Internal medicine; Clinical endpoint; Nausea; Hepatocellular carcinoma; Temozolomide; Phases of clinical research; Regimen; Veliparib; Gastroenterology; Surgery; Progressive disease; Vomiting; Oncology; Clinical trial; Adverse effect; Chemotherapy","score_opus":0.09353586075040868,"score_gpt":0.3560939212492875,"score_spread":0.26255806049887886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1940434397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99501616,0.0019472385,0.00046552878,0.00021850567,0.000060095306,0.0012013755,0.00033933518,0.00006683413,0.00068492925],"genre_scores_gemma":[0.9934243,0.001264377,0.0013797663,0.000281766,0.00011498978,0.001392572,0.0010239906,0.000018576047,0.0010995716],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99967396,0.00016055077,0.000023413604,0.00004967762,0.000034590987,0.000057886864],"domain_scores_gemma":[0.9994553,0.00008888829,0.000109816414,0.000036350662,0.00003219753,0.00027750013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011923817,0.0011331566,0.0027031759,0.00036310736,0.00024019474,0.00061353587,0.0007127662,0.00064250914,0.0023996707],"category_scores_gemma":[0.0006802097,0.0004062124,0.0006746427,0.0003814146,0.000566405,0.0004479967,0.0002794898,0.0019185744,0.0005997996],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61869824,0.0769372,0.013341214,0.001580503,0.0022942035,0.00072402187,0.00035397944,0.0061852736,0.11194808,0.00027786603,0.004448225,0.16321121],"study_design_scores_gemma":[0.5832707,0.38952708,0.012284502,0.000041240066,0.0005271273,0.0007078879,0.00005277055,0.0027005654,0.007901758,0.000109469154,0.0028482294,0.000028613247],"about_ca_topic_score_codex":0.0006047492,"about_ca_topic_score_gemma":0.0015888278,"teacher_disagreement_score":0.0027031759,"about_ca_system_score_codex":0.00069543987,"about_ca_system_score_gemma":0.001287777,"threshold_uncertainty_score":0.008027732},"labels":[],"label_agreement":null},{"id":"W1941265576","doi":"10.1007/s00280-015-2761-4","title":"A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck","year":2015,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre d'expertise et de recherche en infrastructures urbaines","funders":"Symphogen; Merck KGaA","keywords":"Medicine; Tolerability; Cetuximab; Internal medicine; Epidermal growth factor receptor; Adverse effect; Oncology; Head and neck cancer; Antibody; Head and neck squamous-cell carcinoma; Monoclonal antibody; Gastroenterology; Cancer; Immunology","score_opus":0.0269664643091963,"score_gpt":0.35541487793565163,"score_spread":0.3284484136264553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1941265576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99066985,0.0015796479,0.0007380165,0.0009378354,0.0004892718,0.0018819994,0.0006081626,0.00012650572,0.0029687444],"genre_scores_gemma":[0.9867203,0.0020848345,0.0016726119,0.00084552966,0.0002741446,0.0014649078,0.0010492719,0.000025423467,0.0058628735],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996307,0.00019293666,0.00001455713,0.000050429364,0.000029607356,0.000081870785],"domain_scores_gemma":[0.99958676,0.00013078883,0.00004595553,0.000035076006,0.000026186395,0.00017512198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012192351,0.0011024441,0.0017015752,0.00042260738,0.0003632838,0.0008707867,0.0009301131,0.001411387,0.008989709],"category_scores_gemma":[0.0010141582,0.00043803555,0.0014615156,0.00031487233,0.00082413334,0.00094092276,0.0004101979,0.0032329378,0.0011346585],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86470485,0.027248338,0.0014081845,0.0006427395,0.0007545099,0.00019478097,0.000109188884,0.0013543024,0.017164119,0.00053064205,0.0022547513,0.08363355],"study_design_scores_gemma":[0.5477577,0.44117743,0.0040814923,0.000035095385,0.00042648605,0.00011783672,0.00007608067,0.00079271756,0.0024600446,0.00025726104,0.0027923798,0.000025475303],"about_ca_topic_score_codex":0.001002225,"about_ca_topic_score_gemma":0.0031522557,"teacher_disagreement_score":0.008989709,"about_ca_system_score_codex":0.0011479056,"about_ca_system_score_gemma":0.0018602906,"threshold_uncertainty_score":0.030073643},"labels":[],"label_agreement":null},{"id":"W1963733180","doi":"10.1007/s00280-005-0035-2","title":"Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy","year":2005,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Neutropenia; Pharmacodynamics; Population; Pharmacokinetics; Nadir; Internal medicine; Dosing; Body surface area; Pemetrexed; Incidence (geometry); Pharmacology; Oncology; Chemotherapy","score_opus":0.05261056602320502,"score_gpt":0.42377558807928983,"score_spread":0.3711650220560848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963733180","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17631297,0.00062877877,0.80560255,0.0021582274,0.00011674902,0.00043597782,0.00040132555,0.00043272736,0.013910696],"genre_scores_gemma":[0.97363913,0.0002544601,0.022777028,0.00021895763,0.000026933545,0.00025836867,0.0000803552,0.000026162486,0.0027185762],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99969625,0.00015690946,0.000015012074,0.00004618236,0.000059982474,0.000025710948],"domain_scores_gemma":[0.9994562,0.00033932587,0.00007851616,0.000029637438,0.0000701176,0.000026064214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010086419,0.00039512085,0.0007037568,0.00017855354,0.00020023099,0.0008895633,0.000825344,0.000895966,0.0018967937],"category_scores_gemma":[0.0026299423,0.0003055394,0.00060237624,0.00013965019,0.0003915818,0.0006065848,0.00053210935,0.0008858028,0.00028379704],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026545028,0.00014141451,0.0015311678,0.00008961574,0.000051307823,0.00020989534,0.00006312264,0.9700056,0.0054353816,0.01067324,0.00056072325,0.010973137],"study_design_scores_gemma":[0.000027406331,0.00012106617,0.00028554702,0.0000039746715,0.0000115500725,0.0000893111,0.0000060561433,0.9959318,0.00041810315,0.0026594393,0.00043988138,0.000005825381],"about_ca_topic_score_codex":0.0026288081,"about_ca_topic_score_gemma":0.0013464316,"teacher_disagreement_score":0.0026288081,"about_ca_system_score_codex":0.000591822,"about_ca_system_score_gemma":0.0013127264,"threshold_uncertainty_score":0.006345451},"labels":[],"label_agreement":null},{"id":"W1964182986","doi":"10.1007/s00280-002-0524-5","title":"The combi-targeting concept: a novel 3,3-disubstituted nitrosourea with EGFR tyrosine kinase inhibitory properties","year":2003,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Regional Health Centre; Health Canada; Royal Victoria Hospital","funders":"","keywords":"Autophosphorylation; Comet assay; DNA damage; Epidermal growth factor receptor; Chemistry; Sulforhodamine B; A431 cells; Tyrosine kinase; Epidermal growth factor; Tyrosine-kinase inhibitor; Molecular biology; Kinase; Biochemistry; Cancer research; Biology; Signal transduction; Cell; DNA; In vitro; Receptor; Protein kinase A; Cytotoxicity; Cell cycle; Cancer","score_opus":0.01769426798458933,"score_gpt":0.2683996772569544,"score_spread":0.25070540927236507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964182986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93309695,0.0050565265,0.037612855,0.0005540024,0.00014967404,0.00022344712,0.00039096264,0.0003791377,0.022536421],"genre_scores_gemma":[0.9692469,0.002121734,0.017779551,0.0002238888,0.000036825244,0.00013089269,0.00022325321,0.000034427318,0.010202462],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99996376,0.0000045140087,0.0000017383682,0.00000866044,0.000011057704,0.000010180842],"domain_scores_gemma":[0.9999738,0.0000036769486,0.000007699395,0.0000024740498,0.000004911436,0.0000074415084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000095615294,0.0002437931,0.00017286371,0.00018384101,0.00014630526,0.00018206864,0.00029506654,0.0002878955,0.00089537195],"category_scores_gemma":[0.000067627574,0.000084495565,0.00010838102,0.0001444607,0.00013521874,0.00029651745,0.00017022052,0.00030800284,0.00026769482],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014697037,0.00006963595,0.00012348393,0.000069326634,0.0000060067473,0.00018490663,0.000038154325,0.0003702221,0.9745737,0.0034202007,0.0003994722,0.020597862],"study_design_scores_gemma":[0.000043253996,0.0006707058,0.0008577464,0.0000046498744,0.000017314811,0.00072175503,0.000011829306,0.0027469448,0.9741883,0.00038795103,0.02033626,0.000013328182],"about_ca_topic_score_codex":0.00057431246,"about_ca_topic_score_gemma":0.001191133,"teacher_disagreement_score":0.00089537195,"about_ca_system_score_codex":0.00032050323,"about_ca_system_score_gemma":0.0002582434,"threshold_uncertainty_score":0.0029953718},"labels":[],"label_agreement":null},{"id":"W1967553796","doi":"10.1007/s00280-005-0011-x","title":"Role of plasma lipids and lipoproteins in predicting amphotericin B-induced nephrotoxicity in pediatric oncology patients","year":2005,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Antifungal resistance and susceptibility","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's & Women's Health Centre of British Columbia; University of British Columbia","funders":"","keywords":"Nephrotoxicity; Creatinine; Amphotericin B; Triglyceride; Internal medicine; Lipoprotein; Cholesterol; High-density lipoprotein; Chemistry; Potassium; Medicine; Endocrinology; Toxicity; Antifungal","score_opus":0.013240641704968551,"score_gpt":0.3142373012587358,"score_spread":0.30099665955376725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967553796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99882954,0.0005069169,0.00006779365,0.000068925234,0.0000052705605,0.000003841028,0.00003709507,0.0000032985504,0.00047740774],"genre_scores_gemma":[0.9995208,0.00020303308,0.00013782668,0.000021146949,0.000008097094,0.00000318298,0.000042535074,0.0000016029899,0.0000616913],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99969363,0.0001134874,0.000051674273,0.000028164026,0.000061602004,0.00005145588],"domain_scores_gemma":[0.99749124,0.0011616393,0.0006410661,0.00006062888,0.00017500605,0.00047040984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006033237,0.00035481312,0.0004506866,0.00072183553,0.00031418444,0.00062482245,0.00025275024,0.0005298925,0.000705535],"category_scores_gemma":[0.0041917474,0.00026706746,0.00032525687,0.0005499696,0.0003201276,0.00070404087,0.0002937361,0.0008750378,0.00015100132],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020779128,0.000025437872,0.99741215,0.0000062096874,0.0000165743,0.00040890122,0.00003440369,0.000076750766,0.00022896029,0.000014614764,0.000032370168,0.0015359437],"study_design_scores_gemma":[0.000021263202,0.00060980895,0.9899448,0.000023821038,0.000116887735,0.0057082726,0.00040125294,0.0016680864,0.0011383875,0.00006864304,0.00028951964,0.000009289506],"about_ca_topic_score_codex":0.0014181451,"about_ca_topic_score_gemma":0.0017972498,"teacher_disagreement_score":0.0014181451,"about_ca_system_score_codex":0.0003454203,"about_ca_system_score_gemma":0.00046889382,"threshold_uncertainty_score":0.0031906962},"labels":[],"label_agreement":null},{"id":"W1967669588","doi":"10.1007/s00280-005-0145-x","title":"Preferential extravasation and accumulation of liposomal vincristine in tumor comparing to normal tissue enhances antitumor activity","year":2005,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Inimex Pharmaceuticals (Canada)","funders":"","keywords":"Extravasation; Vincristine; Liposome; Pharmacology; Medicine; Cancer research; Chemotherapy; Chemistry; Pathology; Internal medicine; Cyclophosphamide; Biochemistry","score_opus":0.05915090412979619,"score_gpt":0.41597934344471604,"score_spread":0.35682843931491987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967669588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929516,0.0016631002,0.0028536874,0.00004740963,0.000015998867,0.000022599123,0.00009711603,0.000065394284,0.0022830586],"genre_scores_gemma":[0.99654406,0.00043425293,0.0008555454,0.000015678275,0.0000085579995,0.000012849271,0.00008599417,0.000021159589,0.0020218617],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999144,0.000015622445,0.0000047097633,0.000018812414,0.000015540583,0.000030899362],"domain_scores_gemma":[0.9998728,0.000041940784,0.000020154734,0.000016646276,0.000015232102,0.0000331574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001242737,0.00020492736,0.00025733205,0.00025433602,0.00012392082,0.00027378273,0.00011807481,0.00020094073,0.0019123427],"category_scores_gemma":[0.00015610273,0.00012630645,0.00012386424,0.0001250708,0.00017975648,0.0003613745,0.00021231429,0.00036018636,0.00036710643],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016368268,0.00001321547,0.000118835495,0.000024181514,0.0000021218766,0.00002084716,0.0000073118326,0.00004496854,0.99813914,0.00009210136,0.000015102764,0.0013583729],"study_design_scores_gemma":[0.0000069441903,0.00027754533,0.0021807598,0.0000024217031,0.000009362199,0.00019789905,0.000010920464,0.00044186672,0.9961569,0.000035246983,0.0006785247,0.0000016666581],"about_ca_topic_score_codex":0.00032584998,"about_ca_topic_score_gemma":0.00036293955,"teacher_disagreement_score":0.0019123427,"about_ca_system_score_codex":0.00023289747,"about_ca_system_score_gemma":0.00021452436,"threshold_uncertainty_score":0.0063974857},"labels":[],"label_agreement":null},{"id":"W1967866035","doi":"10.1007/s00280-002-0538-z","title":"The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925","year":2002,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Dexrazoxane; Chemistry; Doxorubicin; Pharmacology; Calcein; Pharmacokinetics; Chelation; In vivo; Medicine; Biochemistry; Internal medicine; Chemotherapy; Biology; Organic chemistry","score_opus":0.024255580567516703,"score_gpt":0.30753484986844787,"score_spread":0.28327926930093117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967866035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933767,0.0024885526,0.002702503,0.00012232848,0.000030080635,0.000021189007,0.0002593391,0.00008307715,0.00091634865],"genre_scores_gemma":[0.993601,0.001427826,0.0013224141,0.00004038441,0.000011790454,0.00001393355,0.00039919646,0.000025984049,0.0031573332],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998716,0.00002981996,0.000008010356,0.000039070776,0.000017421002,0.000034123343],"domain_scores_gemma":[0.9998461,0.000017290085,0.00006788038,0.00002414625,0.000013654775,0.000030753028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020341513,0.00041261382,0.00031337855,0.00035492887,0.00023577361,0.00032048798,0.00024262462,0.00036062064,0.0019076876],"category_scores_gemma":[0.00020730373,0.00032861056,0.00026610948,0.00018747986,0.0003509503,0.0004028929,0.00011053685,0.00048283752,0.00047117818],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053310413,0.00009702086,0.001159754,0.0000671999,0.000028500452,0.000110549256,0.00005561109,0.00022827677,0.98501194,0.0003127511,0.000096909615,0.0075003877],"study_design_scores_gemma":[0.00011316616,0.0028291487,0.007898016,0.000010068293,0.0000614733,0.00038633848,0.000057914724,0.00089959434,0.9856477,0.000106027794,0.001975539,0.000015131343],"about_ca_topic_score_codex":0.0020132812,"about_ca_topic_score_gemma":0.002144403,"teacher_disagreement_score":0.0020132812,"about_ca_system_score_codex":0.00039711443,"about_ca_system_score_gemma":0.00044874448,"threshold_uncertainty_score":0.0063818097},"labels":[],"label_agreement":null},{"id":"W1969320029","doi":"10.1007/s00280-010-1530-7","title":"A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients","year":2010,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne; Jewish General Hospital","funders":"Novartis Pharmaceuticals Canada","keywords":"Chlorambucil; Imatinib; Medicine; Fludarabine; Imatinib mesylate; Chronic lymphocytic leukemia; Tyrosine-kinase inhibitor; Pharmacology; Internal medicine; Chemotherapy; Leukemia; Gastroenterology; Oncology; Cancer; Cyclophosphamide","score_opus":0.015285900770481496,"score_gpt":0.3521121000178381,"score_spread":0.33682619924735663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969320029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99364626,0.0027767082,0.0002857832,0.00043639177,0.00013420754,0.0009402714,0.00047875586,0.000047751782,0.0012539033],"genre_scores_gemma":[0.9923114,0.0026318403,0.00065423065,0.0005700324,0.00024339522,0.0011171574,0.0011693594,0.000023424005,0.0012790837],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9992508,0.00035614212,0.0000377686,0.00012633772,0.000044921697,0.00018398323],"domain_scores_gemma":[0.99893934,0.00019230228,0.00014383407,0.000084746855,0.000044377397,0.000595297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014213427,0.001505218,0.0034586,0.0007405225,0.00075644004,0.0011651153,0.0010470244,0.0013440914,0.0031243805],"category_scores_gemma":[0.0010428042,0.0008375376,0.0020470093,0.00079829624,0.0014757288,0.00131071,0.0004824766,0.0036562993,0.0008157522],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8143456,0.06898522,0.008938941,0.00063336,0.0017929907,0.0005430314,0.00038252564,0.0019922336,0.034639228,0.00029123476,0.002150369,0.06530528],"study_design_scores_gemma":[0.47099504,0.5084196,0.0142439455,0.00003220183,0.00067847926,0.0003035913,0.00010487352,0.00057742134,0.0021638172,0.00010017118,0.0023443927,0.000036541376],"about_ca_topic_score_codex":0.0021898064,"about_ca_topic_score_gemma":0.004835744,"teacher_disagreement_score":0.0034586,"about_ca_system_score_codex":0.0012097262,"about_ca_system_score_gemma":0.0018526264,"threshold_uncertainty_score":0.010452092},"labels":[],"label_agreement":null},{"id":"W1970715182","doi":"10.1007/s00280-005-1023-2","title":"Identification of biliary metabolites of ifosfamide using 31P magnetic resonance spectroscopy and mass spectrometry","year":2005,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Chemotherapy-induced organ toxicity mitigation","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Cancer Research UK","keywords":"Ifosfamide; Chemistry; In vivo; Mass spectrometry; Glutathione; Metabolite; Magnetic resonance imaging; Pharmacology; Drug metabolism; Chromatography; Metabolism; Biochemistry; Medicine; Internal medicine; Biology; Chemotherapy; Enzyme; Radiology","score_opus":0.015397605053791973,"score_gpt":0.32209756980289733,"score_spread":0.3066999647491054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970715182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9710641,0.004173593,0.01867789,0.0004014827,0.000064825625,0.000086514694,0.00051863294,0.00014997463,0.004862917],"genre_scores_gemma":[0.97687095,0.0013406749,0.018937845,0.00013486821,0.000029606928,0.00006199516,0.0004146373,0.0000416607,0.0021677404],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987125,0.000041211417,0.0000076141764,0.000022114913,0.000032349464,0.0000254395],"domain_scores_gemma":[0.9998271,0.000034918143,0.000044269837,0.000014494625,0.000049301583,0.000029929943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026997263,0.00037999137,0.00033734768,0.0008055131,0.00043778785,0.00036688114,0.00015980737,0.0005899989,0.0009844773],"category_scores_gemma":[0.00062791025,0.00027807232,0.00016948266,0.00040678476,0.0002787888,0.0004916705,0.0002408063,0.0003451984,0.00036313958],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017285481,0.000033786993,0.004139175,0.000079004734,0.00003254004,0.0004512431,0.000060767532,0.0002307361,0.9806707,0.0003274324,0.0001457868,0.012100297],"study_design_scores_gemma":[0.000038350907,0.00029382168,0.0068223295,0.000009394637,0.000032075088,0.0010784229,0.000057091263,0.0018425173,0.98767066,0.00022885147,0.0019163436,0.000010149398],"about_ca_topic_score_codex":0.00084800116,"about_ca_topic_score_gemma":0.0009344078,"teacher_disagreement_score":0.0009844773,"about_ca_system_score_codex":0.00034321263,"about_ca_system_score_gemma":0.00040291192,"threshold_uncertainty_score":0.0032934546},"labels":[],"label_agreement":null},{"id":"W1973588440","doi":"10.1007/s00280-013-2224-8","title":"A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer","year":2013,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":94,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Novartis Pharmaceuticals Corporation","keywords":"Panobinostat; Medicine; Prostate cancer; Tolerability; Internal medicine; Oncology; Cancer; Clinical endpoint; Prostate-specific antigen; Phases of clinical research; Urology; Adverse effect; Chemotherapy; Clinical trial; Histone deacetylase","score_opus":0.008602750773293795,"score_gpt":0.31324066361341824,"score_spread":0.3046379128401244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973588440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937742,0.0010711346,0.00051918696,0.00046561062,0.00013801607,0.0017125655,0.00080725976,0.00007072308,0.001441267],"genre_scores_gemma":[0.9878236,0.0020015675,0.0017694002,0.00081129576,0.00026950418,0.002115551,0.0021561617,0.00005136709,0.003001511],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995283,0.00021266057,0.000015024619,0.00008133509,0.000029217148,0.00013355458],"domain_scores_gemma":[0.9992799,0.00011652964,0.00007934719,0.000071542905,0.000036445465,0.0004162268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001024118,0.0018408289,0.0029958526,0.00057795044,0.00063808885,0.0009822826,0.00088878087,0.0013353034,0.0043046763],"category_scores_gemma":[0.00089185603,0.00082371105,0.0015142397,0.00066680973,0.001271909,0.001070442,0.000372461,0.0037052243,0.00084081164],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7830135,0.10578672,0.0046064514,0.0004266044,0.00076218107,0.00028044448,0.00025743822,0.0026028238,0.031854823,0.00027409723,0.001921231,0.068213694],"study_design_scores_gemma":[0.4489005,0.53962106,0.006459803,0.000014260266,0.0003006128,0.00015795209,0.00007208582,0.0007532243,0.0021052316,0.00011998394,0.0014705808,0.000024695682],"about_ca_topic_score_codex":0.0025461717,"about_ca_topic_score_gemma":0.005583739,"teacher_disagreement_score":0.0043046763,"about_ca_system_score_codex":0.0008893891,"about_ca_system_score_gemma":0.0021824122,"threshold_uncertainty_score":0.014400601},"labels":[],"label_agreement":null},{"id":"W1975048166","doi":"10.1007/s00280-005-0077-5","title":"A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy","year":2005,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Eli Lilly and Company","keywords":"Pemetrexed; Medicine; Pharmacodynamics; Neutropenia; Population; Pharmacology; Pharmacokinetics; Homocysteine; Internal medicine; Oncology; Chemotherapy","score_opus":0.03385451318269302,"score_gpt":0.3721025579256311,"score_spread":0.3382480447429381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975048166","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08428733,0.0010582595,0.87059,0.004478968,0.00031435915,0.00048328863,0.0019655328,0.00094286434,0.035879474],"genre_scores_gemma":[0.93997633,0.00071374816,0.029469658,0.00094976294,0.00020045348,0.0007939483,0.00044777239,0.00017292995,0.027275449],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9991229,0.00032632472,0.000049837337,0.00017923546,0.00018863131,0.00013310429],"domain_scores_gemma":[0.9981198,0.0010683264,0.00026451383,0.00008553481,0.0003541261,0.00010768189],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019432766,0.0010879776,0.002341959,0.0007645622,0.00078395294,0.0018487613,0.002636734,0.0036736205,0.005251291],"category_scores_gemma":[0.0048156264,0.0014158268,0.0020943584,0.00067788584,0.0014362698,0.0020631293,0.0018910932,0.0023368206,0.0011164476],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053094773,0.000046072517,0.00058094674,0.0000595893,0.0000427558,0.00018497184,0.000068469286,0.9817423,0.000788677,0.014062941,0.00049570715,0.0018743696],"study_design_scores_gemma":[0.00001761564,0.000020782109,0.00018187959,0.0000043598156,0.000015556783,0.000055886434,0.00000842524,0.9966067,0.00007998418,0.0027273952,0.00027103184,0.000010396907],"about_ca_topic_score_codex":0.021272803,"about_ca_topic_score_gemma":0.008241478,"teacher_disagreement_score":0.021272803,"about_ca_system_score_codex":0.002098227,"about_ca_system_score_gemma":0.0030741945,"threshold_uncertainty_score":0.04229796},"labels":[],"label_agreement":null},{"id":"W1975417822","doi":"10.1007/s00280-007-0429-4","title":"Assessing the therapeutic and toxicological effects of cesium chloride following administration to nude mice bearing PC-3 or LNCaP prostate cancer xenografts","year":2007,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Thallium and Germanium Studies","field":"Environmental Science","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"LNCaP; Prostate cancer; Medicine; Prostate; Creatinine; Cancer; Oral administration; Endocrinology; Urology; Internal medicine; Chemistry","score_opus":0.021874364354830745,"score_gpt":0.362844966164183,"score_spread":0.34097060180935224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975417822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98672277,0.0029379104,0.004475282,0.00023867293,0.000094586256,0.00014162969,0.0007606843,0.00025352795,0.0043749698],"genre_scores_gemma":[0.9868744,0.0017426917,0.0017681206,0.00009279051,0.00003494996,0.000070729846,0.00069617643,0.00006547034,0.00865465],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99981743,0.000049905095,0.000010906966,0.000029168797,0.00004180912,0.000050705832],"domain_scores_gemma":[0.99973506,0.00007079169,0.000072369214,0.000034330376,0.000044666496,0.00004283533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042320485,0.0005823372,0.00040886196,0.00051383895,0.0002904407,0.00040468608,0.00048536004,0.0007313476,0.0017169906],"category_scores_gemma":[0.00031606996,0.00031431866,0.0005376281,0.00037355162,0.0005523573,0.00039590264,0.00012848475,0.0008618429,0.0003102024],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022751358,0.00017261086,0.00033589854,0.000036409267,0.0000233533,0.000054276567,0.00005746794,0.00030323313,0.9944772,0.000105426385,0.00009883503,0.002060165],"study_design_scores_gemma":[0.000049754577,0.0032262206,0.0013134676,0.0000028967736,0.000039925697,0.000112143345,0.000025934994,0.00042813033,0.993883,0.000036746216,0.00087447674,0.0000072848916],"about_ca_topic_score_codex":0.0032353448,"about_ca_topic_score_gemma":0.004132145,"teacher_disagreement_score":0.0032353448,"about_ca_system_score_codex":0.00047103336,"about_ca_system_score_gemma":0.00062426494,"threshold_uncertainty_score":0.00643301},"labels":[],"label_agreement":null},{"id":"W1976060118","doi":"10.1007/s00280-011-1556-5","title":"Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology Group","year":2011,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Center for Research Resources; National Cancer Institute","keywords":"Medicine; Single-nucleotide polymorphism; Oncology; Internal medicine; Toxicity; Cisplatin; Radiation therapy; Esophageal cancer; Gastroenterology; Chemotherapy; Genotype; Cancer; Biology; Genetics","score_opus":0.018628931616632486,"score_gpt":0.27345161612749896,"score_spread":0.2548226845108665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976060118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995498,0.00011674913,0.000046783563,0.00003574304,0.0000037532595,0.0000034158115,0.00012276637,0.0000014726796,0.00011949268],"genre_scores_gemma":[0.99957615,0.000051443112,0.000051286508,0.00003135464,0.0000060090833,0.0000028191632,0.00020051004,0.000001995227,0.00007852798],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99971634,0.00009486928,0.00003237905,0.00007289143,0.00004596745,0.000037474198],"domain_scores_gemma":[0.99933237,0.00022157287,0.00020210854,0.00006983272,0.00006128442,0.000112828675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036042387,0.0002796108,0.0003499762,0.00029919873,0.0003517483,0.00048665766,0.00028371505,0.00037766618,0.0005733436],"category_scores_gemma":[0.0012709178,0.00020168281,0.00058037793,0.00065156684,0.00030357076,0.00022930549,0.00026385268,0.00044790233,0.00009579883],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008296034,0.000066748864,0.99509335,0.00000645732,0.00022178356,0.00007219317,0.000047223868,0.00012553713,0.0015175681,0.000010631133,0.000087580636,0.0019213941],"study_design_scores_gemma":[0.000035300716,0.0001910961,0.998914,0.0000015435621,0.00011367023,0.00018776562,0.000056174544,0.00017116223,0.00018887156,0.000023062781,0.00011446827,0.0000029601126],"about_ca_topic_score_codex":0.0030842903,"about_ca_topic_score_gemma":0.004508485,"teacher_disagreement_score":0.0030842903,"about_ca_system_score_codex":0.00031901983,"about_ca_system_score_gemma":0.00026521235,"threshold_uncertainty_score":0.006132722},"labels":[],"label_agreement":null},{"id":"W1976191662","doi":"10.1007/s00280-004-0762-9","title":"A multicenter phase II study of cisplatin and docetaxel (Taxotere) in the first-line treatment of advanced ovarian cancer: a GINECO study","year":2004,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre d'expertise et de recherche en infrastructures urbaines","funders":"","keywords":"Docetaxel; Medicine; Debulking; Neutropenia; Ovarian cancer; Cisplatin; Progressive disease; Chemotherapy; Phases of clinical research; Internal medicine; Oncology; Surgery; Cancer; Tumor Debulking","score_opus":0.03240721167240346,"score_gpt":0.3838513191967099,"score_spread":0.35144410752430644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976191662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937734,0.0015563429,0.00033655614,0.000591282,0.00012229121,0.001827575,0.0007937999,0.000045748693,0.0009530475],"genre_scores_gemma":[0.98631406,0.0024652723,0.0019411412,0.0019005109,0.0003184695,0.0019000089,0.0028531163,0.00006319829,0.0022441624],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99926025,0.00043705865,0.00002328241,0.00010757652,0.000050071256,0.00012179488],"domain_scores_gemma":[0.99842876,0.00021936551,0.00021904419,0.0001241077,0.000065411514,0.00094332994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002542764,0.0015557728,0.0031963456,0.00048763698,0.00045093993,0.0011282412,0.000999785,0.0015399042,0.0022604633],"category_scores_gemma":[0.0016475439,0.0007301352,0.0017642061,0.0006689376,0.0015235621,0.001090391,0.0006633059,0.0037166327,0.00052580005],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9102194,0.0365245,0.00724061,0.0003551076,0.0013226875,0.0001992125,0.00021620023,0.0009870296,0.015361685,0.00024308555,0.0019225425,0.02540802],"study_design_scores_gemma":[0.83130366,0.15254074,0.012344752,0.000015747793,0.00068028644,0.00013690018,0.00005245956,0.0003345171,0.0008782525,0.00010124833,0.0015863709,0.000025096644],"about_ca_topic_score_codex":0.0018104885,"about_ca_topic_score_gemma":0.003588039,"teacher_disagreement_score":0.0031963456,"about_ca_system_score_codex":0.0011962234,"about_ca_system_score_gemma":0.002189091,"threshold_uncertainty_score":0.013447583},"labels":[],"label_agreement":null},{"id":"W1976238224","doi":"10.1007/s00280-004-0817-y","title":"Novel vitamin E analogue and 9-nitro-camptothecin administered as liposome aerosols decrease syngeneic mouse mammary tumor burden and inhibit metastasis","year":2004,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University","funders":"National Institute of Environmental Health Sciences; National Cancer Institute","keywords":"Apoptosis; In vivo; In vitro; Camptothecin; DAPI; Mammary tumor; Molecular biology; Chemistry; Pharmacology; Transfection; Biochemistry; Biology; Medicine; Internal medicine","score_opus":0.015310234798929694,"score_gpt":0.2888894467009151,"score_spread":0.2735792119019854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976238224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993052,0.0018663706,0.002841681,0.00016748603,0.000090062626,0.00005044131,0.00021362156,0.00014130663,0.001577067],"genre_scores_gemma":[0.9942743,0.0008445203,0.0018213085,0.00004198238,0.000024146833,0.000033896096,0.0001498391,0.000020296453,0.0027896718],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992526,0.000009697185,0.0000064762735,0.000016701471,0.000017931567,0.000023966224],"domain_scores_gemma":[0.9999279,0.000018324456,0.000016776703,0.000009266583,0.000006463309,0.000021265947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000100365214,0.0002252245,0.00024766792,0.00024150044,0.00012305794,0.00014522362,0.00027193106,0.00040803303,0.0015908328],"category_scores_gemma":[0.000100348945,0.000100689795,0.00014654946,0.00011608859,0.00026775122,0.00027822002,0.000114334565,0.0005592073,0.00023127194],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009138482,0.000101067235,0.000071835864,0.000030696738,0.0000057950006,0.00004608522,0.00001087253,0.000076366414,0.9958275,0.00016376881,0.00006390335,0.0026882403],"study_design_scores_gemma":[0.000060948027,0.000585135,0.0002560107,0.0000013340563,0.0000103543225,0.000067706365,0.0000072766697,0.0002425315,0.9979499,0.000029152156,0.00078768603,0.0000020458758],"about_ca_topic_score_codex":0.0004921697,"about_ca_topic_score_gemma":0.000740711,"teacher_disagreement_score":0.0015908328,"about_ca_system_score_codex":0.00017527498,"about_ca_system_score_gemma":0.00022703341,"threshold_uncertainty_score":0.0053218007},"labels":[],"label_agreement":null},{"id":"W1976269797","doi":"10.1007/s00280-013-2372-x","title":"Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies","year":2014,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Georgetown Hospital","funders":"","keywords":"Tolerability; Monoclonal antibody; Medicine; Oncology; Internal medicine; Solid tumor; Pharmacology; Antibody; Immunology; Adverse effect; Cancer","score_opus":0.011441081278847342,"score_gpt":0.33948244511454867,"score_spread":0.3280413638357013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976269797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99378175,0.0012192399,0.0005464673,0.00039012896,0.00010544182,0.001453753,0.0011002473,0.00011381739,0.0012891224],"genre_scores_gemma":[0.9873051,0.0013717657,0.0018432016,0.0007800425,0.00023791834,0.0024238285,0.002962066,0.00007916983,0.0029969902],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99940157,0.0002852941,0.000022398319,0.0001231264,0.000044621294,0.00012296399],"domain_scores_gemma":[0.9989237,0.00019738832,0.00021400917,0.000102651094,0.00005810815,0.0005041516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016674481,0.0022932354,0.0030963037,0.00081745867,0.0004945648,0.0010249893,0.0012835384,0.001414785,0.0050934157],"category_scores_gemma":[0.0012574651,0.0009677223,0.0018088064,0.00064332987,0.0015059722,0.0012987978,0.00043545265,0.0045590512,0.0011724913],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8033028,0.09794986,0.0030248703,0.00041857082,0.0010049096,0.00014849157,0.00022636304,0.0026203797,0.03943251,0.00025074245,0.003056567,0.048563924],"study_design_scores_gemma":[0.44102293,0.5456304,0.0067724255,0.000019397707,0.00029910778,0.00016846007,0.000047248293,0.0013100835,0.0032793237,0.00016746775,0.0012527345,0.000030469562],"about_ca_topic_score_codex":0.0018409657,"about_ca_topic_score_gemma":0.0031516084,"teacher_disagreement_score":0.0050934157,"about_ca_system_score_codex":0.0012617662,"about_ca_system_score_gemma":0.0021091308,"threshold_uncertainty_score":0.01703918},"labels":[],"label_agreement":null},{"id":"W1978070269","doi":"10.1007/s00280-008-0916-2","title":"The microtubule-active antitumor compound TTI-237 has both paclitaxel-like and vincristine-like properties","year":2009,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Tubulin; GTP'; Microtubule; Chemistry; Depolymerization; Paclitaxel; Intracellular; Biochemistry; Biophysics; Biology; Cell biology; Enzyme","score_opus":0.016665978335506784,"score_gpt":0.2766505347709534,"score_spread":0.25998455643544666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978070269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96131736,0.010240545,0.003745285,0.00044550886,0.00012306578,0.00006488538,0.0012423758,0.00043504176,0.022385918],"genre_scores_gemma":[0.99015677,0.002596158,0.0013743279,0.000095627576,0.00004023897,0.00002452114,0.0011231008,0.00003749869,0.0045518456],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999523,0.0000033652734,0.000003190072,0.0000059240538,0.000021228572,0.000013955857],"domain_scores_gemma":[0.99990666,0.000013111866,0.000017461036,0.000008982986,0.000010429534,0.000043454693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007794688,0.00028737253,0.00044997208,0.00026217333,0.00021449022,0.00042873697,0.0002754868,0.00024814182,0.0017887631],"category_scores_gemma":[0.00011022581,0.000090202855,0.00019180238,0.00030276377,0.00023010049,0.00019183785,0.00015574649,0.0005341262,0.00079810986],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046514618,0.00007682587,0.0004316072,0.000117078554,0.000019013956,0.00033987002,0.000022131904,0.00080609886,0.9727904,0.0017424809,0.0005644717,0.022624949],"study_design_scores_gemma":[0.00006069723,0.00089100463,0.0014109375,0.0000060480234,0.000025631387,0.00081318687,0.000014094218,0.00039031368,0.98535174,0.00023574095,0.010789936,0.000010589951],"about_ca_topic_score_codex":0.0007110758,"about_ca_topic_score_gemma":0.0006536729,"teacher_disagreement_score":0.0017887631,"about_ca_system_score_codex":0.00033822714,"about_ca_system_score_gemma":0.0005458676,"threshold_uncertainty_score":0.0059840083},"labels":[],"label_agreement":null},{"id":"W1983318447","doi":"10.1007/s00280-004-0942-7","title":"Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours","year":2005,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Drug Transport and Resistance Mechanisms","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Vinorelbine; Multiple drug resistance; Solid tumor; Medicine; Pharmacology; Internal medicine; Chemotherapy; Oncology; Drug resistance; Cancer research; Cancer; Biology; Cisplatin; Genetics","score_opus":0.008023811078206176,"score_gpt":0.30108309324845184,"score_spread":0.2930592821702457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983318447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941004,0.0019339422,0.00041506297,0.0004422394,0.00013739675,0.0011135646,0.00061459467,0.00008119554,0.0011615532],"genre_scores_gemma":[0.9926602,0.002099513,0.0008614655,0.0002820548,0.00012916511,0.00085192255,0.0010720004,0.00003287489,0.0020107913],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995571,0.00018339921,0.00001580042,0.00007507699,0.000030570995,0.00013794424],"domain_scores_gemma":[0.999278,0.00012559429,0.000119269054,0.00007198969,0.000038486993,0.00036667121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010728397,0.0013913752,0.0036677716,0.00061058626,0.00050355203,0.0011081542,0.0011123286,0.0011383243,0.0031390095],"category_scores_gemma":[0.0009978414,0.00087356457,0.0015691798,0.0006245527,0.0012135775,0.000979151,0.0003402723,0.0038868464,0.00067327294],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77122366,0.0736449,0.004695028,0.00088537403,0.0020880776,0.0002924175,0.0004885363,0.0038878703,0.060757622,0.00053542375,0.0035399667,0.07796122],"study_design_scores_gemma":[0.43413478,0.5476398,0.00904881,0.000028723001,0.00068155804,0.00020338476,0.00011263079,0.0013342127,0.004474714,0.00015404834,0.0021507035,0.000036691195],"about_ca_topic_score_codex":0.0027969026,"about_ca_topic_score_gemma":0.005501794,"teacher_disagreement_score":0.0036677716,"about_ca_system_score_codex":0.0011575933,"about_ca_system_score_gemma":0.0017181713,"threshold_uncertainty_score":0.010501087},"labels":[],"label_agreement":null},{"id":"W1984547199","doi":"10.1007/s00280-006-0347-x","title":"A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma","year":2006,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Celecoxib; Cyclophosphamide; Clinical endpoint; Renal cell carcinoma; Internal medicine; Progressive disease; Toxicity; Phases of clinical research; Surgery; Gastroenterology; Clinical trial; Chemotherapy; Urology; Oncology","score_opus":0.0051715397907841345,"score_gpt":0.2636782597352365,"score_spread":0.2585067199444524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984547199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99343663,0.0020145178,0.0002627916,0.0007389246,0.00025754466,0.0012385461,0.0005859853,0.000059055277,0.0014059503],"genre_scores_gemma":[0.9911142,0.0018397889,0.00080881873,0.0009522233,0.0003268012,0.0013008792,0.0015376644,0.000021107891,0.0020985256],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99955744,0.00018292677,0.00002302615,0.00008859624,0.00002979507,0.000118221695],"domain_scores_gemma":[0.9986571,0.00025145095,0.0001400462,0.00011413746,0.00006934297,0.00076798396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012808564,0.001390642,0.0034075447,0.0004716885,0.0007244391,0.0013959622,0.0010767895,0.0015897548,0.0051118666],"category_scores_gemma":[0.0013732852,0.00069947744,0.0016992036,0.000653491,0.0015798827,0.0011970949,0.0004755224,0.0048905592,0.0009867108],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92675906,0.028064646,0.0028324185,0.0003835009,0.0007618249,0.00013752497,0.00013883378,0.0007694977,0.007951927,0.00012665504,0.0015797607,0.0304943],"study_design_scores_gemma":[0.85985076,0.13390128,0.0041452646,0.0000116864585,0.00023821546,0.000074747586,0.000046437865,0.00035566508,0.00051612244,0.00006607753,0.00078099495,0.000012673293],"about_ca_topic_score_codex":0.0024891968,"about_ca_topic_score_gemma":0.0052432567,"teacher_disagreement_score":0.0051118666,"about_ca_system_score_codex":0.0012249022,"about_ca_system_score_gemma":0.0023855735,"threshold_uncertainty_score":0.01710093},"labels":[],"label_agreement":null},{"id":"W1985535018","doi":"10.1007/s00280-004-0955-2","title":"Inhibition by doxycycline of angiogenesis in the chicken chorioallantoic membrane (CAM)","year":2005,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"Cancer Research Society","keywords":"Doxycycline; Chorioallantoic membrane; Angiogenesis; Matrix metalloproteinase; In vivo; Pharmacology; Matrix metalloproteinase inhibitor; Chemistry; Medicine; Biology; Cancer research; Internal medicine; Antibiotics; Biochemistry","score_opus":0.010230482127430553,"score_gpt":0.2954464021296871,"score_spread":0.28521592000225654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985535018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99283904,0.0026798854,0.0010848652,0.00021267029,0.000064162065,0.000037007376,0.00032144733,0.00006591404,0.002695121],"genre_scores_gemma":[0.99528164,0.0009437601,0.0012011015,0.00003589905,0.000011541014,0.000020426123,0.00022825996,0.000010669347,0.0022667272],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990535,0.00001853707,0.000011012786,0.00001721419,0.0000143106445,0.000033619064],"domain_scores_gemma":[0.99986446,0.00005298594,0.000026019467,0.000019756733,0.000011209802,0.000025579795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012723956,0.00018333389,0.00021018468,0.00014079902,0.00015333151,0.00022643826,0.00016858875,0.0001934067,0.00079275406],"category_scores_gemma":[0.00013328536,0.000119446995,0.00011881448,0.00012270489,0.00021929249,0.00017042547,0.00010973219,0.00047809578,0.0001512662],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004613308,0.000050948234,0.00019199208,0.00006932489,0.0000044462954,0.000080336256,0.000021231075,0.00019108185,0.9956535,0.00029356065,0.00014682546,0.0028355236],"study_design_scores_gemma":[0.000030243675,0.00030950684,0.0013092352,0.000004590545,0.0000050370563,0.0000698941,0.000014022481,0.00065344846,0.99567956,0.000020518924,0.0019017404,0.0000022701238],"about_ca_topic_score_codex":0.0026966853,"about_ca_topic_score_gemma":0.0046485243,"teacher_disagreement_score":0.0026966853,"about_ca_system_score_codex":0.00056823,"about_ca_system_score_gemma":0.00038566062,"threshold_uncertainty_score":0.0053619742},"labels":[],"label_agreement":null},{"id":"W1985543168","doi":"10.1007/s00280-009-0968-y","title":"A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours","year":2009,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Ottawa Mental Health Centre","funders":"","keywords":"Pharmacokinetics; Tolerability; Medicine; Adverse effect; Maximum tolerated dose; Vomiting; Pharmacology; Nausea; Response Evaluation Criteria in Solid Tumors; Drug; Internal medicine; Phases of clinical research; Oncology; Toxicity","score_opus":0.013180397049429405,"score_gpt":0.3435477192316031,"score_spread":0.3303673221821737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985543168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99620503,0.00074727763,0.00038685338,0.00025462624,0.00007650853,0.00073083,0.00057245244,0.00009313578,0.0009333433],"genre_scores_gemma":[0.9947136,0.0006636687,0.0008854301,0.00033261438,0.000085690794,0.0006493476,0.0010926097,0.000036500885,0.0015404212],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99955696,0.00014914759,0.00002094965,0.0000937844,0.00005474508,0.00012442056],"domain_scores_gemma":[0.99924386,0.000111596004,0.00015674232,0.00009322186,0.00004064398,0.0003539803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009158655,0.0013855841,0.0025732694,0.00051974907,0.00044662543,0.00088700844,0.0008316558,0.0010201688,0.0028069974],"category_scores_gemma":[0.0009359679,0.0008068563,0.0012154238,0.00060194836,0.0010818106,0.0010037381,0.00036127667,0.0046632476,0.000926425],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6918649,0.08583536,0.004877729,0.00046296738,0.0010982485,0.00021492607,0.00035222853,0.0043973303,0.108772136,0.00030428395,0.0041502407,0.09766969],"study_design_scores_gemma":[0.34935048,0.6175292,0.019629883,0.000013831599,0.0005385735,0.00032802272,0.00007703031,0.0021166485,0.007742685,0.00025033456,0.0023578873,0.000065497086],"about_ca_topic_score_codex":0.0014579493,"about_ca_topic_score_gemma":0.002485995,"teacher_disagreement_score":0.0028069974,"about_ca_system_score_codex":0.0012373934,"about_ca_system_score_gemma":0.0014027142,"threshold_uncertainty_score":0.009390295},"labels":[],"label_agreement":null},{"id":"W1990086381","doi":"10.1007/s00280-010-1389-7","title":"A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer","year":2010,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre; Ottawa Regional Cancer Foundation; University of Toronto","funders":"National Cancer Institute; National Institutes of Health","keywords":"Docetaxel; Prostate cancer; Prednisone; Medicine; Internal medicine; Oncology; Cancer research; Castration; Cancer; Pharmacology; Hormone","score_opus":0.030365239443130243,"score_gpt":0.3928297857683229,"score_spread":0.36246454632519265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990086381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936852,0.0016646037,0.00053057744,0.00033487906,0.0002471974,0.0015930673,0.00055394444,0.00010160957,0.0012889369],"genre_scores_gemma":[0.98851085,0.0028949094,0.0017980352,0.000493281,0.0002812427,0.0015259007,0.0011326107,0.00004301754,0.0033200334],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995801,0.00016816825,0.00001761596,0.00008744838,0.000034942223,0.00011178281],"domain_scores_gemma":[0.99929404,0.00011510778,0.0000854972,0.000055613666,0.000033926935,0.00041577607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010854215,0.0016156405,0.0028943084,0.0008348262,0.00059007684,0.0010945549,0.0013850037,0.0014637372,0.0035925307],"category_scores_gemma":[0.00075650966,0.00088880496,0.0014534087,0.0007188305,0.0015508595,0.0009443748,0.00031596242,0.003900606,0.00080079446],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7024196,0.12980816,0.0021692351,0.0008156095,0.001230922,0.0002913139,0.0003384125,0.004218208,0.07447386,0.00045714583,0.0022998492,0.081477754],"study_design_scores_gemma":[0.35703844,0.6317017,0.003723826,0.000021951735,0.00043878335,0.0001869588,0.000068770496,0.0009672226,0.0044048913,0.00012923806,0.0012809592,0.000037275262],"about_ca_topic_score_codex":0.0035780065,"about_ca_topic_score_gemma":0.008528051,"teacher_disagreement_score":0.0035925307,"about_ca_system_score_codex":0.0010746861,"about_ca_system_score_gemma":0.0027607463,"threshold_uncertainty_score":0.012018204},"labels":[],"label_agreement":null},{"id":"W1990206652","doi":"10.1007/s00280-001-0403-5","title":"Comparison of apoptotic, necrotic and clonogenic cell death and inhibition of cell growth following camptothecin and X-radiation treatment in a human melanoma and a human fibroblast cell line","year":2001,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"National Cancer Institute","keywords":"Camptothecin; Programmed cell death; Propidium iodide; Clonogenic assay; Apoptosis; Cell culture; Cell growth; Biology; Cell; Cancer research; Necrosis; Acridine orange; Molecular biology; Biochemistry","score_opus":0.014444432437030906,"score_gpt":0.3073200835033996,"score_spread":0.2928756510663687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990206652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99257714,0.002334174,0.0015155276,0.000045617082,0.00003121299,0.00003918654,0.00069094717,0.000046648114,0.0027194442],"genre_scores_gemma":[0.99303985,0.0012163826,0.0013124153,0.000029317518,0.000015927926,0.000061965,0.00095966866,0.0000151178265,0.0033493587],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99980086,0.00004517022,0.000022354441,0.000021652086,0.000058701975,0.000051223487],"domain_scores_gemma":[0.9995976,0.00019183183,0.000039590133,0.000046677553,0.00006942894,0.00005482887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028613707,0.00026692593,0.00034468182,0.0005108721,0.0002779936,0.00024064608,0.0002472008,0.0004065574,0.0012687553],"category_scores_gemma":[0.00032059677,0.00017339329,0.0003353121,0.0004767187,0.00028012283,0.00033285614,0.00010889348,0.00043904682,0.00026938104],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010565886,0.00007230639,0.00048109313,0.00006284635,0.00001232,0.00013110541,0.000078712575,0.00017349441,0.9960496,0.00021353367,0.000033393717,0.0016350872],"study_design_scores_gemma":[0.000022991127,0.0008849068,0.01516329,0.0000044238463,0.000019659636,0.00034184378,0.00005888906,0.00062744896,0.9820909,0.000050854564,0.00072978786,0.0000050231583],"about_ca_topic_score_codex":0.0026705284,"about_ca_topic_score_gemma":0.0022110213,"teacher_disagreement_score":0.0026705284,"about_ca_system_score_codex":0.00034090076,"about_ca_system_score_gemma":0.0003077422,"threshold_uncertainty_score":0.0053099394},"labels":[],"label_agreement":null},{"id":"W1990365798","doi":"10.1007/s002800000222","title":"TNF-α further augments natural killer cells when co-administered with an interferon inducer to irradiated, leukemic, bone-marrow-transplanted mice","year":2001,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Tumor necrosis factor alpha; Bone marrow; Cytokine; Haematopoiesis; Immunology; Natural killer cell; Interferon; Cancer research; Biology; Stem cell; Cytotoxic T cell; In vitro; Cell biology","score_opus":0.016780088308106653,"score_gpt":0.2906677799964995,"score_spread":0.27388769168839283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990365798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99548316,0.0009234205,0.0012596013,0.00013738044,0.00013178802,0.00006063472,0.00028876984,0.00015841039,0.0015567014],"genre_scores_gemma":[0.9948308,0.0006155928,0.001251139,0.000060757706,0.00008038065,0.000051074483,0.00034408423,0.000034920904,0.0027313489],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999592,0.00010527389,0.00004133151,0.000049634054,0.00007089614,0.00014080152],"domain_scores_gemma":[0.99929786,0.00018171222,0.0001709314,0.00009724564,0.00003311407,0.00021907184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004516644,0.00097482366,0.0008645567,0.00079954247,0.00028366368,0.0005678448,0.00036790245,0.000621857,0.0017244074],"category_scores_gemma":[0.00032862936,0.0002488602,0.000483829,0.00039392186,0.0007041365,0.00035492887,0.00026758356,0.0018992373,0.0005097847],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003838835,0.00043612995,0.000394879,0.00006575691,0.000016461867,0.00026862987,0.00005230563,0.00022980636,0.99239737,0.00024799956,0.0000770266,0.0019748253],"study_design_scores_gemma":[0.00015620732,0.0019747424,0.00093710807,0.0000080233185,0.000042650936,0.00024320358,0.00003105536,0.00053082634,0.9953139,0.00007449779,0.0006823307,0.0000053769827],"about_ca_topic_score_codex":0.00039610665,"about_ca_topic_score_gemma":0.0006000481,"teacher_disagreement_score":0.0017244074,"about_ca_system_score_codex":0.00026111712,"about_ca_system_score_gemma":0.0005230727,"threshold_uncertainty_score":0.005768776},"labels":[],"label_agreement":null},{"id":"W1991404956","doi":"10.1007/s00280-010-1342-9","title":"Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP","year":2010,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Calicheamicin; Immunoconjugate; CD22; Chemotherapy; CHOP; Cancer research; Medicine; Monoclonal antibody; Antibody; Internal medicine; Immunology","score_opus":0.017626628089461523,"score_gpt":0.3344375505906821,"score_spread":0.31681092250122056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991404956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99602675,0.0013525519,0.00047801796,0.00011291003,0.000082851475,0.00008614377,0.0004757479,0.000075591175,0.0013093932],"genre_scores_gemma":[0.9970462,0.00075805665,0.00034445737,0.00003142483,0.000040524275,0.000059152055,0.0006214757,0.00001515683,0.0010836201],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997968,0.000056140874,0.000010998743,0.000028247337,0.000027714963,0.00008013872],"domain_scores_gemma":[0.9996356,0.00009993933,0.00008288074,0.00003085995,0.000030729963,0.000119934855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003562324,0.00063957594,0.0006201037,0.00046512505,0.00017357145,0.00037788512,0.00055912224,0.00051950634,0.0029951988],"category_scores_gemma":[0.00036943113,0.00033031614,0.00043065194,0.00040994305,0.00047722497,0.0005468099,0.00013738044,0.0015869862,0.0003562747],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07173111,0.016680468,0.0010729554,0.0002609033,0.00016437884,0.00019933573,0.00009417678,0.004734269,0.877831,0.00055412215,0.0012451144,0.025432147],"study_design_scores_gemma":[0.005978985,0.1628957,0.005756411,0.000020503632,0.00041001049,0.0003828757,0.000060514627,0.005539795,0.81683666,0.00019555984,0.0018960121,0.000026925774],"about_ca_topic_score_codex":0.0016760477,"about_ca_topic_score_gemma":0.0015265986,"teacher_disagreement_score":0.0029951988,"about_ca_system_score_codex":0.00056638935,"about_ca_system_score_gemma":0.00071032945,"threshold_uncertainty_score":0.010019898},"labels":[],"label_agreement":null},{"id":"W1992013332","doi":"10.1007/s00280-002-0525-4","title":"Differential responses of EGFR-/AGT-expressing cells to the \"combi-triazene\" SMA41","year":2003,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Chemical Reactions and Mechanisms","field":"Chemistry","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Regional Health Centre; McGill University; Health Canada; Royal Victoria Hospital","funders":"","keywords":"Triazene; Cancer research; Differential (mechanical device); Biology; Chemistry; Pharmacology; Cell biology","score_opus":0.021054060810524248,"score_gpt":0.3148057642350206,"score_spread":0.29375170342449636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992013332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99640226,0.00047865673,0.0006171547,0.00008808409,0.000038985374,0.000022486805,0.00046670038,0.000042561307,0.0018431568],"genre_scores_gemma":[0.9951056,0.0004112202,0.0007910829,0.000050919323,0.000012541404,0.00003441591,0.00080321584,0.000014872706,0.0027760316],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997416,0.000060542963,0.00002626346,0.000030336232,0.00007757755,0.00006373351],"domain_scores_gemma":[0.9998598,0.000053220472,0.000016924329,0.000024987075,0.000026983274,0.000018061548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015415833,0.00022873469,0.00038941004,0.00017987307,0.0001875562,0.00033180966,0.00015545807,0.00038090898,0.0023688697],"category_scores_gemma":[0.00022966848,0.00017087717,0.00028053977,0.00028165302,0.00018263825,0.00020435544,0.00015866375,0.0005459423,0.00041559618],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005696917,0.00005418221,0.00028715027,0.000028575063,0.0000068879363,0.00004210457,0.000030792675,0.00014731158,0.99693716,0.000106741536,0.00009335056,0.0016959828],"study_design_scores_gemma":[0.000019137786,0.00048165667,0.003480245,0.0000013837265,0.000007696683,0.0000829426,0.00003776363,0.0007104091,0.99441385,0.00002406513,0.00073768,0.0000032176933],"about_ca_topic_score_codex":0.0008960194,"about_ca_topic_score_gemma":0.0008871568,"teacher_disagreement_score":0.0023688697,"about_ca_system_score_codex":0.00023696241,"about_ca_system_score_gemma":0.00016258332,"threshold_uncertainty_score":0.007924676},"labels":[],"label_agreement":null},{"id":"W1992368913","doi":"10.1007/s00280-012-2038-0","title":"Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours","year":2012,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Juravinski Cancer Centre; McGill University; Ontario Institute for Cancer Research; BC Cancer Agency; Jewish General Hospital","funders":"Cancer Research UK","keywords":"Ketoconazole; Pharmacokinetics; Medicine; Rifampicin; Pharmacology; Drug interaction; Internal medicine; Gastroenterology; Pathology; Dermatology","score_opus":0.027445500362463033,"score_gpt":0.4104649299551251,"score_spread":0.3830194295926621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992368913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99399394,0.0023392136,0.00050954905,0.00035723305,0.000100614045,0.0010067081,0.0006716298,0.0000821531,0.0009390776],"genre_scores_gemma":[0.99351764,0.0017745964,0.0011250591,0.0003896238,0.00014555304,0.00077070954,0.0011287329,0.00003457432,0.0011134447],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999094,0.00045673322,0.0000501083,0.00013961583,0.00007452115,0.00018492635],"domain_scores_gemma":[0.9983772,0.00034062334,0.0003440945,0.00018474503,0.00011090206,0.00064240454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015396058,0.0016259033,0.003645701,0.0005299094,0.0006585509,0.0014226374,0.0010637479,0.0013603676,0.0023936979],"category_scores_gemma":[0.0021033029,0.0010936632,0.002407442,0.00066531636,0.0014404936,0.0012814684,0.00037451522,0.0052427766,0.000611386],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88129514,0.034343906,0.0035242955,0.0004887038,0.0015432694,0.00014063806,0.00029147696,0.002362503,0.02534638,0.0002304816,0.0012942429,0.049138788],"study_design_scores_gemma":[0.5016257,0.47377113,0.014824329,0.000029639607,0.00085963664,0.00023947521,0.00012592804,0.0011881107,0.0053158407,0.00012273472,0.0018450565,0.000052438525],"about_ca_topic_score_codex":0.0020878967,"about_ca_topic_score_gemma":0.004130338,"teacher_disagreement_score":0.003645701,"about_ca_system_score_codex":0.0015364095,"about_ca_system_score_gemma":0.002311434,"threshold_uncertainty_score":0.011147499},"labels":[],"label_agreement":null},{"id":"W1992550766","doi":"10.1007/s00280-013-2226-6","title":"Pharmacodynamic modeling of cell cycle and apoptotic effects of gemcitabine on pancreatic adenocarcinoma cells","year":2013,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of General Medical Sciences; National Institutes of Health; Public Health Agency of Canada","keywords":"Gemcitabine; Pharmacodynamics; Apoptosis; Adenocarcinoma; Pancreatic cancer; Cell cycle; Cancer research; Internal medicine; Pharmacology; Chemistry; Oncology; Medicine; Biology; Chemotherapy; Pharmacokinetics; Cancer; Biochemistry","score_opus":0.013173311332558186,"score_gpt":0.31446018496275263,"score_spread":0.30128687363019446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992550766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.967747,0.0015705355,0.020856746,0.00032436286,0.000028861135,0.00007888966,0.0010217851,0.00013669483,0.0082352115],"genre_scores_gemma":[0.9961779,0.0005784222,0.0013472448,0.00004376797,0.0000044501903,0.000038013837,0.00021871239,0.00001144288,0.0015799685],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9999211,0.000025159005,0.0000044616204,0.00001489107,0.000020050093,0.000014435618],"domain_scores_gemma":[0.9998661,0.00007827288,0.000026278685,0.0000063758866,0.00001756012,0.0000054686207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013232445,0.00031230957,0.00036942284,0.00022194121,0.00012955088,0.00036985273,0.00029547358,0.00039212735,0.0010696327],"category_scores_gemma":[0.0004924897,0.0001479352,0.0005605237,0.00021607833,0.00009837557,0.00019358697,0.00010304856,0.00032747438,0.00022077911],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012953278,0.00022848787,0.004051161,0.00023959555,0.00011039525,0.000238712,0.00005626406,0.84515226,0.13197124,0.0020074218,0.0005094553,0.014139664],"study_design_scores_gemma":[0.00005821078,0.00090076035,0.0035101895,0.00000990389,0.00010615433,0.00018067933,0.000034325763,0.9143488,0.07868236,0.0006790227,0.0014703331,0.000019355311],"about_ca_topic_score_codex":0.0046264166,"about_ca_topic_score_gemma":0.0030107126,"teacher_disagreement_score":0.0046264166,"about_ca_system_score_codex":0.00056981907,"about_ca_system_score_gemma":0.00044920944,"threshold_uncertainty_score":0.009198964},"labels":[],"label_agreement":null},{"id":"W1993531901","doi":"10.1007/s00280-007-0483-y","title":"Abrogation of ionizing radiation-induced G2 checkpoint and inhibition of nuclear export by Cryptocarya pyrones","year":2007,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thompson Rivers University; University of British Columbia","funders":"National Cancer Institute","keywords":"G2-M DNA damage checkpoint; CHEK1; Cell cycle checkpoint; Nuclear export signal; Mitosis; Kinase; DNA damage; Cancer research; Biology; Cell biology; Cell cycle; DNA repair; Chemistry; Biochemistry; DNA; Cell; Cell nucleus","score_opus":0.009639481280983724,"score_gpt":0.28341223120258374,"score_spread":0.2737727499216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993531901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952199,0.0008256671,0.0015258428,0.000096523494,0.000023460063,0.000036414334,0.00026969775,0.00012576593,0.0018767067],"genre_scores_gemma":[0.99729544,0.00041828072,0.00052998314,0.000023837838,0.000007091897,0.00002130431,0.00025459952,0.000020267853,0.0014292491],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999027,0.00001945259,0.0000077694485,0.000011953276,0.000018436742,0.000039576586],"domain_scores_gemma":[0.99978966,0.000059029167,0.000047002497,0.00005645913,0.000010723736,0.000037235197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014641118,0.00035536967,0.0002586162,0.00022525198,0.0001615019,0.0002446101,0.00025588367,0.00025307166,0.0017482585],"category_scores_gemma":[0.00018029546,0.00017843353,0.00022028919,0.00018072301,0.00034259493,0.00023736013,0.00022683629,0.00069848227,0.00025790755],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007408864,0.000055167613,0.00012340196,0.000035502937,0.000005000277,0.000076972385,0.000015399984,0.00018281997,0.9968135,0.0003294493,0.000037918457,0.0015840598],"study_design_scores_gemma":[0.00003181517,0.00024905292,0.0009795044,0.0000026538332,0.0000037580699,0.000078818586,0.000008117337,0.00018415114,0.9978002,0.0000383814,0.0006214088,0.0000022439967],"about_ca_topic_score_codex":0.00061690365,"about_ca_topic_score_gemma":0.00071130425,"teacher_disagreement_score":0.0017482585,"about_ca_system_score_codex":0.00027401934,"about_ca_system_score_gemma":0.0003680587,"threshold_uncertainty_score":0.005848527},"labels":[],"label_agreement":null},{"id":"W1993832391","doi":"10.1007/s00280-012-1916-9","title":"Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer","year":2012,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Abiraterone acetate; QT interval; Medicine; Prednisone; Prostate cancer; Pharmacokinetics; Adverse effect; Internal medicine; Pharmacology; Abiraterone; Urology; Cancer; Cardiology; Androgen deprivation therapy","score_opus":0.022724383275859676,"score_gpt":0.355739936494965,"score_spread":0.3330155532191053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993832391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995849,0.0032187423,0.00018319485,0.00010228655,0.0000283002,0.00009120765,0.00010945733,0.000030068028,0.00038776489],"genre_scores_gemma":[0.9985026,0.000750157,0.0003106633,0.000065352804,0.000054574175,0.00004097068,0.000109158085,0.000004679197,0.00016192695],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.999548,0.00023949567,0.000034929442,0.000055509096,0.00008737897,0.00003470624],"domain_scores_gemma":[0.998928,0.00037070859,0.00032819432,0.000044282868,0.000039500243,0.00028927604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007318032,0.0005453289,0.0013774079,0.00024380822,0.00018366263,0.00038554575,0.00028309255,0.00031120362,0.0011156083],"category_scores_gemma":[0.0022401006,0.0002112757,0.0005208796,0.00030544677,0.00024519642,0.00028428665,0.00021594694,0.0010908673,0.00020396884],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6402469,0.009825895,0.047840543,0.0011339147,0.0019370553,0.00049826084,0.00041970497,0.004355109,0.06445872,0.00007472155,0.0011753356,0.2280338],"study_design_scores_gemma":[0.12359116,0.5821238,0.27413693,0.00012912885,0.0014779283,0.00160181,0.00015641976,0.0049141594,0.008143395,0.00021635203,0.0034408343,0.00006809851],"about_ca_topic_score_codex":0.000729333,"about_ca_topic_score_gemma":0.002229186,"teacher_disagreement_score":0.0013774079,"about_ca_system_score_codex":0.00034859395,"about_ca_system_score_gemma":0.0005679795,"threshold_uncertainty_score":0.0038701296},"labels":[],"label_agreement":null},{"id":"W1994441302","doi":"10.1007/s00280-013-2346-z","title":"Extraction of tamoxifen and its metabolites from formalin-fixed, paraffin-embedded tissues: an innovative quantitation method using liquid chromatography and tandem mass spectrometry","year":2014,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"Breast Cancer Society of Canada","keywords":"Chromatography; Mass spectrometry; Liquid chromatography–mass spectrometry; Chemistry; Tandem mass spectrometry; Extraction (chemistry); Tamoxifen; High-performance liquid chromatography; Selected reaction monitoring; Medicine; Cancer; Internal medicine; Breast cancer","score_opus":0.015796257930327576,"score_gpt":0.3556537983517138,"score_spread":0.3398575404213862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994441302","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.44188833,0.020743316,0.52956015,0.0006792981,0.00020298503,0.00080524024,0.0024855228,0.0011345115,0.0025007264],"genre_scores_gemma":[0.4235923,0.0117085725,0.55248106,0.00093959336,0.00021658359,0.0013669243,0.0041782237,0.00016155248,0.005355151],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992156,0.00012516533,0.00007899674,0.00024890152,0.00028780627,0.00004351292],"domain_scores_gemma":[0.999481,0.000131878,0.00015324121,0.000043280183,0.00016207247,0.000028546716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007285751,0.00091207394,0.0003879076,0.0013774184,0.00029178648,0.00035933426,0.0004939733,0.00066267943,0.00070811965],"category_scores_gemma":[0.0009589686,0.00027726596,0.00039293265,0.00061277096,0.00036407134,0.0004038766,0.00027316037,0.0005747106,0.00092495425],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003963451,0.00002033809,0.00075921504,0.000074940435,0.000017398694,0.00006598552,0.000016941085,0.0000610668,0.9929531,0.000031478263,0.000051939038,0.005907947],"study_design_scores_gemma":[0.000024885569,0.00042453085,0.01160257,0.000047378337,0.000097660064,0.001486811,0.000042280422,0.0026759994,0.9777378,0.00016341155,0.0056571225,0.000039510196],"about_ca_topic_score_codex":0.00046834574,"about_ca_topic_score_gemma":0.0010415611,"teacher_disagreement_score":0.0013774184,"about_ca_system_score_codex":0.00024904773,"about_ca_system_score_gemma":0.00054480205,"threshold_uncertainty_score":0.0038531423},"labels":[],"label_agreement":null},{"id":"W1994673341","doi":"10.1007/s00280-004-0939-2","title":"In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative","year":2005,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":151,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Geldanamycin; In vivo; Pharmacology; Derivative (finance); Chemistry; Hydrochloride; Medicine; Hsp90; Biochemistry; Biology; Heat shock protein","score_opus":0.015349046276918412,"score_gpt":0.31225544703291863,"score_spread":0.2969064007560002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994673341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939633,0.0019546824,0.0010984875,0.00014651446,0.00011663206,0.000044125947,0.00055528944,0.00014543584,0.001975601],"genre_scores_gemma":[0.9952803,0.0008713136,0.00061824993,0.000034097255,0.000034711946,0.000052245792,0.0006662257,0.000031569558,0.0024110922],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997899,0.00006218453,0.000012315926,0.00002538305,0.00002826296,0.000081995255],"domain_scores_gemma":[0.99968493,0.0001134903,0.00004444666,0.000038807055,0.00001545217,0.00010282684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034650226,0.00053043745,0.0006577859,0.000396058,0.00019490343,0.0001826144,0.00028409183,0.00050491386,0.0019032566],"category_scores_gemma":[0.00020716166,0.0002586732,0.00036243818,0.00022243694,0.00037817197,0.00027338497,0.00010575732,0.0012310616,0.00039836724],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047028363,0.0010955798,0.00036624292,0.00008396526,0.000046421344,0.00008907599,0.00004978422,0.0010471173,0.98703533,0.00019210145,0.00032350243,0.0049680807],"study_design_scores_gemma":[0.0003758403,0.012487818,0.0027184193,0.000006658241,0.00006912461,0.00018391928,0.000017836755,0.001789868,0.98105925,0.00006198855,0.0012204244,0.000008829413],"about_ca_topic_score_codex":0.0010146613,"about_ca_topic_score_gemma":0.00083760417,"teacher_disagreement_score":0.0019032566,"about_ca_system_score_codex":0.00027058285,"about_ca_system_score_gemma":0.00045578272,"threshold_uncertainty_score":0.0063670874},"labels":[],"label_agreement":null},{"id":"W1995170617","doi":"10.1007/s00280-014-2481-1","title":"Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors","year":2014,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Carboplatin; Medicine; Neutropenia; Etoposide; Topotecan; Internal medicine; Leukopenia; Pharmacology; Lung cancer; Docetaxel; Chemotherapy; Febrile neutropenia; Oncology; Gastroenterology; Cisplatin","score_opus":0.00965616637976602,"score_gpt":0.37579528785663024,"score_spread":0.3661391214768642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995170617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837805,0.005356817,0.00097168353,0.0015875653,0.00037437593,0.0028265994,0.0025421411,0.00022839899,0.0023319025],"genre_scores_gemma":[0.9787917,0.0049342327,0.0026725645,0.0014330877,0.00023824716,0.003247078,0.0047077616,0.00008102721,0.0038943833],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994111,0.00021509902,0.000030332421,0.00013994025,0.00004850663,0.00015498884],"domain_scores_gemma":[0.9993019,0.000093212686,0.000114408795,0.000056947236,0.000050148657,0.00038344722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016018554,0.0020371259,0.0040525226,0.0006771261,0.0006284422,0.0014770537,0.0013669481,0.0018435857,0.005646212],"category_scores_gemma":[0.0011219046,0.0008772421,0.002944236,0.0006329625,0.0012368261,0.0014675299,0.00053697044,0.006016306,0.0014311547],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7965353,0.06388994,0.0041958564,0.0012307512,0.0033907786,0.0001898763,0.00040939817,0.004157251,0.021306735,0.00056012446,0.0081093,0.096024655],"study_design_scores_gemma":[0.68494326,0.29956943,0.0072109774,0.00004670082,0.0007171646,0.00023207265,0.00008454733,0.000942198,0.002144581,0.00024498833,0.003826558,0.000037551694],"about_ca_topic_score_codex":0.0020653906,"about_ca_topic_score_gemma":0.005556397,"teacher_disagreement_score":0.005646212,"about_ca_system_score_codex":0.0015912305,"about_ca_system_score_gemma":0.0021658486,"threshold_uncertainty_score":0.018888414},"labels":[],"label_agreement":null},{"id":"W1995389617","doi":"10.1007/s00280-002-0443-5","title":"Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study","year":2002,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Institute on Aging","keywords":"Fludarabine; Medicine; Toxicity; Creatinine; Internal medicine; Renal function; Gastroenterology; Chronic lymphocytic leukemia; Anemia; Neutropenia; Clinical endpoint; Interquartile range; Leukemia; Surgery; Cyclophosphamide; Chemotherapy; Clinical trial","score_opus":0.030700621468147726,"score_gpt":0.3453199439162757,"score_spread":0.31461932244812796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995389617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99917704,0.00024496566,0.0000841238,0.00004977501,0.0000059061645,0.000026282722,0.0003043691,0.0000038713592,0.00010345095],"genre_scores_gemma":[0.99817646,0.00015449814,0.00025140232,0.000092941904,0.000026508025,0.000051497773,0.0011393112,0.000007226821,0.00010024385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99872226,0.0007071205,0.00008686453,0.00017161068,0.00016009015,0.0001519953],"domain_scores_gemma":[0.9973008,0.0007476453,0.0006091712,0.00031934536,0.00030429804,0.0007186675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029519394,0.000979117,0.001544035,0.000798295,0.00077506294,0.0010049279,0.00096799486,0.0009644121,0.0004157129],"category_scores_gemma":[0.0027677985,0.00059672765,0.0009730462,0.0016279295,0.0006132819,0.0005390676,0.0004827471,0.0010868339,0.0001258682],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014038794,0.00047031266,0.9794754,0.000022919206,0.0007746665,0.00011272163,0.00010647373,0.00030721672,0.001477369,0.000020373627,0.00040326963,0.0027905116],"study_design_scores_gemma":[0.0018404714,0.0018804226,0.9944155,0.000005166598,0.00048688124,0.00015566901,0.00011983846,0.000597731,0.00021084261,0.00001607857,0.00025880444,0.000012609243],"about_ca_topic_score_codex":0.019614263,"about_ca_topic_score_gemma":0.023792705,"teacher_disagreement_score":0.019614263,"about_ca_system_score_codex":0.0015468922,"about_ca_system_score_gemma":0.002197025,"threshold_uncertainty_score":0.039000154},"labels":[],"label_agreement":null},{"id":"W1995811281","doi":"10.1007/s00280-006-0362-y","title":"Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors","year":2006,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Medicine; Pharmacokinetics; Tolerability; Neutropenia; Taxane; Internal medicine; Refractory (planetary science); Paclitaxel; Adverse effect; Toxicity; Pharmacology; Oncology; Chemotherapy; Gastroenterology; Cancer; Breast cancer","score_opus":0.01851690814974668,"score_gpt":0.37115694981906044,"score_spread":0.3526400416693138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995811281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934168,0.0009957353,0.00044218238,0.0006374677,0.00014561629,0.0013456271,0.0008031805,0.00012192356,0.0020915281],"genre_scores_gemma":[0.98672473,0.0017985071,0.0011769525,0.000698019,0.0002784686,0.0025715847,0.0017584974,0.000045614084,0.004947643],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997336,0.0001275164,0.000010064177,0.00004529625,0.000016666005,0.00006687843],"domain_scores_gemma":[0.99950004,0.00008654224,0.00006528291,0.00005080414,0.000029574137,0.00026778248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082939037,0.0018078897,0.0024347675,0.00041720676,0.0005807755,0.0007171736,0.00075632834,0.0011340394,0.0053252624],"category_scores_gemma":[0.00075049134,0.0005375384,0.0010479565,0.00032055212,0.0011710504,0.00072102493,0.00039374124,0.0028970963,0.0013296702],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87244606,0.044672895,0.0031230454,0.0004611527,0.00066527666,0.00013706821,0.00020475953,0.0017997785,0.023303458,0.0004802195,0.0040981057,0.04860823],"study_design_scores_gemma":[0.64270073,0.34526792,0.006006973,0.000022941475,0.0003208723,0.00012964153,0.00005806205,0.00089997036,0.0024508017,0.0003300821,0.001792049,0.000019965057],"about_ca_topic_score_codex":0.0011631995,"about_ca_topic_score_gemma":0.0018637807,"teacher_disagreement_score":0.0053252624,"about_ca_system_score_codex":0.0006900408,"about_ca_system_score_gemma":0.0015644908,"threshold_uncertainty_score":0.017814755},"labels":[],"label_agreement":null},{"id":"W1996081258","doi":"10.1007/s00280-008-0730-x","title":"Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults","year":2008,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; BC Children's Hospital; Izaak Walton Killam Health Centre","funders":"","keywords":"Imatinib; Imatinib mesylate; Medicine; Pharmacokinetics; NONMEM; Tyrosine-kinase inhibitor; Pharmacology; Population; Myeloid leukemia; Internal medicine; Dosing; Metabolite; Oncology; Cancer","score_opus":0.01325244747741804,"score_gpt":0.30946617371609253,"score_spread":0.2962137262386745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996081258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986105,0.00046927255,0.00020470134,0.00003281264,0.0000025740364,0.000007108213,0.00027870564,0.00001196548,0.0003822496],"genre_scores_gemma":[0.99873716,0.00031931524,0.00017489941,0.000040235343,0.000009582577,0.00001657035,0.00046035295,0.000008368727,0.00023353983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997459,0.0000760964,0.000019012112,0.000060430393,0.000057542555,0.000040934974],"domain_scores_gemma":[0.9992901,0.00028063275,0.00019776037,0.000038658334,0.000073890886,0.00011901088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042661495,0.00017146344,0.00053556025,0.00022001126,0.00016172581,0.00037617036,0.00010980786,0.00027476624,0.00069984153],"category_scores_gemma":[0.0018021968,0.00020882236,0.00028068878,0.00028000693,0.00018850138,0.000410533,0.00022092336,0.0005442055,0.00018583448],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004757598,0.00015315656,0.96425945,0.00005072308,0.00024782194,0.00051472714,0.000610264,0.0010022547,0.005946521,0.00026388583,0.0009973694,0.021196097],"study_design_scores_gemma":[0.000078605706,0.001658465,0.99318063,0.000005513269,0.000112665046,0.0015156678,0.00029816834,0.00080231135,0.0010250157,0.00010344427,0.0012072686,0.000012267013],"about_ca_topic_score_codex":0.0024150398,"about_ca_topic_score_gemma":0.0022498243,"teacher_disagreement_score":0.0024150398,"about_ca_system_score_codex":0.0004330115,"about_ca_system_score_gemma":0.0003771729,"threshold_uncertainty_score":0.0048019886},"labels":[],"label_agreement":null},{"id":"W1996145189","doi":"10.1007/s00280-008-0704-z","title":"Resveratrol analog trans 3,4,5,4′-tetramethoxystilbene (DMU-212) mediates anti-tumor effects via mechanism different from that of resveratrol","year":2008,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Sirtuins and Resveratrol in Medicine","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Acadia University; University of Alberta","funders":"","keywords":"Resveratrol; Cell cycle; Chemistry; Apoptosis; Tubulin; Cell cycle checkpoint; Cell culture; Viability assay; Western blot; MTT assay; Cell growth; Cell; Microtubule; Biochemistry; Cancer research; Biology; Cell biology; Gene; Genetics","score_opus":0.019522603895097933,"score_gpt":0.30264128342149405,"score_spread":0.28311867952639613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996145189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97984374,0.0066824015,0.0039831293,0.0005420835,0.00020812919,0.000048787468,0.0003740064,0.00037188415,0.007945845],"genre_scores_gemma":[0.9934006,0.0018466103,0.0009581948,0.00014906078,0.000039350583,0.000018548148,0.00038380187,0.000015814661,0.0031882278],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987936,0.0000348777,0.000008594966,0.000020027892,0.000022520066,0.00003455411],"domain_scores_gemma":[0.9999254,0.000012197495,0.00002084531,0.00001553794,0.0000096252825,0.000016344764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001283891,0.0004409462,0.00047043117,0.00030528023,0.000218439,0.00031546515,0.0002975786,0.0005170962,0.0019176324],"category_scores_gemma":[0.00011172988,0.00020020865,0.00039302802,0.00016440915,0.00034117256,0.00035774638,0.00011721617,0.0007869491,0.0007782043],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007841334,0.00007472276,0.00014636538,0.0000500413,0.000015100366,0.00009074523,0.000018324283,0.000046005516,0.99591947,0.00036527019,0.0001325173,0.0023573218],"study_design_scores_gemma":[0.000046883528,0.0008310946,0.0021085418,0.000004737322,0.000031702897,0.00025780432,0.000033800643,0.0002723842,0.9937273,0.000086180786,0.0025934915,0.0000059364556],"about_ca_topic_score_codex":0.0005695443,"about_ca_topic_score_gemma":0.0011107689,"teacher_disagreement_score":0.0019176324,"about_ca_system_score_codex":0.0002626427,"about_ca_system_score_gemma":0.00027006352,"threshold_uncertainty_score":0.0064151287},"labels":[],"label_agreement":null},{"id":"W1996697383","doi":"10.1007/s00280-006-0245-2","title":"A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application","year":2006,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Apotex (Canada)","funders":"","keywords":"Paclitaxel; Pharmacokinetics; Pharmacology; Medicine; Chemotherapy; Internal medicine","score_opus":0.0242078547080019,"score_gpt":0.3711345531872951,"score_spread":0.3469266984792932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996697383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965011,0.0006290765,0.0015046751,0.00011092963,0.00002793635,0.00018282559,0.000098904406,0.00004195695,0.0009026242],"genre_scores_gemma":[0.9965149,0.0006024153,0.0011658968,0.00007189252,0.00004138717,0.0000710233,0.00015767339,0.000029616125,0.0013452186],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997925,0.000071558316,0.000008442634,0.00004918014,0.00003930102,0.000038933566],"domain_scores_gemma":[0.9996618,0.00010234879,0.000090045636,0.00004347982,0.00002634389,0.00007588911],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004586868,0.00038285865,0.000495187,0.00032867197,0.00032425777,0.0005432169,0.00039695704,0.00048128827,0.0022213547],"category_scores_gemma":[0.0006377022,0.00026028344,0.00046382868,0.00027121097,0.00051400135,0.00048319573,0.00012668557,0.0010867402,0.00038204397],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0813751,0.017557116,0.0033578046,0.00040244343,0.0002887542,0.0011361934,0.0003424856,0.003863249,0.7709015,0.0008112431,0.0013751213,0.118588954],"study_design_scores_gemma":[0.019977681,0.49375632,0.01823188,0.000044875753,0.00090166746,0.00411574,0.00020362211,0.013950387,0.43615124,0.00040692062,0.012170684,0.00008901149],"about_ca_topic_score_codex":0.0009645412,"about_ca_topic_score_gemma":0.0009561295,"teacher_disagreement_score":0.0022213547,"about_ca_system_score_codex":0.00046990326,"about_ca_system_score_gemma":0.0007454736,"threshold_uncertainty_score":0.0074311495},"labels":[],"label_agreement":null},{"id":"W1998295128","doi":"10.1007/s00280-009-0965-1","title":"Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy","year":2009,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Ginseng Biological Effects and Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; University of British Columbia Hospital; Vancouver General Hospital","funders":"Health Canada","keywords":"Biodistribution; Pharmacokinetics; Prostate cancer; In vivo; Medicine; Cancer; Prostate; Pharmacology; Distribution (mathematics); Oncology; Internal medicine; Biology; Mathematics","score_opus":0.04347664029488311,"score_gpt":0.4315106341974881,"score_spread":0.38803399390260496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998295128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98733586,0.0020927556,0.005270211,0.00023818594,0.00008814637,0.00070750876,0.0009634345,0.000209693,0.003094149],"genre_scores_gemma":[0.9861013,0.0013573674,0.0035926767,0.00011545502,0.000035597513,0.0003112325,0.0015018225,0.0000963644,0.0068882396],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997756,0.00009399018,0.00000961254,0.00003062963,0.000047644582,0.000042447275],"domain_scores_gemma":[0.99984765,0.000027898534,0.000022460628,0.00003070847,0.000030279702,0.000041059648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007659828,0.0005043713,0.0005239939,0.000247868,0.00022690055,0.00042418932,0.00037389967,0.00028844055,0.0028629764],"category_scores_gemma":[0.0002839359,0.00020718499,0.00040433116,0.00026514864,0.0003252969,0.0003795392,0.00014674144,0.00084110216,0.00086091016],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011209764,0.004722065,0.001240289,0.00023550101,0.00007753632,0.00015607271,0.00015898501,0.0011116755,0.95267063,0.00025661607,0.0010905793,0.02707026],"study_design_scores_gemma":[0.000948267,0.058047876,0.006757853,0.000016484328,0.00017052432,0.00038651863,0.00012297665,0.0019333268,0.91955024,0.00009468343,0.011948824,0.00002236809],"about_ca_topic_score_codex":0.001307771,"about_ca_topic_score_gemma":0.002735663,"teacher_disagreement_score":0.0028629764,"about_ca_system_score_codex":0.00039997802,"about_ca_system_score_gemma":0.00058221066,"threshold_uncertainty_score":0.009577632},"labels":[],"label_agreement":null},{"id":"W1998502989","doi":"10.1007/s00280-009-1128-0","title":"N3-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU","year":2009,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; University of Calgary","funders":"Natural Science Foundation of Chongqing; National Natural Science Foundation of China","keywords":"Hepatocellular carcinoma; Metabolite; In vivo; Prodrug; Chemistry; Cell growth; Pharmacokinetics; Pharmacology; Microsome; In vitro; High-performance liquid chromatography; Fluorouracil; SN-38; Cell culture; Biochemistry; Cancer research; Medicine; Biology; Internal medicine; Chemotherapy; Chromatography; Cancer","score_opus":0.014703945578934166,"score_gpt":0.2976487523657712,"score_spread":0.28294480678683703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998502989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938379,0.0035025517,0.0018618123,0.000034940593,0.000012499545,0.000020276057,0.00011238793,0.00003170806,0.0005859713],"genre_scores_gemma":[0.99682,0.0011189753,0.0009863102,0.000017506773,0.0000071063305,0.000017326194,0.00017499954,0.0000038670255,0.0008539137],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998981,0.000020940099,0.000010303298,0.000016424492,0.000031882246,0.000022419003],"domain_scores_gemma":[0.99993515,0.0000126151135,0.000023397466,0.000008031267,0.000010655419,0.000010225935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012775272,0.00025552214,0.00021453624,0.0001372965,0.00007846706,0.00012834602,0.00011946783,0.00017685675,0.00047459724],"category_scores_gemma":[0.00010661598,0.00007063806,0.0002384951,0.00011831793,0.00010824798,0.00010923221,0.0000942367,0.00020149424,0.00015883191],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019843686,0.00003342509,0.00023833895,0.00003728273,0.0000054029338,0.000041180585,0.000007767488,0.00008588946,0.997265,0.000015676127,0.000015374037,0.00205644],"study_design_scores_gemma":[0.000024232611,0.0017783222,0.0052057737,0.000005422968,0.000021937254,0.0002009342,0.00001045779,0.00094841624,0.99085367,0.0000059428926,0.0009411846,0.0000036414267],"about_ca_topic_score_codex":0.0011090538,"about_ca_topic_score_gemma":0.0017052378,"teacher_disagreement_score":0.0011090538,"about_ca_system_score_codex":0.00019727643,"about_ca_system_score_gemma":0.00021017868,"threshold_uncertainty_score":0.002205193},"labels":[],"label_agreement":null},{"id":"W1998912113","doi":"10.1007/s00280-015-2682-2","title":"Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease","year":2015,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Immune Response and Inflammation","field":"Immunology and Microbiology","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Georgetown Hospital","funders":"National Center for Advancing Translational Sciences; National Center for Research Resources; EMD Serono; National Institutes of Health","keywords":"Medicine; FOLFIRI; Cetuximab; Irinotecan; Colorectal cancer; Gastroenterology; Folinic acid; Neutropenia; Internal medicine; Adverse effect; Phases of clinical research; Chemotherapy; Pharmacology; Cancer","score_opus":0.04090778995048399,"score_gpt":0.3827514266994293,"score_spread":0.3418436367489453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998912113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98989165,0.0019272342,0.00068284274,0.0007021414,0.00031792984,0.0028708396,0.0014268302,0.0001394257,0.0020410984],"genre_scores_gemma":[0.98449486,0.0018500418,0.001957333,0.0011794163,0.000297034,0.002731,0.0025684026,0.000043186283,0.0048787175],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99953735,0.00016806535,0.000015854192,0.00010152998,0.000029159151,0.00014798908],"domain_scores_gemma":[0.9991779,0.00011648708,0.00012291502,0.0000647135,0.00004637833,0.0004716422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013976371,0.0021516965,0.0034434618,0.0005851321,0.0007010214,0.0013519247,0.0011699721,0.0020180466,0.0069451765],"category_scores_gemma":[0.00094193954,0.0010247016,0.0021877643,0.0005146938,0.0017350479,0.0015409823,0.0004250941,0.0054258495,0.0017311004],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9017195,0.05244976,0.001586942,0.00042677336,0.00068724656,0.00008472226,0.00014552366,0.0013065437,0.008649384,0.00016388964,0.0018038551,0.030976001],"study_design_scores_gemma":[0.6360468,0.3556071,0.0045362,0.000021728805,0.0002949779,0.000075440264,0.0000650919,0.0006875652,0.0010927003,0.0001351487,0.0014089494,0.000028308128],"about_ca_topic_score_codex":0.0024234625,"about_ca_topic_score_gemma":0.0071864147,"teacher_disagreement_score":0.0069451765,"about_ca_system_score_codex":0.0014741155,"about_ca_system_score_gemma":0.0020479339,"threshold_uncertainty_score":0.02323389},"labels":[],"label_agreement":null},{"id":"W1998957272","doi":"10.1007/s00280-007-0557-x","title":"The preparation and characterization of anti-VEGFR2 conjugated, paclitaxel-loaded PLLA or PLGA microspheres for the systemic targeting of human prostate tumors","year":2007,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"PLGA; Conjugated system; Paclitaxel; Chemistry; Biophysics; Materials science; Cancer research; Pharmacology; In vitro; Medicine; Chemotherapy; Biochemistry; Surgery; Polymer; Biology; Organic chemistry","score_opus":0.01471589924344024,"score_gpt":0.31121599045389714,"score_spread":0.2965000912104569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998957272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97831887,0.0015583154,0.01799469,0.00010266977,0.000032738306,0.000106283434,0.00028699046,0.00012851295,0.0014708511],"genre_scores_gemma":[0.98743105,0.00047351184,0.008423622,0.000037610338,0.000012404371,0.00007960256,0.00024957178,0.00004803967,0.0032446282],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999908,0.000011582745,0.0000074359114,0.000025034935,0.000028854742,0.000019198118],"domain_scores_gemma":[0.9999237,0.000019960762,0.00002202779,0.000008302556,0.000013193874,0.0000127038265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024168585,0.00019210584,0.00016027539,0.00012787327,0.00015767649,0.00022007275,0.00013331103,0.0002163416,0.0006330316],"category_scores_gemma":[0.00021645695,0.00015787221,0.00013085375,0.000102320344,0.00015176971,0.00019568739,0.00009347917,0.00021339215,0.00019771159],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006667665,0.0000106741445,0.00008501397,0.000023632263,0.0000023472235,0.00002152483,0.000014407093,0.00011029885,0.9981622,0.00006123303,0.000032060125,0.0014098939],"study_design_scores_gemma":[0.0000129832515,0.00012724334,0.0010622534,0.000001473871,0.0000073766537,0.00007624432,0.000004768152,0.0009077079,0.9966428,0.000013577762,0.0011403725,0.0000032537314],"about_ca_topic_score_codex":0.0010646624,"about_ca_topic_score_gemma":0.0017294639,"teacher_disagreement_score":0.0010646624,"about_ca_system_score_codex":0.00029811074,"about_ca_system_score_gemma":0.0003415377,"threshold_uncertainty_score":0.002162993},"labels":[],"label_agreement":null},{"id":"W2000578400","doi":"10.1007/s00280-004-0888-9","title":"Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer","year":2004,"lang":"en","type":"review","venue":"Cancer Chemotherapy and Pharmacology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Irinotecan; Oxaliplatin; Medicine; Capecitabine; Colorectal cancer; Oncology; Internal medicine; Chemotherapy; Fluorouracil; Clinical trial; Cancer","score_opus":0.11949839204300174,"score_gpt":0.4833830811872288,"score_spread":0.36388468914422706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000578400","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007893482,0.99802727,0.00010529692,0.00022191856,0.00009248119,0.000028591718,0.000040708783,0.0000047672,0.00068969285],"genre_scores_gemma":[0.0022765181,0.9964864,0.00028721924,0.000470852,0.00006053062,0.000023759083,0.000066017725,0.0000016281679,0.00032711343],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9997632,0.00007351739,0.00004840277,0.00003459668,0.000060511367,0.00001976636],"domain_scores_gemma":[0.99926203,0.000419802,0.00015903795,0.00001732044,0.0001008411,0.00004090974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001530635,0.0008787305,0.0024276255,0.0012197945,0.00021326912,0.0008384846,0.0009619045,0.0008051643,0.0029386266],"category_scores_gemma":[0.0015455965,0.00026992813,0.0012005217,0.002175784,0.00035744978,0.000689373,0.0003974824,0.0012312211,0.0004998604],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019803923,0.0003007705,0.0004316288,0.06776154,0.0012849106,0.00025735443,0.000099820034,0.000610972,0.0026889448,0.0009716694,0.019337976,0.9042741],"study_design_scores_gemma":[0.0033259564,0.004300476,0.0059164804,0.02418205,0.011205995,0.0024900157,0.00025753223,0.00030738147,0.0032034407,0.0015951548,0.94314605,0.00006935551],"about_ca_topic_score_codex":0.0015392386,"about_ca_topic_score_gemma":0.0060387608,"teacher_disagreement_score":0.0029386266,"about_ca_system_score_codex":0.00066517276,"about_ca_system_score_gemma":0.0012209865,"threshold_uncertainty_score":0.009830713},"labels":[],"label_agreement":null},{"id":"W2002175782","doi":"10.1007/s00280-012-2001-0","title":"Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer","year":2012,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; European Commission","keywords":"Abiraterone acetate; Pharmacokinetics; Prednisone; Theophylline; Pharmacology; Medicine; Dextromethorphan; Prostate cancer; Bioequivalence; Internal medicine; Cancer; Androgen deprivation therapy","score_opus":0.020446399794246364,"score_gpt":0.35373694292767893,"score_spread":0.3332905431334326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002175782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962041,0.0019310977,0.00021215208,0.00032560076,0.000108617205,0.000051253726,0.00018474594,0.000065262095,0.00091720704],"genre_scores_gemma":[0.9982741,0.0006013717,0.0002478119,0.00010220379,0.0001245037,0.000021284193,0.00015473164,0.000019289479,0.0004546614],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99913114,0.0004754311,0.000060131166,0.000102667116,0.00011035623,0.00012021308],"domain_scores_gemma":[0.99774677,0.00089347525,0.00036606938,0.00015064863,0.000070973154,0.00077203993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092440454,0.0007273011,0.002112767,0.00038407475,0.00051833905,0.00090658036,0.00050143735,0.0006402798,0.0012984315],"category_scores_gemma":[0.0054206927,0.0005011807,0.0010275787,0.00060778216,0.0006530872,0.0011906554,0.0003116472,0.002799151,0.00032825206],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8094247,0.0051693437,0.035313707,0.00025939874,0.0013130385,0.0010770293,0.0006218559,0.0054358784,0.033072215,0.0002964224,0.0015415569,0.106474884],"study_design_scores_gemma":[0.11107321,0.39035597,0.42739177,0.00013514954,0.00381417,0.0045131897,0.00089971966,0.02003156,0.02983781,0.0010673844,0.010538871,0.00034119657],"about_ca_topic_score_codex":0.0028051243,"about_ca_topic_score_gemma":0.0054805405,"teacher_disagreement_score":0.0028051243,"about_ca_system_score_codex":0.00087419193,"about_ca_system_score_gemma":0.001570914,"threshold_uncertainty_score":0.006342709},"labels":[],"label_agreement":null},{"id":"W2002606479","doi":"10.1007/s00280-012-2008-6","title":"Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma","year":2012,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Pfizer","keywords":"Pemetrexed; Medicine; Sunitinib; Tolerability; Cisplatin; Lung cancer; Pharmacokinetics; Internal medicine; Mesothelioma; Oncology; Response Evaluation Criteria in Solid Tumors; Dosing; Pharmacology; Chemotherapy; Phases of clinical research; Cancer; Adverse effect; Pathology","score_opus":0.011945402496927991,"score_gpt":0.3474005889607801,"score_spread":0.3354551864638521,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002606479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987186,0.0005195221,0.00010189011,0.00008826899,0.000017086611,0.00011048649,0.00020487778,0.000025637739,0.00021356727],"genre_scores_gemma":[0.99787104,0.0005319009,0.00039132955,0.000110694025,0.000052831252,0.00013113962,0.0005358961,0.000022556085,0.000352614],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99912757,0.00036625465,0.000048357047,0.00020707848,0.000096876895,0.00015395506],"domain_scores_gemma":[0.99885297,0.00027456394,0.0002535971,0.00015481604,0.000060014983,0.0004040388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019561828,0.0015869621,0.0031941922,0.000684934,0.00059187587,0.0011604545,0.0008943353,0.0010215922,0.0017080121],"category_scores_gemma":[0.0017470922,0.00082948286,0.0020466393,0.00093978137,0.0010748294,0.0018326559,0.00036888107,0.003134283,0.00044016822],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73522425,0.05363683,0.04338948,0.00038953745,0.0036949283,0.00034326635,0.0006660779,0.007718976,0.042562805,0.00020148129,0.0022130606,0.1099593],"study_design_scores_gemma":[0.34046954,0.47523388,0.16194071,0.000033591565,0.0026275807,0.0010052035,0.000280884,0.0056031058,0.009593483,0.00034411298,0.0027446437,0.00012327696],"about_ca_topic_score_codex":0.0014632138,"about_ca_topic_score_gemma":0.0029106725,"teacher_disagreement_score":0.0031941922,"about_ca_system_score_codex":0.0014015984,"about_ca_system_score_gemma":0.0012029003,"threshold_uncertainty_score":0.010345399},"labels":[],"label_agreement":null},{"id":"W2004891108","doi":"10.1007/s00280-012-1843-9","title":"A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer","year":2012,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Occupational Cancer Research Centre; BC Cancer Agency","funders":"","keywords":"Irinotecan; Capecitabine; Medicine; Bevacizumab; Internal medicine; Neutropenia; Clinical endpoint; Colorectal cancer; Adverse effect; Phases of clinical research; Gastroenterology; Oncology; Oxaliplatin; Surgery; Chemotherapy; Cancer; Clinical trial","score_opus":0.01766081404963258,"score_gpt":0.33735710684214626,"score_spread":0.31969629279251366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004891108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948677,0.0019359462,0.00026508883,0.00033835575,0.00013451162,0.0011035545,0.00033598367,0.000029780318,0.0009891619],"genre_scores_gemma":[0.9911374,0.0023718656,0.0009846343,0.00066267117,0.0003129097,0.0014468894,0.00105722,0.000023634748,0.0020029447],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9991177,0.00046252416,0.00004108539,0.00014742557,0.00006052099,0.0001707981],"domain_scores_gemma":[0.99847573,0.0003186762,0.00020209617,0.00012747796,0.000082894076,0.00079311815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020620564,0.0016583509,0.0043833875,0.00064597634,0.000728379,0.0011113923,0.0008927402,0.0013588202,0.00349559],"category_scores_gemma":[0.0016880505,0.0011059985,0.0019801615,0.0007935106,0.0015492581,0.0014378184,0.0004395474,0.0042128623,0.00066760805],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8965161,0.05292618,0.004456385,0.00039287665,0.0011089508,0.00017814782,0.0002134384,0.0010172221,0.011681298,0.00013875462,0.0009886003,0.030382084],"study_design_scores_gemma":[0.6449855,0.34402603,0.008056203,0.00001714796,0.0004736912,0.00010594916,0.00006204568,0.0004488387,0.0007218927,0.0000723411,0.0010065185,0.000023714088],"about_ca_topic_score_codex":0.0031535667,"about_ca_topic_score_gemma":0.00848471,"teacher_disagreement_score":0.0043833875,"about_ca_system_score_codex":0.0014377575,"about_ca_system_score_gemma":0.0024413248,"threshold_uncertainty_score":0.0116939545},"labels":[],"label_agreement":null},{"id":"W2005326402","doi":"10.1007/s00280-006-0201-1","title":"A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group","year":2006,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Regional Cancer Foundation; University Health Network; Ottawa Hospital","funders":"National Cancer Institute","keywords":"Medicine; Rash; Nausea; Pharmacokinetics; Tolerability; Vomiting; Internal medicine; Toxicity; Refractory (planetary science); Cancer; Adverse effect; Neutropenia; Gastroenterology","score_opus":0.052890369095027284,"score_gpt":0.4238264113722936,"score_spread":0.3709360422772663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005326402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820983,0.0034893278,0.0007326301,0.0015338853,0.00029251384,0.0029955157,0.005031642,0.00021085625,0.0036152531],"genre_scores_gemma":[0.95731,0.006821519,0.0044529913,0.0042580715,0.0008830652,0.004107647,0.01034368,0.00023922969,0.011583726],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99910647,0.000518574,0.000025162877,0.00007682339,0.000061406805,0.00021148457],"domain_scores_gemma":[0.9980209,0.0004409092,0.00028673824,0.00018310461,0.00010145303,0.0009668495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003374349,0.0038032783,0.005503584,0.0011141235,0.0010082019,0.0015724674,0.0016543524,0.0023024937,0.0058427937],"category_scores_gemma":[0.0019039777,0.0014905491,0.0037368827,0.00091986125,0.0022286356,0.001337117,0.0004870642,0.0067013493,0.0023278012],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8601869,0.05550016,0.008056303,0.00066845043,0.001784641,0.0003635375,0.0003986288,0.0019232599,0.015378473,0.00045657926,0.010773422,0.044509698],"study_design_scores_gemma":[0.78407717,0.20177375,0.008786118,0.00003247091,0.0006605472,0.00022461706,0.00007945528,0.0006241667,0.0013323469,0.00017953094,0.0021857708,0.000044119854],"about_ca_topic_score_codex":0.0033642696,"about_ca_topic_score_gemma":0.009124094,"teacher_disagreement_score":0.0058427937,"about_ca_system_score_codex":0.0014085672,"about_ca_system_score_gemma":0.0031281344,"threshold_uncertainty_score":0.019546151},"labels":[],"label_agreement":null},{"id":"W2007098763","doi":"10.1007/s00280-008-0865-9","title":"Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus","year":2008,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Temsirolimus; Pharmacology; Desipramine; Pharmacokinetics; CYP2D6; Medicine; Drug interaction; CYP3A4; Metabolite; Internal medicine; Cytochrome P450; Chemistry; PI3K/AKT/mTOR pathway; Discovery and development of mTOR inhibitors; Metabolism","score_opus":0.016624250316955975,"score_gpt":0.276635116532381,"score_spread":0.260010866215425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007098763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99759406,0.0006411976,0.0007139453,0.00008424811,0.000033875553,0.000022051,0.00013723708,0.00005912769,0.0007142852],"genre_scores_gemma":[0.99841726,0.00024430483,0.00053642906,0.0000317301,0.000026200794,0.000009355153,0.00013126197,0.0000114691275,0.00059195363],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998266,0.00007059449,0.000011511669,0.000030230476,0.00003039282,0.00003064513],"domain_scores_gemma":[0.999843,0.000028652945,0.000055357028,0.000015945892,0.000013403416,0.000043770637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015050883,0.00025639238,0.00057028607,0.00016718566,0.00013716341,0.00041518355,0.00013117869,0.00026683457,0.0009151733],"category_scores_gemma":[0.00046313062,0.00015883645,0.00020193007,0.00018635436,0.00018760466,0.00030724297,0.00008691711,0.00062255707,0.00025278082],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.105151564,0.001337295,0.01968349,0.00018296558,0.00051514216,0.0013754992,0.00024001111,0.001537593,0.77036214,0.00041991245,0.0016656076,0.097528785],"study_design_scores_gemma":[0.0028495584,0.051592316,0.094923116,0.000038228485,0.0009188097,0.005146629,0.000305876,0.016506612,0.8165754,0.00024354915,0.010838647,0.00006127426],"about_ca_topic_score_codex":0.00094062876,"about_ca_topic_score_gemma":0.0014733004,"teacher_disagreement_score":0.00094062876,"about_ca_system_score_codex":0.0002958375,"about_ca_system_score_gemma":0.00041403837,"threshold_uncertainty_score":0.003061533},"labels":[],"label_agreement":null},{"id":"W2010348633","doi":"10.1007/s00280-003-0619-7","title":"Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide","year":2003,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Dexrazoxane; Pharmacology; Pharmacokinetics; Etoposide; Chemistry; Medicine; Chemotherapy; Cancer; Internal medicine; Breast cancer","score_opus":0.01904655638343964,"score_gpt":0.31370586718684657,"score_spread":0.2946593108034069,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010348633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99821436,0.0011293851,0.00015951035,0.000044495322,0.000012334948,0.000011386256,0.00007198511,0.00001241951,0.0003441542],"genre_scores_gemma":[0.9993211,0.00022101069,0.00015472413,0.000015888703,0.000005643334,0.000003867087,0.00009053996,0.000003117853,0.00018420843],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998342,0.00009375308,0.000010950475,0.00001927836,0.000016452253,0.000025370235],"domain_scores_gemma":[0.9998603,0.000027873622,0.00004442132,0.000016169983,0.00001243917,0.000038754606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022939908,0.00030421917,0.00061722036,0.00021542113,0.0001660136,0.00024505594,0.0002145217,0.00037121004,0.001159073],"category_scores_gemma":[0.000476048,0.00018875858,0.00027216345,0.00017878164,0.00023287414,0.00023398073,0.00012410767,0.00048708302,0.0001828742],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15095338,0.00073589256,0.059451967,0.00023319591,0.00047634883,0.0039264015,0.00055740605,0.0018398534,0.7374977,0.00036730868,0.00065056037,0.043309998],"study_design_scores_gemma":[0.0037341984,0.0542219,0.29333383,0.000056492147,0.0008743806,0.009080141,0.00080172886,0.009684943,0.62275213,0.00022335298,0.0051706643,0.00006634707],"about_ca_topic_score_codex":0.001005041,"about_ca_topic_score_gemma":0.0010904304,"teacher_disagreement_score":0.001159073,"about_ca_system_score_codex":0.0002588908,"about_ca_system_score_gemma":0.00025520514,"threshold_uncertainty_score":0.003877461},"labels":[],"label_agreement":null},{"id":"W2010805828","doi":"10.1007/s00280-010-1532-5","title":"Primary tumor and patient characteristics in breast cancer as predictors of adjuvant therapy regimen: a regression model","year":2010,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McMaster University","funders":"","keywords":"Medicine; Breast cancer; Regimen; Internal medicine; Odds ratio; Oncology; Logistic regression; Confidence interval; Chemotherapy; Hormonal therapy; Stage (stratigraphy); Univariate analysis; Multivariate analysis; Chemotherapy regimen; Adjuvant therapy; Cancer; Surgery","score_opus":0.006683265854655013,"score_gpt":0.2763086582364524,"score_spread":0.2696253923817974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010805828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97787994,0.0026236477,0.01306314,0.0016233675,0.00037041007,0.00014621437,0.0026925737,0.00037504127,0.0012256749],"genre_scores_gemma":[0.98623925,0.0008626797,0.0030931423,0.00018062617,0.00030349343,0.00024014949,0.0016773404,0.00013076863,0.0072725564],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99322456,0.0047398186,0.00029302106,0.00083769154,0.00036686327,0.00053800945],"domain_scores_gemma":[0.9652938,0.028575156,0.0016030916,0.0020828512,0.0010604851,0.0013845476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013494601,0.0033706594,0.0034812714,0.0020755443,0.0010249736,0.0023095324,0.004615821,0.0030841029,0.008036414],"category_scores_gemma":[0.014149194,0.0017621206,0.0050424826,0.0020657827,0.00094975857,0.0016538721,0.0013823332,0.006020579,0.0021038775],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043549795,0.0038215006,0.8240827,0.0003503294,0.017965164,0.0011474421,0.00047862346,0.07101633,0.003032038,0.0013562021,0.006495038,0.026704885],"study_design_scores_gemma":[0.002780557,0.006402516,0.31126785,0.00020950478,0.013179244,0.0014062689,0.0007783494,0.6551473,0.0017022826,0.0028495626,0.0040271976,0.0002493198],"about_ca_topic_score_codex":0.014227902,"about_ca_topic_score_gemma":0.0065000067,"teacher_disagreement_score":0.014227902,"about_ca_system_score_codex":0.0008132062,"about_ca_system_score_gemma":0.0029721034,"threshold_uncertainty_score":0.071367085},"labels":[],"label_agreement":null},{"id":"W2010993787","doi":"10.1007/s00280-012-1867-1","title":"The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas","year":2012,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Center for Research Resources; National Cancer Institute","keywords":"Temozolomide; Bevacizumab; Glioma; Medicine; U87; Glioblastoma; Oncology; Internal medicine; Cancer research; Pharmacology; Chemotherapy","score_opus":0.020777456025469033,"score_gpt":0.3745197170617356,"score_spread":0.35374226103626655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010993787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99538827,0.0027301493,0.00021264896,0.00016425924,0.00004470131,0.0000118982425,0.00013263836,0.000026221143,0.0012891325],"genre_scores_gemma":[0.9980558,0.0007890968,0.0002063988,0.00003937147,0.000024420227,0.000008313969,0.00017565687,0.000011132272,0.0006898442],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9997819,0.00006794823,0.000011805673,0.0000180265,0.000050418912,0.000069954476],"domain_scores_gemma":[0.99982435,0.000061071994,0.000034223147,0.000013610107,0.00002723495,0.00003946682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020500182,0.00023362895,0.00050480367,0.0002210778,0.00014215628,0.0005071766,0.00023440678,0.00029106328,0.0010146159],"category_scores_gemma":[0.0008485428,0.0001594173,0.00021155228,0.00023567092,0.00022449491,0.00037480955,0.00016502688,0.0006252206,0.00019017672],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.073314466,0.0018444987,0.009505262,0.0002081165,0.0003460984,0.00045224885,0.00017612998,0.002423067,0.7788222,0.0005174014,0.0024160019,0.12997447],"study_design_scores_gemma":[0.001707631,0.03457578,0.13383718,0.00003711503,0.000712663,0.0012003313,0.00027958312,0.011319597,0.8065183,0.00042912504,0.009321972,0.000060795002],"about_ca_topic_score_codex":0.0070484937,"about_ca_topic_score_gemma":0.01343501,"teacher_disagreement_score":0.0070484937,"about_ca_system_score_codex":0.00062322436,"about_ca_system_score_gemma":0.0006095852,"threshold_uncertainty_score":0.0140149},"labels":[],"label_agreement":null},{"id":"W2011760818","doi":"10.1007/s00280-013-2126-9","title":"A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies","year":2013,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; Carboplatin; Pharmacokinetics; Neutropenia; Pharmacodynamics; Rash; Febrile neutropenia; Adverse effect; Internal medicine; Nausea; Lung cancer; Gastroenterology; Mucositis; Pharmacology; Chemotherapy","score_opus":0.02949049664627675,"score_gpt":0.38000288019242273,"score_spread":0.350512383546146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011760818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99469745,0.0008038804,0.00044298344,0.00037691617,0.000084719126,0.0015273246,0.00061715255,0.000095477,0.0013541124],"genre_scores_gemma":[0.9905065,0.0009249137,0.002092339,0.0007284257,0.00017986761,0.0016913412,0.0017712995,0.00005140154,0.0020541332],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9991773,0.00040746888,0.000038458427,0.00014948187,0.00007448985,0.0001528399],"domain_scores_gemma":[0.99874663,0.00018307532,0.00022328453,0.00010214389,0.000054884003,0.0006900465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018261726,0.0019407388,0.0026927192,0.00066677475,0.0006032429,0.0011441747,0.0012605992,0.0018127796,0.0038084723],"category_scores_gemma":[0.0014811694,0.00075240363,0.0013499234,0.00082823733,0.0020064646,0.001615822,0.0004917676,0.004582922,0.0010304992],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8646362,0.051483676,0.0036480525,0.00026180982,0.00085325283,0.0001708709,0.00021423961,0.0020712414,0.02682746,0.00040499851,0.0019693612,0.047458835],"study_design_scores_gemma":[0.5477063,0.44001105,0.0057363193,0.000014581733,0.00033108666,0.00018835816,0.000036934962,0.001199718,0.0033032678,0.00022243471,0.001222293,0.000027713153],"about_ca_topic_score_codex":0.0016267828,"about_ca_topic_score_gemma":0.003055126,"teacher_disagreement_score":0.0038084723,"about_ca_system_score_codex":0.0014758053,"about_ca_system_score_gemma":0.0023814167,"threshold_uncertainty_score":0.012740612},"labels":[],"label_agreement":null},{"id":"W2014514137","doi":"10.1007/s00280-005-0155-8","title":"Antiproliferative and Antiproteolytic activity of Pentoxifylline in cultures of B16F10 Melanoma cells","year":2005,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Protease and Inhibitor Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Pentoxifylline; Chemistry; Matrix metalloproteinase; Pharmacology; Zymography; Extracellular matrix; MTT assay; Cell adhesion; Cell growth; In vitro; Cytotoxicity; Cell culture; Molecular biology; Cell; Biochemistry; Biology","score_opus":0.008637095251625556,"score_gpt":0.2991862646148014,"score_spread":0.2905491693631759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014514137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99211794,0.0035187437,0.0010658039,0.00010978841,0.000055757522,0.0000308199,0.0007028636,0.000039339262,0.0023589812],"genre_scores_gemma":[0.9911986,0.0024176287,0.0015850827,0.000056374323,0.000028226154,0.000039149734,0.0012677198,0.000016480193,0.0033906403],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998424,0.00003254046,0.00001917664,0.000021188825,0.00003422148,0.00005045202],"domain_scores_gemma":[0.99985635,0.00004700792,0.000020940302,0.000024774055,0.000019329045,0.000031612435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017151823,0.0003503838,0.00035819376,0.00022481449,0.00016131936,0.00022071112,0.00016954633,0.00021037496,0.0010460886],"category_scores_gemma":[0.00012328473,0.00013245332,0.00023410367,0.00025690574,0.00015890949,0.00019575718,0.000107194704,0.0005427224,0.0002688622],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027736486,0.000034884382,0.000118747856,0.000028657068,0.0000039029537,0.000062236366,0.000019974288,0.000045300512,0.9984652,0.0000311645,0.00003784639,0.00087478093],"study_design_scores_gemma":[0.00001492188,0.00047594754,0.0029971655,0.000003718975,0.000008768156,0.0001276658,0.000023161678,0.00022075402,0.99527377,0.000009330307,0.0008430103,0.000001770506],"about_ca_topic_score_codex":0.0024034325,"about_ca_topic_score_gemma":0.0027806647,"teacher_disagreement_score":0.0024034325,"about_ca_system_score_codex":0.0002221508,"about_ca_system_score_gemma":0.00024086943,"threshold_uncertainty_score":0.0047789216},"labels":[],"label_agreement":null},{"id":"W2014573616","doi":"10.1007/s00280-004-0947-2","title":"Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models","year":2005,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":156,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Geldanamycin; Hsp90; Heat shock protein; Hsp90 inhibitor; Cancer research; Clonogenic assay; Melanoma; Chemistry; In vitro; Biology; Biochemistry","score_opus":0.028818357196587374,"score_gpt":0.3692101097795229,"score_spread":0.3403917525829355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014573616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99243367,0.005066962,0.00084632344,0.000084242965,0.00008283421,0.000035855363,0.00036850243,0.000058805792,0.0010229221],"genre_scores_gemma":[0.9906747,0.0036047362,0.0024270301,0.000043189393,0.00003266676,0.00006230718,0.0008988623,0.000026773821,0.0022298053],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998134,0.000044859717,0.00002335489,0.000024028857,0.000035137902,0.000059229627],"domain_scores_gemma":[0.9996321,0.00010536059,0.000061569444,0.00004978709,0.000042578413,0.00010857423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030742667,0.0005016044,0.00071292784,0.0003574912,0.00019501125,0.00019682587,0.00031894777,0.00037017852,0.0012773691],"category_scores_gemma":[0.00028026736,0.00026125408,0.00048866693,0.00025646327,0.00021071121,0.00022436332,0.00015755356,0.0005052174,0.00035133073],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002585997,0.00020149226,0.00033931268,0.000122056554,0.000037405356,0.000053305426,0.000040907693,0.0003133358,0.9917794,0.00008087135,0.000080793325,0.0043652127],"study_design_scores_gemma":[0.000058277783,0.002446244,0.001965469,0.0000052062883,0.000038134673,0.00013618548,0.000016561748,0.0002425917,0.9937164,0.000020937287,0.0013484497,0.000005473477],"about_ca_topic_score_codex":0.0010586996,"about_ca_topic_score_gemma":0.0019188649,"teacher_disagreement_score":0.0012773691,"about_ca_system_score_codex":0.00029024552,"about_ca_system_score_gemma":0.00042559867,"threshold_uncertainty_score":0.004273176},"labels":[],"label_agreement":null},{"id":"W2015268376","doi":"10.1007/s00280-011-1679-8","title":"Hematologic adverse events associated with temozolomide","year":2011,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Pancytopenia; Medicine; Aplastic anemia; Internal medicine; Adverse effect; Myelodysplastic syndromes; Temozolomide; Bone marrow suppression; Bone marrow failure; Bone Marrow Aplasia; Pediatrics; Surgery; Bone marrow; Chemotherapy","score_opus":0.04505727237691332,"score_gpt":0.3367991244967081,"score_spread":0.2917418521197948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015268376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9754612,0.012389515,0.0016678035,0.000426324,0.00006814882,0.00010192867,0.00046600858,0.000056230478,0.009362795],"genre_scores_gemma":[0.9956727,0.0020506636,0.0006435492,0.00023754663,0.000042614265,0.000025085248,0.00020014576,0.0000057793814,0.0011220352],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9997191,0.00012800044,0.000033642948,0.000013775642,0.000079840946,0.00002565422],"domain_scores_gemma":[0.99925524,0.0002497555,0.00030449772,0.000031671676,0.000082955936,0.000075909484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042321027,0.00013643515,0.00025551533,0.00016630656,0.00018947157,0.0001787242,0.00012650617,0.00014502463,0.0012813782],"category_scores_gemma":[0.0013728713,0.00005295344,0.0003148333,0.00028867632,0.00010076568,0.000118278556,0.00015075719,0.0005670911,0.000094951196],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02330428,0.0012766144,0.2477126,0.0015559698,0.0016876158,0.009939558,0.00020823002,0.0021544606,0.10198107,0.0011467664,0.005893134,0.60313964],"study_design_scores_gemma":[0.0010716288,0.011784785,0.8914546,0.00016045751,0.0009819947,0.022890503,0.00016035562,0.0023238263,0.03510751,0.00044118476,0.03359559,0.00002760517],"about_ca_topic_score_codex":0.0012264444,"about_ca_topic_score_gemma":0.0038647347,"teacher_disagreement_score":0.0012813782,"about_ca_system_score_codex":0.0004194919,"about_ca_system_score_gemma":0.00028931227,"threshold_uncertainty_score":0.004286647},"labels":[],"label_agreement":null},{"id":"W2016501792","doi":"10.1007/s002800050037","title":"Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: abrogation of S/G 2 arrest","year":2000,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Camptothecin; Cytotoxicity; Cancer research; Pharmacology; Breast cancer; Chemistry; Medicine; Cancer; Internal medicine; In vitro; Biochemistry","score_opus":0.009885625366621123,"score_gpt":0.28713966258694773,"score_spread":0.2772540372203266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016501792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99421954,0.0013498011,0.0007994947,0.00022077818,0.00006017985,0.00008106971,0.0004474416,0.0001232234,0.0026985044],"genre_scores_gemma":[0.994399,0.0011040112,0.0010714061,0.0000556361,0.0000150289625,0.00006814565,0.00058502617,0.000022388776,0.0026793417],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99983954,0.000031066676,0.000018461262,0.000016033426,0.00003820676,0.00005663787],"domain_scores_gemma":[0.99984574,0.000049492734,0.000021290416,0.000032204734,0.00001772145,0.00003338476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018803071,0.00042071313,0.00045872707,0.00036217205,0.00031228366,0.00033453555,0.00034061537,0.00039479233,0.0018457333],"category_scores_gemma":[0.00021914138,0.00021008632,0.0002730893,0.00037381667,0.00038517304,0.00024345235,0.00017288367,0.000978378,0.0003759031],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005264302,0.00014517331,0.00013952384,0.00006297162,0.0000067726437,0.0000911994,0.000043795862,0.00019400935,0.9960382,0.00022160812,0.00012372131,0.0024065373],"study_design_scores_gemma":[0.00003349514,0.00034582854,0.0014384527,0.000004337031,0.0000061369,0.00010977399,0.000019294532,0.0004143309,0.9965018,0.00001623703,0.0011075959,0.000002716494],"about_ca_topic_score_codex":0.0037951733,"about_ca_topic_score_gemma":0.005451764,"teacher_disagreement_score":0.0037951733,"about_ca_system_score_codex":0.0006689679,"about_ca_system_score_gemma":0.000752971,"threshold_uncertainty_score":0.0075461864},"labels":[],"label_agreement":null},{"id":"W2016651596","doi":"10.1007/s00280-010-1499-2","title":"The uptake of paclitaxel and docetaxel into ex vivo porcine bladder tissue from polymeric micelle formulations","year":2010,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Docetaxel; Paclitaxel; Ex vivo; In vivo; Micelle; Pharmacology; Chemistry; Pharmacokinetics; Cancer research; Chemotherapy; Medicine; Internal medicine; Biology; Biotechnology","score_opus":0.01197922883307866,"score_gpt":0.3274978254427914,"score_spread":0.3155185966097127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016651596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99261624,0.0015069643,0.0037645735,0.000076116026,0.00002462945,0.000023175211,0.00013994898,0.000025251757,0.0018231471],"genre_scores_gemma":[0.9933329,0.0007916669,0.0018136193,0.000051843628,0.000009045083,0.000019748684,0.00023614352,0.000025734429,0.0037194018],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998796,0.000022024697,0.000006695427,0.000031024723,0.00002355876,0.00003703179],"domain_scores_gemma":[0.999876,0.000055761066,0.000027524948,0.000008815129,0.000018297418,0.000013516679],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025255754,0.00022506286,0.00016235885,0.00016049118,0.00015217313,0.0003654292,0.00017659555,0.00031353664,0.00094622053],"category_scores_gemma":[0.0002783113,0.00015988738,0.0002627083,0.00014163536,0.00021431338,0.00048225705,0.00013024763,0.00048040255,0.00027854464],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003714244,0.00002415394,0.00015048879,0.000051426443,0.0000065599543,0.00006829387,0.00004702443,0.0002906568,0.997001,0.00008219474,0.000032287808,0.0018745065],"study_design_scores_gemma":[0.000013312591,0.0005594352,0.0013223058,0.0000068758172,0.000023856934,0.00010901702,0.000043135966,0.0017192297,0.99512416,0.00002071582,0.0010513274,0.000006622841],"about_ca_topic_score_codex":0.0015860904,"about_ca_topic_score_gemma":0.0010435013,"teacher_disagreement_score":0.0015860904,"about_ca_system_score_codex":0.00030383107,"about_ca_system_score_gemma":0.00024208761,"threshold_uncertainty_score":0.0031654239},"labels":[],"label_agreement":null},{"id":"W2017811988","doi":"10.1007/s00280-008-0743-5","title":"A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites","year":2008,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"Eli Lilly and Company","keywords":"Gemcitabine; Medicine; Pancreatic cancer; Tolerability; Pharmacokinetics; Perfusion; Urology; Extracorporeal; Internal medicine; Chemotherapy; Cancer; Adverse effect","score_opus":0.020385617590590877,"score_gpt":0.3470636198025388,"score_spread":0.3266780022119479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017811988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99764913,0.00043707405,0.00039219423,0.00015541715,0.00004389557,0.0004837263,0.00019748684,0.000028940245,0.0006121583],"genre_scores_gemma":[0.99637765,0.0006485441,0.00081397337,0.00024870422,0.00011280974,0.0006011768,0.00045043646,0.000028729677,0.0007179704],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99942696,0.00029005963,0.000015982367,0.00010036389,0.000038186772,0.00012843398],"domain_scores_gemma":[0.99907315,0.00021265335,0.00015868628,0.00012408102,0.000032627377,0.00039877984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010528187,0.0013534604,0.002355131,0.00046904804,0.00065956154,0.0010349251,0.0008809016,0.0010900104,0.0021336784],"category_scores_gemma":[0.0011724248,0.0007336225,0.0011094227,0.0006848279,0.001500227,0.0013097591,0.00041294453,0.0037994226,0.00045953097],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.721301,0.1177601,0.008929646,0.00045968706,0.0010651996,0.00054348004,0.0007548849,0.0062743356,0.065679915,0.00059904595,0.0026141508,0.07401852],"study_design_scores_gemma":[0.26566842,0.7069313,0.01382285,0.000022207289,0.00043489077,0.00041047973,0.00018212818,0.0023911775,0.007244116,0.00021911145,0.0026164004,0.00005689731],"about_ca_topic_score_codex":0.0016477619,"about_ca_topic_score_gemma":0.002477457,"teacher_disagreement_score":0.002355131,"about_ca_system_score_codex":0.001051423,"about_ca_system_score_gemma":0.001767984,"threshold_uncertainty_score":0.0076286793},"labels":[],"label_agreement":null},{"id":"W2017908039","doi":"10.1007/s00280-013-2176-z","title":"Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues","year":2013,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Topotecan; Mitoxantrone; Doxorubicin; Pharmacology; Medicine; Distribution (mathematics); Anticancer drug; Chemotherapy; Drug; Cancer research; Internal medicine","score_opus":0.005373125667298539,"score_gpt":0.2637172799360422,"score_spread":0.2583441542687437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017908039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9699543,0.014714527,0.0049613835,0.0002034528,0.00004394272,0.000026982216,0.00090979045,0.00012608503,0.009059502],"genre_scores_gemma":[0.9877296,0.00349966,0.0015976469,0.000039594514,0.000018220831,0.000037593807,0.0005521375,0.000037711372,0.006487663],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998299,0.000031383093,0.000011205289,0.00004364868,0.00003995569,0.0000438853],"domain_scores_gemma":[0.9998197,0.00004816017,0.00002116972,0.000013271497,0.000040787887,0.00005686915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013943636,0.00015336806,0.00022215227,0.0009049778,0.00024772837,0.00051106984,0.00022506608,0.00020565886,0.0018334499],"category_scores_gemma":[0.0002726733,0.0001907666,0.00013516666,0.0004750888,0.00030956103,0.00037996442,0.0001957191,0.0003751497,0.0003891226],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016718501,0.000035622586,0.0043696812,0.00014632333,0.000037960643,0.00024420724,0.000089780755,0.0003290213,0.97281355,0.0015088891,0.00026213983,0.01849101],"study_design_scores_gemma":[0.00006163873,0.0010468531,0.13097297,0.000028597175,0.000117817384,0.0020743513,0.0004403467,0.0023031295,0.8470666,0.00073787913,0.015121386,0.000028410752],"about_ca_topic_score_codex":0.0028552036,"about_ca_topic_score_gemma":0.0017387534,"teacher_disagreement_score":0.0028552036,"about_ca_system_score_codex":0.00063679664,"about_ca_system_score_gemma":0.0006136985,"threshold_uncertainty_score":0.006133437},"labels":[],"label_agreement":null},{"id":"W2018133817","doi":"10.1007/s00280-010-1442-6","title":"Cell cycle and apoptosis regulatory protein (CARP)-1 is a novel, adriamycin-inducible, diffuse large B-cell lymphoma (DLBL) growth suppressor","year":2010,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Cancer Institute","keywords":"Cancer research; Apoptosis; Biology; CHOP; Cell growth; Growth inhibition; Lymphoma; Immunology; Biochemistry","score_opus":0.009250837476188,"score_gpt":0.2699156145872909,"score_spread":0.2606647771111029,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018133817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815832,0.0057933726,0.0069764787,0.0005625018,0.000114309085,0.00006825141,0.0005496009,0.00047595825,0.0038762817],"genre_scores_gemma":[0.9860389,0.001688713,0.004400052,0.00012466266,0.00003885779,0.000053348766,0.0011351471,0.000044659577,0.0064756107],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998598,0.00001289098,0.000008675931,0.000037160753,0.00005609506,0.000025282916],"domain_scores_gemma":[0.9998989,0.000014438671,0.000035060606,0.000010014098,0.000011295117,0.000030240042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014459604,0.00042537658,0.0002591963,0.00037077838,0.00031467518,0.00048675714,0.0004203469,0.00034023434,0.00086685363],"category_scores_gemma":[0.00019534603,0.0001557817,0.00018760968,0.00020418133,0.00039669432,0.00021785621,0.0002691364,0.0008329394,0.0004313631],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018179358,0.000035867608,0.0004243302,0.00003695496,0.000004996476,0.00027563627,0.00000929507,0.00014111055,0.9948396,0.00034667092,0.00025784347,0.0034458512],"study_design_scores_gemma":[0.00011708671,0.00065801106,0.007219901,0.000013047319,0.000045480854,0.0046798433,0.00003793691,0.0026566205,0.96555626,0.00022524953,0.01877759,0.00001299675],"about_ca_topic_score_codex":0.0003431521,"about_ca_topic_score_gemma":0.0005911444,"teacher_disagreement_score":0.00086685363,"about_ca_system_score_codex":0.00071685377,"about_ca_system_score_gemma":0.00038230175,"threshold_uncertainty_score":0.005201161},"labels":[],"label_agreement":null},{"id":"W2018801391","doi":"10.1007/s00280-010-1512-9","title":"Metastatic gastrointestinal stromal tumors","year":2010,"lang":"en","type":"review","venue":"Cancer Chemotherapy and Pharmacology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; Centre Hospitalier de l’Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"Stromal cell; Medicine; GiST; Cancer research; Pathology; Internal medicine; Oncology","score_opus":0.07303234549703767,"score_gpt":0.43347715911941015,"score_spread":0.36044481362237246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018801391","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023965476,0.9975057,0.00013720398,0.00019001604,0.00026674272,0.000009519594,0.000030137186,0.000009599566,0.0016113677],"genre_scores_gemma":[0.0015315041,0.99611855,0.0001769778,0.00026479538,0.00027301023,0.000008728249,0.00005471318,0.0000013677296,0.0015703397],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999897,0.000016557127,0.000017988335,0.000018458204,0.000037543934,0.000012453894],"domain_scores_gemma":[0.99986637,0.00004608629,0.000038301947,0.000005671887,0.0000287769,0.000014832204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024009787,0.0008570318,0.0014791864,0.0020051436,0.00020032113,0.00064946606,0.00047472687,0.00051349204,0.005207752],"category_scores_gemma":[0.00042918883,0.00025466795,0.000406683,0.0018635464,0.0002936048,0.00086897984,0.0005814407,0.0010670455,0.0018752668],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009461234,0.00006235931,0.00013788376,0.012362185,0.0000786945,0.00030260996,0.000020839982,0.00025648248,0.0020807819,0.00069039984,0.030181706,0.9537315],"study_design_scores_gemma":[0.000075826065,0.00021140516,0.0013015384,0.003303568,0.00033024122,0.0036607657,0.00003920378,0.00014010041,0.00095200166,0.0006611807,0.9893066,0.00001766549],"about_ca_topic_score_codex":0.0008455677,"about_ca_topic_score_gemma":0.0032126368,"teacher_disagreement_score":0.005207752,"about_ca_system_score_codex":0.00038400994,"about_ca_system_score_gemma":0.00070043304,"threshold_uncertainty_score":0.017421663},"labels":[],"label_agreement":null},{"id":"W2020299781","doi":"10.1007/s00280-011-1671-3","title":"PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma","year":2011,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Aldose Reductase and Taurine","field":"Biochemistry, Genetics and Molecular Biology","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact","funders":"","keywords":"Sorafenib; Hepatocellular carcinoma; Medicine; Neutropenia; Internal medicine; Gastroenterology; Discontinuation; Liver function; Cohort; Pharmacokinetics; Pharmacology; Oncology; Toxicity","score_opus":0.011152513875904433,"score_gpt":0.24495265218455115,"score_spread":0.2338001383086467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020299781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99220157,0.0053593563,0.00018065581,0.0004808134,0.00012543508,0.00008137517,0.00014341377,0.000034679237,0.0013927122],"genre_scores_gemma":[0.99748707,0.0013848391,0.00018595952,0.00018090305,0.0000829383,0.000038700102,0.00021937105,0.000003913663,0.00041634074],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99973303,0.00011444354,0.000030767682,0.00003211144,0.000028332273,0.0000613177],"domain_scores_gemma":[0.99964535,0.000090398906,0.00006724555,0.000017958717,0.000021226551,0.00015781538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005779576,0.00057075184,0.002026519,0.00029694405,0.00029968575,0.0004978478,0.00025133172,0.00039802067,0.0013440799],"category_scores_gemma":[0.0010441645,0.00026869666,0.001121003,0.00048369804,0.00026166014,0.00066763064,0.00026359118,0.001207578,0.00022843001],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48868316,0.0053037726,0.14665084,0.0015728878,0.0032410321,0.0030028822,0.00040988458,0.004032022,0.019390129,0.00041341604,0.003464634,0.3238353],"study_design_scores_gemma":[0.1147435,0.25607258,0.5892162,0.0002775402,0.0063217874,0.005783516,0.0007995273,0.0070220586,0.0057087406,0.0012932558,0.012588972,0.00017231778],"about_ca_topic_score_codex":0.0009629636,"about_ca_topic_score_gemma":0.0025959231,"teacher_disagreement_score":0.002026519,"about_ca_system_score_codex":0.00050188013,"about_ca_system_score_gemma":0.0006761199,"threshold_uncertainty_score":0.0044963956},"labels":[],"label_agreement":null},{"id":"W2020371671","doi":"10.1007/s00280-013-2229-3","title":"Scheduling of paclitaxel and gefitinib to inhibit repopulation for optimal treatment of human cancer cells and xenografts that overexpress the epidermal growth factor receptor","year":2013,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Canadian Institutes of Health Research","keywords":"Gefitinib; Paclitaxel; Epidermal growth factor receptor; Cancer research; Chemotherapy; Medicine; Pharmacology; Cell cycle; Cancer; Oncology; Biology; Internal medicine","score_opus":0.0884284157506157,"score_gpt":0.4195852517613815,"score_spread":0.3311568360107658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020371671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96285814,0.003281766,0.021319678,0.00064186426,0.00081279466,0.00077276776,0.0008762379,0.00080080645,0.008635915],"genre_scores_gemma":[0.98424685,0.0006675245,0.0107510425,0.00017092172,0.00008544419,0.00027550964,0.00060247356,0.00011313472,0.0030871173],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99981254,0.000023724513,0.000014147328,0.00003981221,0.000044297656,0.00006543137],"domain_scores_gemma":[0.99986553,0.000023175831,0.00002617869,0.000016824555,0.000021407583,0.000046820976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021179143,0.0003886685,0.0006656925,0.00042463237,0.00040787397,0.00040394414,0.0003797243,0.00028578864,0.0037588582],"category_scores_gemma":[0.00045322414,0.00021749256,0.00039233227,0.0004191172,0.00018338232,0.00037843437,0.00017469985,0.0006538355,0.0007081952],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022749951,0.0032639743,0.0040968396,0.00022102385,0.00010958411,0.00021557153,0.00011721416,0.0154640535,0.8222279,0.0020163897,0.007207443,0.12231007],"study_design_scores_gemma":[0.0012069298,0.0110957995,0.016150814,0.000017189219,0.00022110256,0.000512928,0.00012364417,0.027479906,0.92151874,0.0012425525,0.020345606,0.00008481479],"about_ca_topic_score_codex":0.0013870529,"about_ca_topic_score_gemma":0.0042784093,"teacher_disagreement_score":0.0037588582,"about_ca_system_score_codex":0.0009729258,"about_ca_system_score_gemma":0.0013609651,"threshold_uncertainty_score":0.012574613},"labels":[],"label_agreement":null},{"id":"W2020714490","doi":"10.1007/s00280-010-1410-1","title":"A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies","year":2010,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Howard Hughes Medical Institute; Sidney Kimmel Comprehensive Cancer Center; National Center for Research Resources; Alvin J. Siteman Cancer Center; Johns Hopkins University","keywords":"Irinotecan; Medicine; Pharmacokinetics; Pharmacodynamics; Internal medicine; Gastroenterology; Pharmacology; Urology; Colorectal cancer; Cancer","score_opus":0.008558402501655257,"score_gpt":0.29609063095178156,"score_spread":0.2875322284501263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020714490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99550617,0.0015111024,0.00039987187,0.00019290695,0.00004014926,0.0012485579,0.00026793385,0.000052055402,0.00078133505],"genre_scores_gemma":[0.99167836,0.0015824554,0.0018708078,0.0003909675,0.00009334666,0.0015190905,0.0012670512,0.00002518069,0.0015728179],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9993455,0.00031028458,0.000029464567,0.00013690037,0.00007682075,0.00010100034],"domain_scores_gemma":[0.9993729,0.00008496964,0.00014528671,0.000053572872,0.000036574067,0.00030664998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012766412,0.0015603431,0.0022425458,0.00046109068,0.0005146735,0.0008150833,0.0009804374,0.0009811429,0.0027262282],"category_scores_gemma":[0.00086517853,0.00064479845,0.0010654746,0.00048511187,0.0011890267,0.0007830301,0.00037580548,0.00277667,0.0005775958],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5029773,0.14029722,0.020226106,0.0014240458,0.002113711,0.0010501422,0.00079078844,0.007882138,0.1469327,0.00038949866,0.004394677,0.17152162],"study_design_scores_gemma":[0.22517599,0.73834217,0.018012503,0.00004069447,0.00047547015,0.0009834998,0.0000881371,0.002052579,0.011263607,0.000115352304,0.0034132714,0.000036714497],"about_ca_topic_score_codex":0.000990313,"about_ca_topic_score_gemma":0.002683343,"teacher_disagreement_score":0.0027262282,"about_ca_system_score_codex":0.0012776527,"about_ca_system_score_gemma":0.0019959023,"threshold_uncertainty_score":0.009270072},"labels":[],"label_agreement":null},{"id":"W2021381932","doi":"10.1007/s00280-006-0224-7","title":"Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1α gene","year":2006,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":253,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Ottawa","keywords":"A549 cell; Gene silencing; RNA interference; Cisplatin; Doxorubicin; Cancer research; Transfection; Biology; MTT assay; Flow cytometry; Cell; Molecular biology; Cell culture; Chemistry; Chemotherapy; RNA; Gene; Biochemistry","score_opus":0.006711336621092121,"score_gpt":0.268401795022745,"score_spread":0.2616904584016529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021381932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99371547,0.0015663923,0.002434041,0.0002070016,0.000048875143,0.000045845605,0.00026276437,0.00009812497,0.0016213203],"genre_scores_gemma":[0.9958753,0.0005831793,0.00071524247,0.000036641788,0.0000070690176,0.000037578753,0.00032521467,0.00001986738,0.002399893],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998956,0.000021455768,0.000010072028,0.00001851703,0.000027231308,0.00002724562],"domain_scores_gemma":[0.99992704,0.00001610023,0.000018512526,0.000013112996,0.000007373782,0.00001784041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014852673,0.00020206874,0.0002856489,0.00021877707,0.00016261124,0.00021739493,0.00020596183,0.00015161668,0.0015247966],"category_scores_gemma":[0.0001112642,0.0002007326,0.00020597795,0.00014643394,0.00018849294,0.00018302543,0.00013733395,0.0005484991,0.0003143058],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016037833,0.000038615475,0.00011664301,0.000015259373,0.0000051803454,0.000024191118,0.000008554624,0.00007720508,0.9979625,0.00012818514,0.000099819736,0.0013634948],"study_design_scores_gemma":[0.000042831525,0.0002863503,0.0037303674,0.00000335807,0.000013322425,0.00020660157,0.000013198884,0.0016132109,0.9916854,0.000046162262,0.0023554016,0.0000038401895],"about_ca_topic_score_codex":0.00066203333,"about_ca_topic_score_gemma":0.0010874128,"teacher_disagreement_score":0.0015247966,"about_ca_system_score_codex":0.00031514623,"about_ca_system_score_gemma":0.00021427723,"threshold_uncertainty_score":0.0051009655},"labels":[],"label_agreement":null},{"id":"W2023396498","doi":"10.1007/s00280-006-0244-3","title":"Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties","year":2006,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Drug Transport and Resistance Mechanisms","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Deutsche Forschungsgemeinschaft; Broad Institute","keywords":"Mitoxantrone; Daunorubicin; P-glycoprotein; Pharmacology; Efflux; Cytotoxicity; Multiple drug resistance; Abcg2; ATP-binding cassette transporter; Chemistry; Potency; In vitro; Transporter; Biology; Biochemistry; Chemotherapy; Immunology; Leukemia; Antibiotics","score_opus":0.012653364079430508,"score_gpt":0.2511435030696107,"score_spread":0.23849013899018018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023396498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9456835,0.022269163,0.015280076,0.00062255666,0.0001860188,0.00024127646,0.0005804543,0.0007047229,0.014432152],"genre_scores_gemma":[0.97473776,0.009566789,0.0070650545,0.00029312112,0.000058395723,0.00012369592,0.00069931266,0.000041925578,0.0074139135],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99994385,0.000012025598,0.0000036564384,0.000009037404,0.000011122835,0.000020354126],"domain_scores_gemma":[0.9999509,0.000008806941,0.00001132569,0.000004906089,0.000009580233,0.00001455449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019604259,0.0002931092,0.00047129497,0.00026334525,0.00018213235,0.00025584854,0.0005355694,0.00022862,0.0012285174],"category_scores_gemma":[0.00011616465,0.00012817419,0.00016033776,0.00017116615,0.00016874379,0.00026977787,0.00018626981,0.0005114465,0.0003941972],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074270234,0.00026244664,0.0003679114,0.00020588636,0.000030997868,0.00038878404,0.000107416665,0.0008224043,0.9369577,0.0019205156,0.0014872267,0.05670596],"study_design_scores_gemma":[0.001131042,0.008959955,0.011069973,0.000057614387,0.00018583366,0.003594566,0.000090238485,0.0064085503,0.8986742,0.00068772066,0.069062784,0.000077397795],"about_ca_topic_score_codex":0.0005592632,"about_ca_topic_score_gemma":0.0018492206,"teacher_disagreement_score":0.0012285174,"about_ca_system_score_codex":0.000305753,"about_ca_system_score_gemma":0.00016803155,"threshold_uncertainty_score":0.0041098},"labels":[],"label_agreement":null},{"id":"W2026686575","doi":"10.1007/s00280-004-0828-8","title":"Ascorbate modulation of H2O2 and camptothecin-induced cell death in Jurkat cells","year":2004,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Vitamin C and Antioxidants Research","field":"Nursing","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"Cancer Research Society","keywords":"Jurkat cells; Apoptosis; Programmed cell death; Camptothecin; Necrosis; Intracellular; Biology; Lactate dehydrogenase; Ascorbic acid; Molecular biology; Biochemistry; Immunology; T cell; Enzyme","score_opus":0.026227356420781778,"score_gpt":0.34263332505016486,"score_spread":0.3164059686293831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026686575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99394363,0.0014167172,0.0007290514,0.000168122,0.00007649284,0.00004806772,0.0007568384,0.000054139324,0.002807008],"genre_scores_gemma":[0.9944349,0.00081135804,0.0004390879,0.000056774446,0.000021049884,0.000037440255,0.00061291613,0.000007558571,0.0035789458],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99979407,0.000042595388,0.000019313564,0.000022275826,0.000044389282,0.00007744694],"domain_scores_gemma":[0.99989855,0.000026448572,0.000014057102,0.00001935672,0.00002358191,0.000017947066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014245942,0.00024131882,0.00041050639,0.0002637747,0.0003822281,0.00039338035,0.0002225553,0.0003182692,0.0026946166],"category_scores_gemma":[0.00012615419,0.0001531699,0.00034817,0.00044513078,0.00023774178,0.00025576734,0.00013065239,0.00076727226,0.00048833055],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012705972,0.00012598367,0.00024865987,0.0000625937,0.0000144806145,0.00015555424,0.00010557677,0.00006502232,0.9961817,0.00018739584,0.00013691933,0.0014455386],"study_design_scores_gemma":[0.00007031152,0.0005020505,0.006711694,0.000005375239,0.00002113782,0.00015185434,0.00014118965,0.00048713235,0.9899567,0.000052597254,0.0018944306,0.000005524425],"about_ca_topic_score_codex":0.0036988298,"about_ca_topic_score_gemma":0.0036721602,"teacher_disagreement_score":0.0036988298,"about_ca_system_score_codex":0.00039087542,"about_ca_system_score_gemma":0.0004036181,"threshold_uncertainty_score":0.009014368},"labels":[],"label_agreement":null},{"id":"W2026761112","doi":"10.1007/s002800050044","title":"N , N -diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine (DPPE), a chemopotentiating and cytoprotective agent in clinical trials: interaction with histamine at cytochrome P450 3A4 and other isozymes that metabolize antineoplastic drugs","year":2000,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Mast cells and histamine","field":"Immunology and Microbiology","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Medical Research Council Canada; Research Manitoba; Manitoba Health Research Council; Bristol-Myers Squibb","keywords":"Cytochrome P450; CYP3A4; Chemistry; Isozyme; Microsome; Pharmacology; Glucuronidation; Metabolism; Biochemistry; In vitro; Enzyme; Biology","score_opus":0.048768260185246576,"score_gpt":0.36296607132866276,"score_spread":0.31419781114341616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026761112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97255266,0.011052798,0.005449777,0.00061122526,0.00018532384,0.00020775128,0.0003242302,0.000145044,0.0094713215],"genre_scores_gemma":[0.9884144,0.0040366007,0.0025274584,0.00025004122,0.00009401233,0.00009397504,0.0004318383,0.000014711374,0.0041369474],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998981,0.000033856748,0.000005013952,0.000014757358,0.000018000625,0.000030341818],"domain_scores_gemma":[0.99991417,0.000025757763,0.000018892071,0.000008464316,0.0000051493375,0.000027599019],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002471584,0.00022015606,0.00032107026,0.00019235934,0.00021309673,0.00014993487,0.00023036654,0.00039752448,0.0020816827],"category_scores_gemma":[0.00020850918,0.00012598577,0.00014840129,0.00013208404,0.00021129001,0.00019328705,0.00016422804,0.00055651384,0.0005037224],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004659186,0.00060070964,0.0010957287,0.00016337399,0.00004058355,0.00045434802,0.000020150372,0.00019306345,0.94210875,0.00032063093,0.0006330002,0.049710475],"study_design_scores_gemma":[0.0038833749,0.0361268,0.027306233,0.000048804446,0.0001242264,0.0052382057,0.000068100446,0.0016816095,0.90220344,0.0003113413,0.02298397,0.00002392528],"about_ca_topic_score_codex":0.00031262595,"about_ca_topic_score_gemma":0.00089107954,"teacher_disagreement_score":0.0020816827,"about_ca_system_score_codex":0.00011628624,"about_ca_system_score_gemma":0.00023312186,"threshold_uncertainty_score":0.0069639683},"labels":[],"label_agreement":null},{"id":"W2026772196","doi":"10.1007/s00280-008-0739-1","title":"Human concentrative nucleoside transporter 3 is a determinant of fludarabine transportability and cytotoxicity in human renal proximal tubule cell cultures","year":2008,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Cytotoxicity; Nucleoside transporter; Human kidney; Fludarabine; Transporter; Nucleoside; Proximal tubule; Human cell; Cell culture; Pharmacology; Kidney; Cancer research; Hematopoietic cell; Chemistry; Biology; Cell biology; Biochemistry; Medicine; Internal medicine; Gene; Endocrinology; Genetics; Chemotherapy; In vitro; Stem cell","score_opus":0.013442763202349479,"score_gpt":0.30197691392643766,"score_spread":0.28853415072408817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026772196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99312747,0.0010376255,0.0031794365,0.00012156971,0.000020969846,0.000024041428,0.00087125367,0.000042080497,0.0015754767],"genre_scores_gemma":[0.9939715,0.00047915586,0.0017945997,0.000040462855,0.000008539498,0.000018895847,0.0016645427,0.000023176242,0.0019991694],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99969816,0.00006350202,0.000034686167,0.000060041424,0.0000702181,0.000073392956],"domain_scores_gemma":[0.9997708,0.00008039867,0.000019381658,0.00004014943,0.000058610432,0.000030615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029396557,0.000106079824,0.00042784854,0.00024389909,0.00045692985,0.0005915191,0.00022416808,0.00027870853,0.0023203946],"category_scores_gemma":[0.0003465049,0.00020319395,0.00034985426,0.0004930285,0.00024317444,0.0003329869,0.00020011896,0.00044324808,0.00071050314],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040198883,0.000052350413,0.0016565538,0.00003099654,0.000015082425,0.00014262382,0.00011437772,0.0000874987,0.9963217,0.00022388306,0.000112829664,0.00084012054],"study_design_scores_gemma":[0.00004128972,0.00032198432,0.026682865,0.0000064145834,0.000061645136,0.0010399849,0.0002916155,0.0026204456,0.96403897,0.00011059528,0.0047676982,0.00001664375],"about_ca_topic_score_codex":0.00699093,"about_ca_topic_score_gemma":0.0073756883,"teacher_disagreement_score":0.00699093,"about_ca_system_score_codex":0.0004677019,"about_ca_system_score_gemma":0.0004492319,"threshold_uncertainty_score":0.013900518},"labels":[],"label_agreement":null},{"id":"W2028767751","doi":"10.1007/s00280-011-1771-0","title":"A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)","year":2011,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Research Resources; National Institutes of Health; Eisai","keywords":"Bexarotene; Vinorelbine; Cisplatin; Pharmacology; Pharmacokinetics; Lung cancer; Medicine; Chemotherapy; Oncology; Internal medicine; Chemistry; Biochemistry","score_opus":0.007263555608815975,"score_gpt":0.27197506356176077,"score_spread":0.2647115079529448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028767751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952819,0.0009954587,0.0005356348,0.0002837555,0.00010505094,0.0012921832,0.00046979624,0.00005595753,0.0009803453],"genre_scores_gemma":[0.99352866,0.0011680147,0.0012922105,0.0003078716,0.00015501292,0.0011602504,0.0008603256,0.000050458013,0.0014771512],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9988243,0.0006119823,0.000041022202,0.00022768203,0.00009060824,0.00020429089],"domain_scores_gemma":[0.99822325,0.0003521884,0.00026398856,0.00027044097,0.000077038916,0.0008132522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018509933,0.0017550597,0.0042708535,0.0006582663,0.00085990544,0.0016832903,0.0015266547,0.0017630275,0.0027188694],"category_scores_gemma":[0.0022531848,0.0013607454,0.0017907567,0.0009790844,0.0019008323,0.0022335886,0.0004786525,0.005960837,0.00082248164],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7838965,0.09301047,0.007751465,0.0003681603,0.0012329734,0.00029914972,0.0005495202,0.004298873,0.053036693,0.00046838954,0.0016937385,0.05339414],"study_design_scores_gemma":[0.38479155,0.58826274,0.0147895245,0.000022083044,0.0005471168,0.00033281674,0.00016036145,0.0017749515,0.006467061,0.00021851,0.002564164,0.00006914473],"about_ca_topic_score_codex":0.003321885,"about_ca_topic_score_gemma":0.0052928193,"teacher_disagreement_score":0.0042708535,"about_ca_system_score_codex":0.0017138803,"about_ca_system_score_gemma":0.0027592056,"threshold_uncertainty_score":0.012435198},"labels":[],"label_agreement":null},{"id":"W2028849325","doi":"10.1007/s00280-011-1755-0","title":"A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer","year":2011,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Pfizer","keywords":"Medicine; Pemetrexed; Sunitinib; Neutropenia; Lung cancer; Internal medicine; Dosing; Pharmacokinetics; Adverse effect; Febrile neutropenia; Oncology; Cancer; Pharmacology; Chemotherapy; Cisplatin","score_opus":0.015190002316557639,"score_gpt":0.34029376063834094,"score_spread":0.3251037583217833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028849325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977469,0.0007175088,0.00023944606,0.00010311174,0.000022048236,0.00062534434,0.00015182223,0.000040118888,0.0003537744],"genre_scores_gemma":[0.9959513,0.00067124807,0.0012152565,0.00017343872,0.000043535325,0.00073854084,0.0005933225,0.000012202839,0.00060108176],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99954444,0.00021826453,0.000026574597,0.000086843065,0.000053472057,0.00007037409],"domain_scores_gemma":[0.9994943,0.000077814846,0.0001226035,0.000055260778,0.000030450625,0.00021953198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013953083,0.0012836955,0.0018532677,0.00041313138,0.00034915272,0.00064127275,0.000763488,0.0007237159,0.0015690633],"category_scores_gemma":[0.0007798282,0.0005158903,0.0010636066,0.0004273741,0.000664327,0.0006806773,0.00028800036,0.0024252143,0.00038528233],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47922257,0.13246748,0.022950407,0.001234846,0.0023999156,0.0006851513,0.0009398595,0.010229133,0.13919257,0.0002981666,0.0039699282,0.20640993],"study_design_scores_gemma":[0.3375503,0.5998034,0.042096592,0.000033178945,0.00059619924,0.00081382744,0.000088713336,0.003728704,0.011609784,0.00016814232,0.0034623789,0.000048708254],"about_ca_topic_score_codex":0.0005561069,"about_ca_topic_score_gemma":0.0017289419,"teacher_disagreement_score":0.0018532677,"about_ca_system_score_codex":0.0008907163,"about_ca_system_score_gemma":0.0012514229,"threshold_uncertainty_score":0.007379234},"labels":[],"label_agreement":null},{"id":"W2030098953","doi":"10.1007/s00280-006-0225-6","title":"Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2′-deoxycytidine (decitabine) on human breast carcinoma cells","year":2006,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Decitabine; Deoxycytidine; Histone deacetylase inhibitor; Chemistry; Cancer research; Histone deacetylase; Pharmacology; Azacitidine; Histone; Medicine; Internal medicine; Chemotherapy; DNA methylation; Biochemistry; DNA","score_opus":0.011365571777535558,"score_gpt":0.3456122280967449,"score_spread":0.33424665631920936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030098953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98918694,0.004971641,0.00041057897,0.00023507673,0.00014995334,0.000048368172,0.00059683877,0.0001729292,0.004227682],"genre_scores_gemma":[0.9919572,0.002839045,0.00052298285,0.00009036299,0.000032133812,0.000047468464,0.0009289355,0.00001945738,0.0035624004],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988246,0.000031700027,0.00000979986,0.000014849342,0.000016533048,0.000044613986],"domain_scores_gemma":[0.9999083,0.000030937448,0.00000789176,0.000016259506,0.000014430135,0.000022151702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018021606,0.00034511072,0.0008546615,0.00029893414,0.0002892403,0.0002735638,0.00046857836,0.00040089778,0.0040456443],"category_scores_gemma":[0.00019548168,0.0002517939,0.00031614353,0.0003630077,0.00018632328,0.00023318498,0.00015895888,0.00072738883,0.0008553458],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032252069,0.00057005236,0.00055257115,0.00023077558,0.00006108491,0.00025873727,0.00009016803,0.00046435138,0.9812211,0.0003014224,0.00071988255,0.012304721],"study_design_scores_gemma":[0.0004274074,0.0031763616,0.0076362663,0.000017823651,0.00007605421,0.00021950675,0.0000683751,0.0015320936,0.98230195,0.000053818763,0.0044767205,0.000013637864],"about_ca_topic_score_codex":0.0034403868,"about_ca_topic_score_gemma":0.00468737,"teacher_disagreement_score":0.0040456443,"about_ca_system_score_codex":0.00032839857,"about_ca_system_score_gemma":0.00048653054,"threshold_uncertainty_score":0.013534009},"labels":[],"label_agreement":null},{"id":"W2031710547","doi":"10.1007/s00280-011-1796-4","title":"Going past the data for temozolomide","year":2011,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Temozolomide; Medicine; Adjuvant; Oncology; Radiation therapy; Internal medicine; Clinical trial; Adjuvant therapy; Glioblastoma; Randomized controlled trial; Cancer; Cancer research","score_opus":0.11105953602588882,"score_gpt":0.3787718905292375,"score_spread":0.2677123545033487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031710547","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01908744,0.6083078,0.0048311236,0.28703576,0.02119861,0.00030583155,0.012604055,0.00048076856,0.046148755],"genre_scores_gemma":[0.1850531,0.5161491,0.014288793,0.2155238,0.018679421,0.00032940716,0.01283289,0.0008653045,0.0362782],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962631,0.0014042291,0.00088970305,0.00037333023,0.0007612901,0.00030836026],"domain_scores_gemma":[0.97689986,0.009653288,0.0035462088,0.0019338318,0.0063102418,0.0016565636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0088763,0.00079214154,0.0028558255,0.0014351433,0.0005942856,0.0036848637,0.0013105066,0.0018926447,0.024941128],"category_scores_gemma":[0.026610235,0.00034625028,0.0028956009,0.0021162985,0.0013194807,0.006095314,0.0016146078,0.0092612645,0.0055725663],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069614574,0.00035487043,0.005094267,0.013742518,0.00211922,0.0002866326,0.00018730013,0.0006744184,0.004541382,0.0118651185,0.17482077,0.77935195],"study_design_scores_gemma":[0.0011029184,0.0041913795,0.010114647,0.0074983505,0.003617922,0.0006275822,0.00033560753,0.0003764452,0.0028597408,0.008405899,0.96075463,0.00011489298],"about_ca_topic_score_codex":0.0071015405,"about_ca_topic_score_gemma":0.024716912,"teacher_disagreement_score":0.024941128,"about_ca_system_score_codex":0.0032627133,"about_ca_system_score_gemma":0.0051771877,"threshold_uncertainty_score":0.08343637},"labels":[],"label_agreement":null},{"id":"W2032395096","doi":"10.1007/s00280-013-2237-3","title":"A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer","year":2013,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Novartis Pharmaceuticals Corporation","keywords":"Panobinostat; Medicine; Pharmacology; Active metabolite; Metabolite; CYP2D6; Pharmacokinetics; Internal medicine; Chemistry; Biochemistry","score_opus":0.008480293005227362,"score_gpt":0.3258972695176337,"score_spread":0.31741697651240636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032395096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98739547,0.007685608,0.0002922014,0.00022949003,0.000049105656,0.00011766675,0.00047387017,0.000022042443,0.0037345577],"genre_scores_gemma":[0.9962786,0.0018545158,0.00029561378,0.00018264032,0.00005045495,0.000048038226,0.0004440529,0.000003548722,0.0008425241],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997254,0.00010367389,0.000030004458,0.000056230096,0.000055476285,0.000029267507],"domain_scores_gemma":[0.999574,0.00011264208,0.000111153444,0.00002493735,0.00006833717,0.00010895064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046027298,0.00030374184,0.0007584933,0.0002722439,0.00027262987,0.00037359522,0.00016803876,0.00029785364,0.0014600737],"category_scores_gemma":[0.0008897078,0.00014145167,0.00036944027,0.0006010821,0.0002128849,0.0002526399,0.00014498759,0.00059779844,0.00021786075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07583482,0.0021422508,0.7360524,0.00063534355,0.0010358309,0.0011694446,0.00027006888,0.00047002625,0.036895145,0.00026389956,0.0012501455,0.1439806],"study_design_scores_gemma":[0.004939556,0.051721275,0.9131978,0.00005537662,0.0016064717,0.0026274093,0.000307889,0.00086820027,0.013383281,0.00023306088,0.011025382,0.00003423064],"about_ca_topic_score_codex":0.0005141988,"about_ca_topic_score_gemma":0.0009959134,"teacher_disagreement_score":0.0014600737,"about_ca_system_score_codex":0.00026285235,"about_ca_system_score_gemma":0.00037174337,"threshold_uncertainty_score":0.004884422},"labels":[],"label_agreement":null},{"id":"W2034826891","doi":"10.1007/s00280-013-2078-0","title":"An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo","year":2013,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Heart, Lung, and Blood Institute; Georgia Cancer Coalition; Health Canada; National Institute on Aging; Aflac; U.S. Food and Drug Administration; National Cancer Institute; National Institutes of Health","keywords":"Bortezomib; In vivo; Protein kinase B; PI3K/AKT/mTOR pathway; Angiogenesis; Proteasome inhibitor; Phosphoinositide 3-kinase; Cancer research; Medicine; Pharmacology; Multiple myeloma; Biology; Immunology; Signal transduction; Cell biology","score_opus":0.013212464662288427,"score_gpt":0.2847992486588463,"score_spread":0.2715867839965579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034826891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881665,0.0050031575,0.001636078,0.00042867614,0.00012763892,0.000041244082,0.0008345088,0.00035040887,0.0034116392],"genre_scores_gemma":[0.99192905,0.0022875855,0.0014686737,0.000082463266,0.00003079077,0.000031339012,0.001438534,0.000027507907,0.0027041293],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999863,0.00001641931,0.000012667802,0.000020728477,0.00003842728,0.00004882404],"domain_scores_gemma":[0.99991715,0.0000125885435,0.000022083597,0.000011520871,0.00000767274,0.00002908387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021010335,0.00055541215,0.0006870273,0.00036756485,0.000250956,0.00035650557,0.00025118917,0.00036086293,0.0014392512],"category_scores_gemma":[0.00012088836,0.00019337093,0.00033255894,0.0003632168,0.0002135279,0.0002251734,0.00008818326,0.0011055503,0.00039680075],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001804374,0.00032358465,0.00038558154,0.00008335765,0.00003383303,0.00006520181,0.000017321354,0.00032839683,0.9883432,0.0001193598,0.00045925347,0.0080365315],"study_design_scores_gemma":[0.00023477174,0.002221886,0.0029480916,0.000004148477,0.00005110713,0.00034393408,0.0000107649485,0.0008471529,0.9907803,0.000039837207,0.0025122117,0.000005698545],"about_ca_topic_score_codex":0.0014773956,"about_ca_topic_score_gemma":0.002635889,"teacher_disagreement_score":0.0014773956,"about_ca_system_score_codex":0.00036432792,"about_ca_system_score_gemma":0.00041428176,"threshold_uncertainty_score":0.004814744},"labels":[],"label_agreement":null},{"id":"W2035008632","doi":"10.1007/s00280-009-1182-7","title":"Putative chemopreventive molecules can increase Nrf2-regulated cell defense in some human cancer cell lines, resulting in resistance to common cytotoxic therapies","year":2009,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Genomics, phytochemicals, and oxidative stress","field":"Biochemistry, Genetics and Molecular Biology","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Cancer Research Society","keywords":"Sulforaphane; Cancer cell; Cancer research; Cytotoxic T cell; Biology; Cancer; Cell culture; Pharmacology; Biochemistry; In vitro; Genetics","score_opus":0.010332737099755804,"score_gpt":0.30223571200281507,"score_spread":0.2919029749030593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035008632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915207,0.0035159478,0.0023210822,0.00025241394,0.00003227344,0.00005057415,0.0005124714,0.000082555816,0.0017120367],"genre_scores_gemma":[0.99434245,0.0016591474,0.001213518,0.00006928268,0.000010838244,0.00003172331,0.0007916984,0.000008399989,0.0018729629],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992263,0.000020247098,0.00000769544,0.000014125871,0.000017695756,0.000017577415],"domain_scores_gemma":[0.99989605,0.000031426054,0.00001480633,0.000019317964,0.000025290998,0.000013187974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022283259,0.00022249887,0.00027129427,0.00036760236,0.00019093728,0.00021280292,0.000108925895,0.00025176245,0.0028710521],"category_scores_gemma":[0.00018223173,0.000111325426,0.00024896607,0.00032376382,0.00014231945,0.00016301191,0.00011333257,0.00037214812,0.0003079048],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016173974,0.000052532698,0.00081180624,0.000060858383,0.000012966881,0.00006812748,0.000024824323,0.000036048703,0.9963264,0.00016048858,0.00007517739,0.0022090364],"study_design_scores_gemma":[0.000025078598,0.0005551539,0.010232191,0.0000077276,0.000046178542,0.0003389772,0.000062049716,0.0001404367,0.9847093,0.00009134435,0.0037883215,0.000003296367],"about_ca_topic_score_codex":0.00043170026,"about_ca_topic_score_gemma":0.0010502057,"teacher_disagreement_score":0.0028710521,"about_ca_system_score_codex":0.00013370911,"about_ca_system_score_gemma":0.00015940392,"threshold_uncertainty_score":0.009604692},"labels":[],"label_agreement":null},{"id":"W2035597050","doi":"10.1007/s00280-014-2535-4","title":"Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children’s Oncology Group","year":2014,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institute of General Medical Sciences; National Cancer Institute","keywords":"Daunorubicin; Pharmacogenomics; Pharmacokinetics; Medicine; Oncology; Biopharmaceutics; Internal medicine; Pharmacology; Chemotherapy; Pharmacognosy; Genetics; Biology","score_opus":0.011274481276181707,"score_gpt":0.3070790529990172,"score_spread":0.29580457172283553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035597050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935349,0.0023692474,0.0005455282,0.00070850336,0.000019149522,0.000031876953,0.00093333237,0.00002673476,0.0018307078],"genre_scores_gemma":[0.9949922,0.0028909976,0.0006984895,0.00032595516,0.000028642216,0.000017789072,0.0006241766,0.000017350889,0.00040450017],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99957305,0.000071014976,0.000048768186,0.00007248969,0.00016043462,0.00007425808],"domain_scores_gemma":[0.99918705,0.00023027598,0.00023915998,0.000048199425,0.00021882082,0.00007643509],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005117079,0.00027323357,0.00035322705,0.00058458635,0.00033696726,0.00048159028,0.00014527334,0.00027791646,0.0003277533],"category_scores_gemma":[0.001483062,0.0001940421,0.00045725578,0.0007921895,0.00035489618,0.00019870038,0.00021780447,0.0006811688,0.00009853648],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003397152,0.00008898908,0.96411586,0.00007274904,0.00015214128,0.0022392944,0.0005171822,0.00044114172,0.008530374,0.000194325,0.0018413574,0.021466931],"study_design_scores_gemma":[0.000028138287,0.00057210744,0.971142,0.000028162609,0.00024935647,0.0080275005,0.0005623495,0.00032241223,0.010503962,0.000056247307,0.008484817,0.000022925493],"about_ca_topic_score_codex":0.019668007,"about_ca_topic_score_gemma":0.014963179,"teacher_disagreement_score":0.019668007,"about_ca_system_score_codex":0.0010989248,"about_ca_system_score_gemma":0.001319154,"threshold_uncertainty_score":0.039107084},"labels":[],"label_agreement":null},{"id":"W2035613220","doi":"10.1007/s00280-001-0395-1","title":"The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase","year":2001,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Bioactive Compounds and Antitumor Agents","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Tirapazamine; Quinone; Chemistry; Moiety; Benzoquinone; Enzyme; Stereochemistry; Mitomycin C; Cytotoxicity; Pharmacology; Biochemistry; Combinatorial chemistry; In vitro; Medicine","score_opus":0.05966073775841671,"score_gpt":0.40343111872770565,"score_spread":0.3437703809692889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035613220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993511,0.0009694509,0.0026653344,0.00009651852,0.000033131382,0.000026379852,0.0001377581,0.00008274008,0.0024775176],"genre_scores_gemma":[0.99778026,0.00032263115,0.0007421915,0.000028441502,0.0000050841013,0.000009975512,0.00010311096,0.000014308489,0.0009939569],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988914,0.000022946464,0.00000820057,0.000021790265,0.000020737107,0.00003710837],"domain_scores_gemma":[0.99984956,0.00007669138,0.000022705175,0.000022163966,0.000014318895,0.000014650967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002705854,0.0003201365,0.00017081398,0.0001140546,0.00015813934,0.00013939104,0.00034520958,0.00029975234,0.0022616133],"category_scores_gemma":[0.00025857257,0.00013441207,0.00016359413,0.000108690576,0.00029194148,0.0002864021,0.0001224844,0.00035909127,0.0002461669],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042463074,0.000027267915,0.000064507185,0.000046129004,0.000007014189,0.000042556254,0.000034076318,0.00013199924,0.9969988,0.0002743597,0.000047743266,0.001900985],"study_design_scores_gemma":[0.0000060058283,0.00011832213,0.00019917518,0.0000010143016,0.0000036141955,0.00002163508,0.0000033960027,0.0001275047,0.99914336,0.000017608445,0.00035666153,0.0000018116748],"about_ca_topic_score_codex":0.00071202684,"about_ca_topic_score_gemma":0.00078653416,"teacher_disagreement_score":0.0022616133,"about_ca_system_score_codex":0.00019311481,"about_ca_system_score_gemma":0.00014401303,"threshold_uncertainty_score":0.007565856},"labels":[],"label_agreement":null},{"id":"W2036337218","doi":"10.1007/s00280-004-0850-x","title":"A 150-kDa glycoprotein isolated from Solanum nigrum L. has cytotoxic and apoptotic effects by inhibiting the effects of protein kinase C alpha, nuclear factor-kappa B and inducible nitric oxide in HCT-116 cells","year":2004,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Phytochemical Studies and Bioactivities","field":"Biochemistry, Genetics and Molecular Biology","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Chonnam National University","keywords":"Cytotoxic T cell; Apoptosis; Solanum nigrum; Nitric oxide; Chemistry; Molecular biology; Cytotoxicity; Tumor necrosis factor alpha; Biochemistry; Alpha (finance); Kinase; Glycoprotein; Biology; Pharmacology; Immunology; In vitro; Medicine; Endocrinology; Botany","score_opus":0.005917512531633621,"score_gpt":0.22933492527757068,"score_spread":0.22341741274593707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036337218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99472284,0.002761912,0.0010527306,0.00013627713,0.00004338706,0.000017276327,0.00014236112,0.000053252297,0.0010699969],"genre_scores_gemma":[0.9938945,0.0019930857,0.0013570273,0.00011546882,0.000028361908,0.0000095661535,0.00096177374,0.000015246631,0.0016249323],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999682,0.0000053855993,0.0000023243279,0.0000048722814,0.000009765667,0.00000955691],"domain_scores_gemma":[0.9999628,0.0000054723996,0.000008659779,0.0000039250904,0.0000058508217,0.000013204838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005224624,0.00037308148,0.00019743468,0.00023608698,0.00012315818,0.00015456148,0.000106614345,0.00019500084,0.00040399056],"category_scores_gemma":[0.0000698707,0.00007534938,0.0002459989,0.00018651239,0.00018109042,0.0001147412,0.0000950368,0.00035325703,0.00025312547],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008935027,0.0000253844,0.000112987254,0.000023810759,0.000004510379,0.00006210682,0.000008518243,0.00002004564,0.9984633,0.00002289404,0.000028192342,0.0011388102],"study_design_scores_gemma":[0.00005340911,0.0012275764,0.010252862,0.000013833446,0.00007342612,0.0010965901,0.000051771563,0.00044357483,0.9815322,0.00010334745,0.005142539,0.000008883921],"about_ca_topic_score_codex":0.00061479234,"about_ca_topic_score_gemma":0.0008112948,"teacher_disagreement_score":0.00061479234,"about_ca_system_score_codex":0.00015036941,"about_ca_system_score_gemma":0.00016101387,"threshold_uncertainty_score":0.0013515353},"labels":[],"label_agreement":null},{"id":"W2038893680","doi":"10.1007/s00280-009-1096-4","title":"UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib","year":2009,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Neonatal Health and Biochemistry","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Sorafenib; Hepatocellular carcinoma; Medicine; Bilirubin; Unconjugated hyperbilirubinemia; Internal medicine; Gastroenterology; Cirrhosis; Glucuronosyltransferase; Doxorubicin; Pharmacology; Chemotherapy; Chemistry; Biochemistry; Microsome","score_opus":0.010973269801906781,"score_gpt":0.3202515898681827,"score_spread":0.3092783200662759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038893680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99648416,0.0003467026,0.00015349152,0.0011785994,0.000056079978,0.000015484877,0.00006647225,0.000016522219,0.0016824458],"genre_scores_gemma":[0.9991761,0.0001338696,0.00007613039,0.00022671984,0.000088826004,0.0000024591036,0.000032338565,0.000004379518,0.00025909903],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9996511,0.000060631657,0.000053631087,0.00007374943,0.00004908032,0.000111811],"domain_scores_gemma":[0.99918526,0.00031705314,0.00014966766,0.0000373605,0.00004208883,0.0002685463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028507158,0.00089703244,0.00088473066,0.0013140398,0.0018451982,0.00071069883,0.00060335186,0.0023883895,0.0026471613],"category_scores_gemma":[0.002009335,0.00065227295,0.0010558019,0.0009726487,0.00087074406,0.0008565794,0.00044611588,0.0021881652,0.00028526134],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011295169,0.00043726945,0.22127213,0.00002972942,0.00009328411,0.77053964,0.0003397741,0.00021238625,0.0031034197,0.00022360352,0.000520975,0.0020981831],"study_design_scores_gemma":[0.00016076743,0.0014800495,0.21776497,0.000030716466,0.00031627578,0.77420443,0.0010120197,0.0020229009,0.0016455927,0.00035980827,0.0009484904,0.000054007563],"about_ca_topic_score_codex":0.005531489,"about_ca_topic_score_gemma":0.004320272,"teacher_disagreement_score":0.005531489,"about_ca_system_score_codex":0.0009962949,"about_ca_system_score_gemma":0.00069998164,"threshold_uncertainty_score":0.010998607},"labels":[],"label_agreement":null},{"id":"W2040107189","doi":"10.1007/s00280-004-0843-9","title":"Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGF?-RII, KRAS2, TP53 and/or CDNK2A","year":2004,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal General Hospital; McGill University Health Centre; Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"Cancer research; Radiosensitivity; Ovarian cancer; Biology; Cancer; Cell culture; Oncology; Internal medicine; Medicine; Pathology; Radiation therapy; Genetics","score_opus":0.02130002559684653,"score_gpt":0.3164080200461256,"score_spread":0.2951079944492791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040107189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951564,0.0008887182,0.0011547648,0.000094108495,0.000019306965,0.000034069802,0.0010540803,0.000047490896,0.0015510572],"genre_scores_gemma":[0.99197584,0.0010026814,0.0012808999,0.00007504159,0.000008598955,0.000057252586,0.0030809024,0.000019415707,0.0024993576],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998344,0.000041151387,0.000029801336,0.000020686415,0.0000434009,0.00003055406],"domain_scores_gemma":[0.99972934,0.00011503772,0.000019554947,0.000046254852,0.000058674214,0.00003114111],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002289878,0.00017772413,0.00021904112,0.00041108282,0.00018108715,0.00026508165,0.00014373357,0.0002925963,0.0016925258],"category_scores_gemma":[0.00030729244,0.00014469851,0.00022123301,0.0003933046,0.0002040482,0.00012667409,0.00014742812,0.00036091128,0.00035168073],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003917931,0.00008624941,0.0026298403,0.000045022894,0.00002292426,0.00011249097,0.00016652794,0.00038199505,0.99357444,0.00020669706,0.00018866814,0.0021933056],"study_design_scores_gemma":[0.00004064571,0.0011310381,0.035945214,0.0000064005417,0.00008320558,0.0008209153,0.00019994007,0.0016747771,0.9570186,0.00006948971,0.0029976314,0.000012260984],"about_ca_topic_score_codex":0.0042753597,"about_ca_topic_score_gemma":0.002754202,"teacher_disagreement_score":0.0042753597,"about_ca_system_score_codex":0.00016999393,"about_ca_system_score_gemma":0.00012865712,"threshold_uncertainty_score":0.008500934},"labels":[],"label_agreement":null},{"id":"W2040176056","doi":"10.1007/s00280-009-1041-6","title":"A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation","year":2009,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":205,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; BC Cancer Agency","funders":"National Cancer Institute","keywords":"Lapatinib; Pharmacokinetics; Medicine; Toxicity; Pharmacology; Gastroenterology; Phases of clinical research; Internal medicine; Oral administration; Cancer; Breast cancer; Trastuzumab","score_opus":0.029161902429656193,"score_gpt":0.41835744305058226,"score_spread":0.38919554062092604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040176056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99567986,0.0009966625,0.00038510753,0.00049635454,0.000082220424,0.00066940265,0.00077720894,0.000076901866,0.0008362599],"genre_scores_gemma":[0.9909395,0.0011770631,0.0011837222,0.0009173903,0.00015506643,0.0010235078,0.002731398,0.000047137648,0.0018251297],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999308,0.00032318494,0.000032269174,0.000117238196,0.000050703635,0.00016852829],"domain_scores_gemma":[0.99908173,0.00013052343,0.00017441914,0.00010042773,0.00004937937,0.0004635346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022596205,0.0019420553,0.0031237002,0.0006312314,0.00038056527,0.0010617782,0.00084933185,0.0012845497,0.0024918208],"category_scores_gemma":[0.0012297385,0.0005794775,0.0017288482,0.0006640678,0.0015118468,0.001323173,0.00053586584,0.0031280257,0.0008881955],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83868617,0.030274006,0.008872303,0.00040376352,0.0018152957,0.0002836075,0.00019960046,0.002379734,0.030991588,0.00035809164,0.0042725448,0.081463344],"study_design_scores_gemma":[0.6690417,0.30710444,0.013924941,0.000022818676,0.00082695304,0.00041222604,0.00008929571,0.0018263013,0.00462629,0.000474111,0.0015885371,0.000062376996],"about_ca_topic_score_codex":0.0015780162,"about_ca_topic_score_gemma":0.0033928568,"teacher_disagreement_score":0.0031237002,"about_ca_system_score_codex":0.0013585957,"about_ca_system_score_gemma":0.001884633,"threshold_uncertainty_score":0.011950195},"labels":[],"label_agreement":null},{"id":"W2040193157","doi":"10.1007/s00280-008-0750-6","title":"Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2′-deoxycytidine","year":2008,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Université de Montréal","funders":"Cancer Research Society","keywords":"Cytidine deaminase; Deoxycytidine; Cytidine; Deamination; Deoxycytidine kinase; Molecular biology; Adenosine deaminase; Chemistry; Biology; Biochemistry; Enzyme; Chemotherapy; Gemcitabine","score_opus":0.017088398571403533,"score_gpt":0.3026246787053595,"score_spread":0.28553628013395593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040193157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99112916,0.0035141336,0.001666406,0.00018786005,0.000076865465,0.000029235029,0.0002624404,0.000111008805,0.0030228866],"genre_scores_gemma":[0.9953276,0.001393359,0.0009181063,0.00003963657,0.000015998228,0.000014035743,0.00027093838,0.000020315745,0.0019999437],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989176,0.000024693129,0.000008955361,0.000015438894,0.000021232632,0.000037902373],"domain_scores_gemma":[0.9998311,0.00006438148,0.00002856946,0.000024997606,0.00001659255,0.000034329583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018259246,0.00031926384,0.00041539496,0.00022018336,0.00013307326,0.0002916057,0.00032418757,0.0002988928,0.0024837838],"category_scores_gemma":[0.00023817399,0.00018940799,0.00021211963,0.00016728786,0.0002244078,0.00028233108,0.00019947601,0.0006759569,0.00057304365],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004657604,0.00003746257,0.000099836754,0.00003392598,0.0000078952635,0.000039819526,0.000011342051,0.00009927677,0.9966174,0.00013390042,0.0000621832,0.0023913705],"study_design_scores_gemma":[0.000022771317,0.00025334445,0.0010853264,0.0000024829153,0.000008983639,0.0000574306,0.000006311401,0.00026623195,0.99711776,0.000019234842,0.001157821,0.0000022269344],"about_ca_topic_score_codex":0.0013854027,"about_ca_topic_score_gemma":0.0023481671,"teacher_disagreement_score":0.0024837838,"about_ca_system_score_codex":0.0003578146,"about_ca_system_score_gemma":0.00036147475,"threshold_uncertainty_score":0.008309066},"labels":[],"label_agreement":null},{"id":"W2041411173","doi":"10.1007/s00280-004-0997-5","title":"Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models","year":2005,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital; Inimex Pharmaceuticals (Canada)","funders":"","keywords":"Clusterin; Docetaxel; Paclitaxel; In vivo; Chemistry; LNCaP; Chitosan; Pharmacology; Prostate; Medicine; Chemotherapy; Cancer; Apoptosis; Internal medicine; Biochemistry; Biology","score_opus":0.03062380523653499,"score_gpt":0.3576672029075239,"score_spread":0.3270433976709889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041411173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955165,0.00084555644,0.0018725902,0.00008106761,0.00009254857,0.000073977244,0.00020690978,0.000105354244,0.0012055184],"genre_scores_gemma":[0.994331,0.0005339924,0.0016413103,0.000021512793,0.000018256975,0.000045882316,0.00017939224,0.000034532073,0.0031941307],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99985087,0.000025219502,0.000009027949,0.000036370533,0.00003815294,0.000040339564],"domain_scores_gemma":[0.9998423,0.0000378962,0.000039043185,0.000015832326,0.000023339913,0.000041507305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024550685,0.00041817274,0.0003591613,0.00025529397,0.00019684013,0.00026344697,0.00027119985,0.00031323396,0.0011177213],"category_scores_gemma":[0.00016274542,0.0001843622,0.00022094126,0.00020163992,0.00033085883,0.00029850638,0.00009293247,0.0006083701,0.00018727726],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012538765,0.0002517308,0.000072762145,0.000048062488,0.00001212536,0.0000252854,0.000027719354,0.00038292768,0.99575377,0.00009141819,0.000089645044,0.0019907039],"study_design_scores_gemma":[0.000075152544,0.0021634025,0.0005332016,0.0000020476052,0.000030219033,0.000034642097,0.000009678906,0.0010512619,0.99546057,0.000009356332,0.0006241215,0.0000063375896],"about_ca_topic_score_codex":0.005159613,"about_ca_topic_score_gemma":0.004851817,"teacher_disagreement_score":0.005159613,"about_ca_system_score_codex":0.0005024397,"about_ca_system_score_gemma":0.0006496381,"threshold_uncertainty_score":0.010259151},"labels":[],"label_agreement":null},{"id":"W2042603355","doi":"10.1007/s00280-013-2155-4","title":"Bevacizumab and central nervous system (CNS) hemorrhage","year":2013,"lang":"en","type":"review","venue":"Cancer Chemotherapy and Pharmacology","topic":"Neurological Complications and Syndromes","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Bevacizumab; Central nervous system; Medicine; Neuroscience; Chemotherapy; Internal medicine; Biology","score_opus":0.060671572450236556,"score_gpt":0.37634657304408864,"score_spread":0.31567500059385206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042603355","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010228293,0.9990938,0.000045941102,0.00009768231,0.0000814148,0.0000026611665,0.000009432432,0.000003351672,0.0005635235],"genre_scores_gemma":[0.0009378701,0.99832493,0.000111504116,0.0001528946,0.00010164627,0.0000034496916,0.000020096186,7.2985864e-7,0.00034684705],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99987113,0.00001959093,0.00002905614,0.00002025546,0.00004706469,0.000012829349],"domain_scores_gemma":[0.99978334,0.00011181343,0.000048323946,0.000004444351,0.000035991474,0.000016145901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003579333,0.00063353224,0.0011572719,0.0018915397,0.0001936091,0.0007397767,0.00056971674,0.0007004641,0.002600996],"category_scores_gemma":[0.0008237302,0.00024588493,0.0004227865,0.001983284,0.00030579788,0.00074876467,0.0004799464,0.00121134,0.00072809757],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012188535,0.00006569606,0.00027462287,0.017985163,0.00015515438,0.00024302318,0.000029136358,0.00028521533,0.0008764321,0.0011695321,0.02412539,0.9546688],"study_design_scores_gemma":[0.00012671809,0.00018529882,0.0023214766,0.009816045,0.00085515674,0.0026085286,0.00006536383,0.00021617232,0.0006509258,0.0016892902,0.9814315,0.00003350661],"about_ca_topic_score_codex":0.0024176696,"about_ca_topic_score_gemma":0.006608825,"teacher_disagreement_score":0.002600996,"about_ca_system_score_codex":0.0005128053,"about_ca_system_score_gemma":0.0010101108,"threshold_uncertainty_score":0.008701205},"labels":[],"label_agreement":null},{"id":"W2044562269","doi":"10.1007/s00280-011-1772-z","title":"The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer","year":2011,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta","funders":"University of Texas Health Science Center at San Antonio; National Institutes of Health; Eisai","keywords":"Bexarotene; Pharmacology; Atorvastatin; Fenofibrate; Pharmacokinetics; Medicine; Carboplatin; Chemotherapy; Paclitaxel; Drug interaction; Lung cancer; Oncology; Internal medicine; Cisplatin; Chemistry","score_opus":0.006956540471565487,"score_gpt":0.2784354975765501,"score_spread":0.27147895710498465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044562269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99508804,0.0021447744,0.00032158854,0.00048440872,0.00008378233,0.00042548947,0.0005754932,0.000052486925,0.0008240423],"genre_scores_gemma":[0.9936487,0.0022147554,0.000905882,0.00038859565,0.00020783351,0.0004082112,0.00095858495,0.000042605418,0.0012247469],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9991129,0.00048439862,0.00004636364,0.00012270465,0.000073201285,0.00016045423],"domain_scores_gemma":[0.99842155,0.00044175616,0.0002941332,0.0001503868,0.00006968376,0.0006225291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017663151,0.0015420059,0.003817396,0.00048589124,0.0005648938,0.001173584,0.0008121352,0.0013591466,0.0023969943],"category_scores_gemma":[0.0020835635,0.00064397743,0.0020300401,0.00081354217,0.0014233124,0.0015033889,0.00031842943,0.0040852926,0.0005590951],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90350205,0.019095073,0.0035213854,0.0003006089,0.0012845172,0.000107627384,0.00013208456,0.0014663137,0.023821183,0.00012911542,0.0009065602,0.04573344],"study_design_scores_gemma":[0.5689686,0.40081158,0.021108711,0.000021207054,0.0011771299,0.00019690732,0.000069646485,0.00095067493,0.004874565,0.00017806662,0.0015885903,0.000054327866],"about_ca_topic_score_codex":0.0018218039,"about_ca_topic_score_gemma":0.0038922504,"teacher_disagreement_score":0.003817396,"about_ca_system_score_codex":0.0011879428,"about_ca_system_score_gemma":0.0014674063,"threshold_uncertainty_score":0.00934124},"labels":[],"label_agreement":null},{"id":"W2046529949","doi":"10.1007/s00280-010-1288-y","title":"An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity","year":2010,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":159,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Epirubicin; Toxicity; Pharmacokinetics; Lean body mass; Internal medicine; Medicine; Pharmacology; Endocrinology; Cancer; Breast cancer","score_opus":0.02030484285912247,"score_gpt":0.37386616716232884,"score_spread":0.35356132430320636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046529949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993998,0.000040562376,0.00020194857,0.000013515074,0.0000026997043,0.000020866762,0.000058686208,0.000003184125,0.00025860156],"genre_scores_gemma":[0.999257,0.000017262802,0.00021911388,0.0000185203,0.000006862897,0.000023134575,0.000057120687,0.0000029445202,0.00039793376],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99923,0.00048457462,0.000028110859,0.000071165625,0.000087932975,0.000098168006],"domain_scores_gemma":[0.998018,0.0010833412,0.00025914895,0.00017385036,0.00010619914,0.0003594312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00129734,0.0004497667,0.0004688359,0.000442377,0.00064965826,0.0004988163,0.00027637757,0.0003834959,0.0021768254],"category_scores_gemma":[0.0026237906,0.00026502882,0.00071237166,0.0004971559,0.0005494522,0.000580066,0.00044476855,0.00070427504,0.0002894193],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028421419,0.003596369,0.9434398,0.000035232086,0.00034417905,0.00053886534,0.0004902965,0.0005347412,0.0133935865,0.00029329775,0.00011123837,0.00880104],"study_design_scores_gemma":[0.00028124964,0.019372705,0.97414905,0.00000468376,0.0001900899,0.00058438594,0.00056062266,0.0017184528,0.0025082023,0.00017985029,0.0004356287,0.000015146783],"about_ca_topic_score_codex":0.001840341,"about_ca_topic_score_gemma":0.0016935654,"teacher_disagreement_score":0.0021768254,"about_ca_system_score_codex":0.00039345218,"about_ca_system_score_gemma":0.00083672715,"threshold_uncertainty_score":0.0072821975},"labels":[],"label_agreement":null},{"id":"W2046548773","doi":"10.1007/s00280-012-1821-2","title":"Safety, tolerability, and pharmacokinetics of amuvatinib from three phase 1 clinical studies in healthy volunteers","year":2012,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Celerion (Canada)","funders":"Astex Pharmaceuticals","keywords":"Pharmacokinetics; Tolerability; Adverse effect; Medicine; Pharmacology; Internal medicine","score_opus":0.13440256156235775,"score_gpt":0.4982005911692453,"score_spread":0.36379802960688756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046548773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959111,0.001755937,0.00074045506,0.0001350344,0.00003369115,0.00024424976,0.0005193788,0.000060484137,0.0005995198],"genre_scores_gemma":[0.99754506,0.00051580137,0.00045976994,0.00015827533,0.00004343578,0.00014841901,0.0006727898,0.000019125318,0.00043733369],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99898964,0.0004827479,0.00009878735,0.0002046824,0.00011503222,0.000109042514],"domain_scores_gemma":[0.9989299,0.00034899343,0.00024732025,0.00014093025,0.00012775799,0.00020509024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025926298,0.0008033751,0.0012599252,0.00034253107,0.0006458182,0.0006580994,0.00040620388,0.00088413496,0.0015534253],"category_scores_gemma":[0.0024304872,0.00049124024,0.0011099624,0.0003420082,0.0008172679,0.0007936145,0.0003077871,0.0013420589,0.00041145863],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5799666,0.010515843,0.06291546,0.00091638573,0.0033652107,0.0011908133,0.001725446,0.0029095572,0.16395274,0.0003178844,0.0041736388,0.16805047],"study_design_scores_gemma":[0.091074534,0.5059513,0.33453593,0.00007590346,0.004463805,0.00418233,0.0008235268,0.0033963034,0.04564362,0.0009993978,0.008602982,0.00025037577],"about_ca_topic_score_codex":0.0006822389,"about_ca_topic_score_gemma":0.0011242845,"teacher_disagreement_score":0.0025926298,"about_ca_system_score_codex":0.00039768082,"about_ca_system_score_gemma":0.0005051339,"threshold_uncertainty_score":0.013711274},"labels":[],"label_agreement":null},{"id":"W2047075888","doi":"10.1007/s00280-011-1770-1","title":"A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)","year":2011,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Center for Research Resources; National Institutes of Health; Eisai","keywords":"Bexarotene; Carboplatin; Pharmacokinetics; Pharmacology; Paclitaxel; Medicine; Lung cancer; Chemotherapy; Concomitant; Oncology; Internal medicine; Cisplatin; Chemistry","score_opus":0.0075742791439560265,"score_gpt":0.27052403872635666,"score_spread":0.26294975958240063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047075888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99589914,0.0008812517,0.0004591201,0.00026634286,0.000089383066,0.0010663349,0.00036681737,0.000054671604,0.00091688],"genre_scores_gemma":[0.9934628,0.0012227626,0.0012490755,0.0003246243,0.00015879999,0.0010737473,0.0008650129,0.0000481496,0.0015949588],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999092,0.00046765682,0.000032994405,0.00016531568,0.00007439362,0.00016764046],"domain_scores_gemma":[0.99856406,0.0002975852,0.00021262487,0.0002049956,0.00006774609,0.00065303844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001686253,0.0016276955,0.0035472482,0.00061646634,0.00084895565,0.0014523559,0.0011493958,0.0015376001,0.0022826446],"category_scores_gemma":[0.0019060605,0.0010570463,0.0016070573,0.00089790556,0.0016380777,0.0018516497,0.00040968912,0.00566365,0.0007453819],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7629904,0.097662084,0.009648952,0.00035712324,0.0010511702,0.0003716853,0.00060918,0.0036982954,0.06086111,0.00038370813,0.0017442234,0.060622115],"study_design_scores_gemma":[0.35594502,0.6126555,0.017970039,0.000020472751,0.0005459705,0.00040815075,0.0001705974,0.0018115717,0.0075157876,0.00019824873,0.0026977067,0.00006098381],"about_ca_topic_score_codex":0.0029753281,"about_ca_topic_score_gemma":0.005024026,"teacher_disagreement_score":0.0035472482,"about_ca_system_score_codex":0.0014456215,"about_ca_system_score_gemma":0.002537628,"threshold_uncertainty_score":0.010488749},"labels":[],"label_agreement":null},{"id":"W2047269416","doi":"10.1007/s00280-014-2474-0","title":"A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors","year":2014,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Everolimus; Medicine; Panitumumab; Internal medicine; Regimen; Mucositis; Refractory (planetary science); Fluorouracil; Sirolimus; Oxaliplatin; Colorectal cancer; Gastroenterology; Oncology; Toxicity; Surgery; Chemotherapy; Cancer; KRAS","score_opus":0.008706825118384477,"score_gpt":0.2963860966402916,"score_spread":0.2876792715219071,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047269416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98973745,0.0030621022,0.0005940179,0.0011847282,0.00034679568,0.0013172129,0.0011900085,0.00013534144,0.0024323273],"genre_scores_gemma":[0.9870984,0.002280773,0.0018468165,0.001147362,0.00024530815,0.001439205,0.002506351,0.00004772175,0.0033880624],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99963796,0.00013802474,0.000018656385,0.00007840734,0.000023207243,0.00010365998],"domain_scores_gemma":[0.9994593,0.00008614808,0.00006561649,0.000043699543,0.000022399334,0.00032283433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012410335,0.0016655584,0.0026630887,0.0005051303,0.0004963808,0.0011484552,0.00086542586,0.0013164086,0.0037790758],"category_scores_gemma":[0.00079059944,0.0006973619,0.002026875,0.0005153293,0.0010464425,0.0011643836,0.00038134152,0.0044999984,0.0009106246],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85667014,0.031005088,0.0027682607,0.000564179,0.0018289323,0.00023472522,0.00023329671,0.0032009939,0.024780622,0.00039977505,0.0042269323,0.07408704],"study_design_scores_gemma":[0.7059111,0.28087357,0.0057690237,0.00002966453,0.00065431854,0.00022830066,0.000054054948,0.0010419214,0.0023515818,0.00023186182,0.0028224688,0.00003206415],"about_ca_topic_score_codex":0.0013891099,"about_ca_topic_score_gemma":0.00424696,"teacher_disagreement_score":0.0037790758,"about_ca_system_score_codex":0.0011150547,"about_ca_system_score_gemma":0.0014958668,"threshold_uncertainty_score":0.012642264},"labels":[],"label_agreement":null},{"id":"W2047405239","doi":"10.1007/s00280-005-0161-x","title":"Liposome formulation of a novel hydrophobic aryl-imidazole compound for anti-cancer therapy","year":2005,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Lipid Membrane Structure and Behavior","field":"Biochemistry, Genetics and Molecular Biology","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Liposome; In vivo; Pharmacokinetics; Bioavailability; Chemistry; Ethylene glycol; PEG ratio; Pharmacology; Toxicity; Drug; Phosphatidylcholine; Drug delivery; Solubility; Chromatography; Medicine; Biochemistry; Phospholipid; Biology; Organic chemistry; Membrane","score_opus":0.02425954105668785,"score_gpt":0.3342592471305177,"score_spread":0.3099997060738298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047405239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98014534,0.0034414306,0.011555615,0.00038971534,0.00015452616,0.00014174574,0.00018440504,0.00012463196,0.0038626294],"genre_scores_gemma":[0.9927128,0.0012268205,0.002678235,0.00006964558,0.000019591529,0.000042390122,0.00010191171,0.00000996394,0.0031384598],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99996686,0.000006491805,0.0000025013817,0.000006194878,0.000006995137,0.00001094938],"domain_scores_gemma":[0.999979,0.0000039505,0.000004675304,0.0000014675051,0.0000045567726,0.000006381589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000111207344,0.00016078788,0.00017205582,0.00008220213,0.000109130284,0.00019078661,0.00014539433,0.0002529366,0.0012800052],"category_scores_gemma":[0.00006836462,0.00006034212,0.00009092951,0.00006272312,0.00008426752,0.00022238858,0.00012102215,0.00029223194,0.00029517966],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036273614,0.00007247112,0.000036979873,0.000063533946,0.00000504671,0.00006612178,0.000012602975,0.00017620336,0.99402374,0.00028308562,0.00013918856,0.0047582965],"study_design_scores_gemma":[0.0000910871,0.0007167299,0.00033087158,0.000006216285,0.000022550434,0.00012102646,0.000012378356,0.0013469628,0.9936312,0.000034405184,0.0036814574,0.000005251247],"about_ca_topic_score_codex":0.00042658485,"about_ca_topic_score_gemma":0.00047702854,"teacher_disagreement_score":0.0012800052,"about_ca_system_score_codex":0.0002203539,"about_ca_system_score_gemma":0.00019328135,"threshold_uncertainty_score":0.0042820573},"labels":[],"label_agreement":null},{"id":"W2049287536","doi":"10.1007/s00280-008-0901-9","title":"Evaluation of the antitumoral effect of dihydrocucurbitacin-B in both in vitro and in vivo models","year":2009,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Advances in Cucurbitaceae Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"Universidade Federal de Santa Catarina; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior","keywords":"In vivo; In vitro; Pharmacology; Chemistry; Cancer research; Medicine; Biology; Biochemistry; Genetics","score_opus":0.020296621734548444,"score_gpt":0.3809015879668969,"score_spread":0.36060496623234845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049287536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98538893,0.0045750276,0.0051160194,0.00018139444,0.000095481286,0.00018604423,0.00080056966,0.00021945444,0.0034371314],"genre_scores_gemma":[0.98846453,0.0025635036,0.0030278799,0.000041646967,0.00003226901,0.00016907946,0.00090080436,0.000043708253,0.0047566304],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99970216,0.00011572385,0.000017444518,0.000031091186,0.000057979276,0.00007553382],"domain_scores_gemma":[0.9996952,0.00008084149,0.000042744334,0.00004570891,0.00006183142,0.000073703886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005857825,0.00071385043,0.00059928163,0.000652712,0.0003294927,0.00030393302,0.00045286526,0.00040634527,0.001616566],"category_scores_gemma":[0.00020064818,0.0002266467,0.00034261745,0.00048641974,0.0004283401,0.0004179763,0.0001440008,0.001091673,0.0004016129],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013746456,0.0005417771,0.0002190431,0.00012888672,0.00002175833,0.00004403955,0.000043883716,0.0003553251,0.9936325,0.00018149147,0.00010479976,0.003351901],"study_design_scores_gemma":[0.0000402881,0.0019801075,0.00056384027,0.0000029925914,0.000020347388,0.000040159746,0.000019232433,0.0005561543,0.9959656,0.000018787345,0.00078883965,0.0000036830643],"about_ca_topic_score_codex":0.002738684,"about_ca_topic_score_gemma":0.0025066268,"teacher_disagreement_score":0.002738684,"about_ca_system_score_codex":0.00041154845,"about_ca_system_score_gemma":0.0006159334,"threshold_uncertainty_score":0.0054454207},"labels":[],"label_agreement":null},{"id":"W2050286670","doi":"10.1007/s00280-002-0530-7","title":"Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts","year":2002,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Drug Transport and Resistance Mechanisms","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Armand Frappier Museum","funders":"","keywords":"HL60; Anthracycline; Cytarabine; Pharmacology; Cancer research; Biology; Leukemia; Medicine; Myeloid leukemia; Cancer; Internal medicine; Immunology","score_opus":0.02620409909074753,"score_gpt":0.32018289020110385,"score_spread":0.2939787911103563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050286670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99585706,0.0015850051,0.0002881629,0.000087756416,0.000039997827,0.00003900166,0.00018015827,0.000044044213,0.0018788317],"genre_scores_gemma":[0.9957736,0.0011926068,0.0004395054,0.00002171776,0.000016691904,0.000026791524,0.00043042054,0.000012896291,0.0020858268],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998858,0.000037724403,0.000008581965,0.000017020382,0.000016509908,0.000034238146],"domain_scores_gemma":[0.9998809,0.00004597765,0.000015259358,0.000020917823,0.000008591537,0.00002832876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003190618,0.00022863221,0.0003960912,0.0002254806,0.00018876397,0.00022225249,0.00022788506,0.000308646,0.0017331138],"category_scores_gemma":[0.00026055137,0.00017160378,0.00015440358,0.00018309892,0.00019839822,0.00024318905,0.000103469785,0.0005575279,0.0002343605],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026492889,0.00052241026,0.00051635853,0.00010732451,0.00002458059,0.00016502148,0.00008165192,0.0011824021,0.9846229,0.0002949225,0.00047355215,0.009359697],"study_design_scores_gemma":[0.0008811199,0.021522123,0.0064348606,0.000023030003,0.00006615241,0.0008259136,0.0000661244,0.0029665949,0.96219265,0.00007703289,0.0049313796,0.000012930161],"about_ca_topic_score_codex":0.0011809602,"about_ca_topic_score_gemma":0.0015173019,"teacher_disagreement_score":0.0017331138,"about_ca_system_score_codex":0.00026456884,"about_ca_system_score_gemma":0.0003197116,"threshold_uncertainty_score":0.005797863},"labels":[],"label_agreement":null},{"id":"W2051365306","doi":"10.1007/s00280-009-1064-z","title":"A phase II study of biweekly pemetrexed and gemcitabine in patients with metastatic breast cancer","year":2009,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada); Ottawa Regional Cancer Foundation; Ottawa Hospital","funders":"Eli Lilly Canada","keywords":"Gemcitabine; Pemetrexed; Medicine; Oncology; Internal medicine; Metastatic breast cancer; Breast cancer; Phases of clinical research; Antimetabolite; Cancer; Chemotherapy; Cisplatin","score_opus":0.016613805612389933,"score_gpt":0.35902117151985685,"score_spread":0.3424073659074669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051365306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935648,0.0017688707,0.0003806177,0.00051372615,0.00017101713,0.0016127991,0.00057398976,0.000068647125,0.0013455299],"genre_scores_gemma":[0.98837215,0.0025019192,0.0015103837,0.0007815598,0.00030765697,0.002412071,0.0012990318,0.000040465107,0.002774804],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9992169,0.00039976294,0.000035567606,0.00013986902,0.00004570788,0.00016207044],"domain_scores_gemma":[0.9986947,0.00027086973,0.00016894077,0.00015514177,0.000052996074,0.00065742893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001888938,0.0017255486,0.0037876144,0.00079058815,0.00071415224,0.0012607576,0.0014597629,0.0020517616,0.0053254343],"category_scores_gemma":[0.0014388093,0.001166249,0.0018939539,0.0008285195,0.0015689692,0.0019846947,0.00062262116,0.0058829593,0.0013079105],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87627345,0.07061214,0.0020013184,0.00032844456,0.0007192519,0.00008466776,0.00019753564,0.0012680577,0.010371817,0.00012650831,0.0010509259,0.036965944],"study_design_scores_gemma":[0.67843866,0.31458312,0.004188565,0.000015282369,0.00027445753,0.000073511044,0.000060479437,0.00043974578,0.0008626975,0.000092030794,0.00095100835,0.000020424788],"about_ca_topic_score_codex":0.0019262653,"about_ca_topic_score_gemma":0.0040373392,"teacher_disagreement_score":0.0053254343,"about_ca_system_score_codex":0.0011899337,"about_ca_system_score_gemma":0.0021977047,"threshold_uncertainty_score":0.017815351},"labels":[],"label_agreement":null},{"id":"W2052488949","doi":"10.1007/s002800000231","title":"Upregulation of gap junctional intercellular communication and connexin 43 expression by cyclic-AMP and all- trans -retinoic acid is associated with glutathione depletion and chemosensitivity in neuroblastoma cells","year":2001,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Connexins and lens biology","field":"Biochemistry, Genetics and Molecular Biology","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Steacie Institute for Molecular Sciences; McGill University; Jewish General Hospital","funders":"National Cancer Institute","keywords":"Connexin; Retinoic acid; Downregulation and upregulation; Intracellular; Gap junction; Neuroblastoma; Glutathione; Chemistry; Cell biology; Tretinoin; Biology; Cell culture; Biochemistry; Enzyme; Gene; Genetics","score_opus":0.014233740315112795,"score_gpt":0.2694739558026567,"score_spread":0.2552402154875439,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052488949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944443,0.0025548197,0.0007981173,0.000112044254,0.000023496998,0.000019020901,0.00060957065,0.00004394751,0.0013946841],"genre_scores_gemma":[0.99539435,0.0008880663,0.00064163894,0.000024771034,0.0000056452263,0.000039161358,0.00079003436,0.000008438303,0.002207869],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997819,0.000029514706,0.000033804943,0.000034778583,0.0000574019,0.000062531806],"domain_scores_gemma":[0.9998437,0.00002773025,0.000026760912,0.00003392427,0.000026912527,0.000040813222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018205632,0.0002197425,0.00057501986,0.0003767564,0.000382003,0.00039306548,0.00022806787,0.00029553278,0.0010456643],"category_scores_gemma":[0.0001878997,0.00029972807,0.00037622088,0.0003697447,0.00032393733,0.00046377385,0.0003165881,0.0005553193,0.00027189398],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003469733,0.000025323172,0.00064146245,0.000029744118,0.000008757665,0.00013218758,0.000071284616,0.000047955407,0.99792236,0.0001848635,0.000047843765,0.0005411478],"study_design_scores_gemma":[0.000016184775,0.00022981528,0.038297847,0.0000061111664,0.00002497379,0.00039745405,0.00020382478,0.0005166083,0.958202,0.00009466772,0.0020017338,0.0000087282415],"about_ca_topic_score_codex":0.0063142264,"about_ca_topic_score_gemma":0.0107096005,"teacher_disagreement_score":0.0063142264,"about_ca_system_score_codex":0.00085511565,"about_ca_system_score_gemma":0.0005681022,"threshold_uncertainty_score":0.012554944},"labels":[],"label_agreement":null},{"id":"W2057044337","doi":"10.1007/s00280-004-0853-7","title":"Evaluation of the cassette dosing approach for assessing the pharmacokinetics of geldanamycin analogues in mice","year":2004,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Pharmacokinetics; Geldanamycin; Pharmacology; Chemistry; Dosing; In vivo; Hsp90; Medicine; Heat shock protein; Biology; Biochemistry","score_opus":0.052465528900801674,"score_gpt":0.41054589129474733,"score_spread":0.35808036239394564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057044337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9727906,0.0010962841,0.021317182,0.00047355003,0.00021920998,0.0006376066,0.0013242718,0.0005108932,0.0016303507],"genre_scores_gemma":[0.9685611,0.0013084491,0.02332584,0.00019426395,0.00009813004,0.0008402561,0.0013832571,0.00021777995,0.0040709903],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991761,0.00023574996,0.000043186672,0.00016331807,0.00023750406,0.00014404731],"domain_scores_gemma":[0.99928075,0.00015515689,0.00022095541,0.00015051276,0.00008413253,0.00010848909],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008043576,0.00086030946,0.0009310352,0.00059898355,0.0002238503,0.00095647847,0.0007924526,0.001285245,0.0011726682],"category_scores_gemma":[0.00092643953,0.00045095198,0.00044013446,0.0004888736,0.0005804592,0.0006466814,0.00023383064,0.0025222579,0.00040199363],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018327528,0.0006598549,0.00040607282,0.000046285364,0.000037059242,0.000034446424,0.000052595704,0.0018074793,0.9847111,0.000341839,0.0003221048,0.009748439],"study_design_scores_gemma":[0.00030754553,0.012511591,0.002055227,0.000008644259,0.000075644646,0.00011085152,0.000027802884,0.004710677,0.9778529,0.000101417856,0.0022052384,0.00003246611],"about_ca_topic_score_codex":0.0015453832,"about_ca_topic_score_gemma":0.0018467773,"teacher_disagreement_score":0.0015453832,"about_ca_system_score_codex":0.0008436337,"about_ca_system_score_gemma":0.0007574217,"threshold_uncertainty_score":0.00612098},"labels":[],"label_agreement":null},{"id":"W2058737189","doi":"10.1007/s00280-007-0417-8","title":"Role of NADPH cytochrome P450 reductase in activation of RH1","year":2007,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Bioactive Compounds and Antitumor Agents","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Cytochrome P450; Reductase; Chemistry; Cytochrome P450 reductase; Pharmacology; Biochemistry; Cell biology; Enzyme; Biology; Cytochrome c; Apoptosis; Coenzyme Q – cytochrome c reductase","score_opus":0.06604078805472001,"score_gpt":0.44078947350474135,"score_spread":0.3747486854500213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058737189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.952966,0.00828639,0.01803609,0.0013662033,0.00019043263,0.00015530316,0.0009108843,0.0002991666,0.017789599],"genre_scores_gemma":[0.9898425,0.00091557886,0.0021131753,0.000062696396,0.00004247181,0.000016994616,0.0005020601,0.000019905474,0.0064847167],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999833,0.00006483008,0.0000063495113,0.000023957205,0.000026354886,0.00004556305],"domain_scores_gemma":[0.9998716,0.000042802218,0.00002079701,0.000017020935,0.000024249513,0.000023640381],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002757225,0.00034012683,0.00020420995,0.0001881916,0.0002634957,0.00024687106,0.00026586224,0.00028132292,0.0046974737],"category_scores_gemma":[0.00026565648,0.00010700566,0.00024013841,0.00008674647,0.00016887467,0.00018926697,0.00013194217,0.00038343138,0.0011086562],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011112187,0.00008716746,0.0013613066,0.00011388084,0.000031957818,0.0006280949,0.00005649399,0.0002868936,0.9823072,0.0021327788,0.0005321912,0.011350835],"study_design_scores_gemma":[0.000015066222,0.0002375589,0.004897581,0.0000048755355,0.000015584164,0.00081099564,0.000032310672,0.0006952476,0.98910284,0.00035105748,0.0038308706,0.0000060376397],"about_ca_topic_score_codex":0.0008588192,"about_ca_topic_score_gemma":0.00067780993,"teacher_disagreement_score":0.0046974737,"about_ca_system_score_codex":0.0003192745,"about_ca_system_score_gemma":0.00017873239,"threshold_uncertainty_score":0.015714586},"labels":[],"label_agreement":null},{"id":"W2060082838","doi":"10.1007/s00280-004-0776-3","title":"Inhibition of ?-glutamyl transpeptidase activity decreases intracellular cysteine levels in cervical carcinoma","year":2004,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Sulfur Compounds in Biology","field":"Biochemistry, Genetics and Molecular Biology","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Cysteine; In vivo; Glutathione; Intracellular; Cell culture; In vitro; Enzyme inhibitor; Enzyme; Biology; Biochemistry; Internal medicine; Chemistry; Molecular biology; Medicine","score_opus":0.01858617316590961,"score_gpt":0.2935874404988378,"score_spread":0.2750012673329282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060082838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967566,0.0011903945,0.00048693916,0.00016092685,0.00004433485,0.000022326029,0.00013171259,0.000059382404,0.0011473307],"genre_scores_gemma":[0.9968646,0.0007030362,0.00038288042,0.000039748502,0.000014649415,0.000026240683,0.00022008298,0.000013519299,0.0017352842],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998609,0.000029993102,0.000013626189,0.0000139288395,0.00002813566,0.000053486285],"domain_scores_gemma":[0.99984145,0.000046284003,0.000022988124,0.000025283176,0.000019500727,0.00004436337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019636979,0.0003062971,0.0006415778,0.00037137466,0.00034515877,0.00033507275,0.00042209725,0.00039789188,0.0018064831],"category_scores_gemma":[0.0003075225,0.00023661833,0.00026239414,0.00041186556,0.0003842168,0.00022137142,0.00018333197,0.0008369105,0.00031582898],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026222058,0.00023437754,0.00058276765,0.000057412428,0.000022787397,0.00010170857,0.000045965262,0.00018445325,0.99116397,0.0001841404,0.00019765426,0.004602487],"study_design_scores_gemma":[0.00012702572,0.0019143106,0.0029701623,0.0000045116417,0.000038272774,0.00017280424,0.000049579452,0.0009518166,0.9924488,0.00005564685,0.0012604567,0.0000066836774],"about_ca_topic_score_codex":0.0039021408,"about_ca_topic_score_gemma":0.005651914,"teacher_disagreement_score":0.0039021408,"about_ca_system_score_codex":0.00063343206,"about_ca_system_score_gemma":0.00067120296,"threshold_uncertainty_score":0.007758856},"labels":[],"label_agreement":null},{"id":"W2061780793","doi":"10.1007/s00280-007-0449-0","title":"Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model","year":2007,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":72,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute","keywords":"Paclitaxel; Ovarian cancer; Tolerability; Medicine; Drug delivery; Drug; Biocompatible material; Pharmacology; Intraperitoneal chemotherapy; Chemotherapy; Oncology; Cancer; Internal medicine; Adverse effect; Chemistry; Biomedical engineering","score_opus":0.02333756305921233,"score_gpt":0.3146053325226493,"score_spread":0.29126776946343697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061780793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99370474,0.00058859296,0.0044377963,0.000090830996,0.000049848088,0.000036570887,0.00009952296,0.0001608602,0.00083118386],"genre_scores_gemma":[0.99243104,0.000324994,0.0044024386,0.00003835529,0.000018507279,0.000031171687,0.00017785306,0.000043020333,0.0025327413],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992394,0.0000108040995,0.0000057755224,0.000023779463,0.0000147063465,0.00002109836],"domain_scores_gemma":[0.99992335,0.0000146836055,0.000024487024,0.000009480105,0.000009567315,0.000018562456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001414185,0.0003225967,0.0002504025,0.00029123787,0.00014206211,0.00022381784,0.00021235317,0.00029321454,0.001094496],"category_scores_gemma":[0.00012192054,0.00017406352,0.00020595948,0.00015127096,0.000198845,0.00032583694,0.0001109506,0.0004225071,0.00021318189],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036473328,0.00014947883,0.00008599308,0.000021396452,0.0000047077037,0.000031075233,0.000011611789,0.00009596149,0.99660647,0.00006203325,0.000073860676,0.0024926318],"study_design_scores_gemma":[0.000048304926,0.0007317805,0.0007910464,0.0000016159745,0.00002221233,0.00007421168,0.000004327926,0.0007922211,0.99676174,0.000010125465,0.0007584962,0.0000038497224],"about_ca_topic_score_codex":0.0007386337,"about_ca_topic_score_gemma":0.0009927097,"teacher_disagreement_score":0.001094496,"about_ca_system_score_codex":0.00027679052,"about_ca_system_score_gemma":0.0002687356,"threshold_uncertainty_score":0.0036614537},"labels":[],"label_agreement":null},{"id":"W2062565671","doi":"10.1007/s00280-014-2433-9","title":"DrugPath: a database for academic investigators to match oncology molecular targets with drugs in development","year":2014,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Computational Drug Discovery Methods","field":"Computer Science","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; BC Cancer Agency","funders":"","keywords":"Drug development; Identification (biology); Anticancer drug; Computational biology; Drug; Drug discovery; Molecular oncology; Medicine; Database; Bioinformatics; Pharmacology; Cancer; Computer science; Biology; Internal medicine","score_opus":0.023974330634110957,"score_gpt":0.3680921221212126,"score_spread":0.34411779148710164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062565671","genre_codex":"dataset","genre_gemma":"software","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"software","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01474004,0.004800371,0.0740126,0.0031593803,0.0003930707,0.00081778714,0.80875903,0.06816938,0.025148345],"genre_scores_gemma":[0.092434995,0.0072800773,0.11363838,0.0027993352,0.00024779883,0.001730904,0.7694592,0.0058532837,0.00655602],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993837,0.00013659404,0.00012925683,0.00014505044,0.00015833556,0.000047049503],"domain_scores_gemma":[0.993721,0.00312461,0.0008020844,0.0011718438,0.0006150252,0.0005654601],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021164818,0.0012137681,0.0014959275,0.0066202204,0.0005142346,0.0020476875,0.0025992857,0.0013881954,0.040062148],"category_scores_gemma":[0.014182409,0.0006824255,0.0010183835,0.007023532,0.00031528086,0.0018309314,0.0018135504,0.0012733077,0.0133236125],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002135851,0.0004086414,0.014103637,0.0029598656,0.0006218918,0.00056370656,0.00014707002,0.008316886,0.0035441595,0.018495923,0.79086334,0.15783906],"study_design_scores_gemma":[0.0016524289,0.00025123768,0.0067312126,0.00047958625,0.00084695005,0.0014461908,0.00017231137,0.03376835,0.00845387,0.028686136,0.9173821,0.00012957434],"about_ca_topic_score_codex":0.002598271,"about_ca_topic_score_gemma":0.0036064256,"teacher_disagreement_score":0.040062148,"about_ca_system_score_codex":0.000898357,"about_ca_system_score_gemma":0.003383375,"threshold_uncertainty_score":0.13402128},"labels":[],"label_agreement":null},{"id":"W2064175713","doi":"10.1007/s002800100294","title":"Antineoplastic action of 5-aza-2′-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor β and estrogen receptor α genes in breast carcinoma cells","year":2001,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":119,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Université de Montréal","funders":"","keywords":"Trichostatin A; DNA methylation; Molecular biology; Histone deacetylase; Cancer research; Biology; Histone deacetylase inhibitor; Retinoic acid receptor; Gene expression; Histone; Gene; Biochemistry","score_opus":0.0106146836701716,"score_gpt":0.27976561231300534,"score_spread":0.26915092864283374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064175713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98945576,0.007079117,0.00039865437,0.000126989,0.00008099418,0.000020812871,0.00037093688,0.000045554272,0.00242109],"genre_scores_gemma":[0.9913345,0.004581209,0.00046243556,0.000055400626,0.000025591411,0.000029101262,0.00066799374,0.000010773416,0.0028329208],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99985564,0.00003581933,0.00001406991,0.000018759873,0.000027756696,0.000047914604],"domain_scores_gemma":[0.999853,0.000051344858,0.00001920089,0.000024884104,0.000018434032,0.000033085988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019774496,0.0002193956,0.0005094198,0.00028496343,0.0001904086,0.00021707657,0.00027648115,0.00029148758,0.0018261577],"category_scores_gemma":[0.00026331138,0.00022766985,0.000246024,0.00035660042,0.00016825795,0.00016871742,0.00009902895,0.000538628,0.00027268523],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021213142,0.00018865765,0.0006188643,0.00010249199,0.000044625805,0.00017365444,0.00006392796,0.0003423928,0.9890553,0.0004121798,0.0002661037,0.0066105686],"study_design_scores_gemma":[0.00018221726,0.0021299284,0.01201568,0.000010771668,0.00006451437,0.0003521389,0.00006256657,0.0010231661,0.97936374,0.00006201263,0.004723205,0.0000099047475],"about_ca_topic_score_codex":0.0024575058,"about_ca_topic_score_gemma":0.004631617,"teacher_disagreement_score":0.0024575058,"about_ca_system_score_codex":0.00030675268,"about_ca_system_score_gemma":0.00037296326,"threshold_uncertainty_score":0.0061091185},"labels":[],"label_agreement":null},{"id":"W2066832802","doi":"10.1007/s00280-003-0711-z","title":"Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent","year":2003,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Etoposide; Pharmacokinetics; Dexrazoxane; Pharmacology; Medicine; Toxicity; Chemotherapy; Cancer; Internal medicine; Breast cancer; Anthracycline","score_opus":0.019167464852908944,"score_gpt":0.35378738882824584,"score_spread":0.3346199239753369,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066832802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997419,0.0011917003,0.00032418233,0.00010077777,0.000027517444,0.00004161835,0.00015671381,0.00004671804,0.00069189304],"genre_scores_gemma":[0.99861026,0.00023342666,0.0003046241,0.000062030296,0.00003643744,0.000026226686,0.0002510108,0.00002033266,0.00045570347],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9994185,0.00035500812,0.000027239996,0.00006414107,0.00006787393,0.000067211375],"domain_scores_gemma":[0.9989562,0.00037784214,0.00019967528,0.00013572449,0.000053718868,0.0002767655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007177308,0.00043854173,0.0013186553,0.0003150384,0.00031958392,0.00070647424,0.00038633126,0.0006127009,0.0014933029],"category_scores_gemma":[0.0026418036,0.0005128622,0.00057405856,0.00034733204,0.0005724388,0.0010918305,0.00019033236,0.0015005291,0.0004125894],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5770436,0.0047248392,0.072219655,0.00023758425,0.001312616,0.0020152815,0.0011003315,0.009601157,0.25553542,0.00082757085,0.0032980447,0.07208388],"study_design_scores_gemma":[0.033684824,0.24913107,0.5240502,0.000066822286,0.0016481227,0.0076929396,0.0010085043,0.026386779,0.14452443,0.00086230936,0.010704433,0.00023961971],"about_ca_topic_score_codex":0.0012631039,"about_ca_topic_score_gemma":0.0012055115,"teacher_disagreement_score":0.0014933029,"about_ca_system_score_codex":0.00061473204,"about_ca_system_score_gemma":0.000568454,"threshold_uncertainty_score":0.0049955845},"labels":[],"label_agreement":null},{"id":"W2067495120","doi":"10.1007/s00280-011-1606-z","title":"A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer","year":2011,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"FOLFOX; Oxaliplatin; Bevacizumab; Capecitabine; Medicine; Pharmacokinetics; Dosing; Colorectal cancer; Internal medicine; Oncology; Chemotherapy; Pharmacology; Gastroenterology; Cancer","score_opus":0.06911846102860347,"score_gpt":0.3775572727830627,"score_spread":0.30843881175445925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067495120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99699783,0.0005246936,0.00044139475,0.00023622812,0.00014410015,0.00089401024,0.00029958563,0.00005025339,0.00041195162],"genre_scores_gemma":[0.99420714,0.00041644377,0.0013879355,0.0005516189,0.00036117347,0.0013526605,0.0007689504,0.00003107987,0.00092308066],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99851316,0.0008199163,0.0000674817,0.00031307634,0.00009566792,0.00019058725],"domain_scores_gemma":[0.9972445,0.0006826812,0.00067087344,0.00034415346,0.00014038809,0.0009174459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026370273,0.0019632184,0.003758426,0.0004154304,0.00069631625,0.0013258411,0.0010218575,0.0018168973,0.0036463041],"category_scores_gemma":[0.0030566119,0.0011381421,0.0017077308,0.0006214867,0.002283104,0.002306094,0.0005731447,0.0042702393,0.0008413109],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97807866,0.010662908,0.0013543639,0.00006553583,0.0003062598,0.000020773079,0.00004342155,0.0003189671,0.0032066118,0.00005091791,0.00023935825,0.0056522205],"study_design_scores_gemma":[0.82116115,0.17317675,0.0037313844,0.000006813363,0.00028362562,0.000036231166,0.000021936492,0.00067399954,0.00049038604,0.00008312368,0.00031435868,0.000020149435],"about_ca_topic_score_codex":0.001160899,"about_ca_topic_score_gemma":0.001884207,"teacher_disagreement_score":0.003758426,"about_ca_system_score_codex":0.0014155053,"about_ca_system_score_gemma":0.0021030037,"threshold_uncertainty_score":0.013946116},"labels":[],"label_agreement":null},{"id":"W2071607258","doi":"10.1007/s002800000228","title":"A review of dose-limiting events in phase I trials: antimetabolites show unpredictable relationships between dose and toxicity","year":2000,"lang":"en","type":"review","venue":"Cancer Chemotherapy and Pharmacology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute","keywords":"Toxicity; Maximum tolerated dose; Limiting; Pharmacology; Medicine; Oncology; Internal medicine","score_opus":0.7038922919024159,"score_gpt":0.6398705854915662,"score_spread":0.0640217064108497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071607258","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001437718,0.99818796,0.0009960074,0.0002961809,0.00010035875,0.00002789526,0.00004028561,0.0000138288315,0.00019381254],"genre_scores_gemma":[0.0018043075,0.995994,0.001472295,0.00037812098,0.00014274109,0.0000557238,0.000033119042,0.0000062472336,0.00011352812],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9972065,0.00117885,0.0007135883,0.00019190682,0.00066721305,0.00004185205],"domain_scores_gemma":[0.9862088,0.011009484,0.0017851776,0.00017951142,0.00073287927,0.00008413154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054079643,0.0011457053,0.005260456,0.0024524098,0.00017234332,0.0012384505,0.0009787024,0.0008536205,0.0021044482],"category_scores_gemma":[0.015620579,0.0004689242,0.0018381516,0.0041548605,0.00062005344,0.0011854108,0.0004755623,0.0012554121,0.00062307465],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028205817,0.0000330322,0.00020995835,0.1210028,0.0010424415,0.000052828615,0.000040558756,0.0009120018,0.00039535065,0.0017849649,0.0138084,0.8604357],"study_design_scores_gemma":[0.0012531895,0.0014931778,0.006385588,0.14670572,0.018049961,0.0030773617,0.00015674514,0.0018379174,0.002106577,0.014131248,0.8046558,0.00014681795],"about_ca_topic_score_codex":0.0009304646,"about_ca_topic_score_gemma":0.002598354,"teacher_disagreement_score":0.0054079643,"about_ca_system_score_codex":0.0010605737,"about_ca_system_score_gemma":0.002602439,"threshold_uncertainty_score":0.028600335},"labels":[],"label_agreement":null},{"id":"W2071913509","doi":"10.1007/s00280-008-0712-z","title":"A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies","year":2008,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Proteoglycans and glycosaminoglycans research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute","keywords":"Medicine; Docetaxel; Pharmacokinetics; Gastroenterology; Internal medicine; Nausea; Chemotherapy; Pharmacology; Toxicity","score_opus":0.024059450511623004,"score_gpt":0.33412436485760605,"score_spread":0.31006491434598304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071913509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933507,0.0019387128,0.00044335297,0.0004286936,0.00010489941,0.0014671887,0.00081354624,0.000050722458,0.0014021219],"genre_scores_gemma":[0.98818123,0.003005993,0.0014800702,0.00074107427,0.00024691114,0.0019086064,0.0017542215,0.00003874089,0.0026430548],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99915695,0.0003967178,0.00003324479,0.00011222492,0.000065017724,0.00023578796],"domain_scores_gemma":[0.9989525,0.00022132459,0.00012943885,0.0001552545,0.000055047767,0.0004864154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015429343,0.001656742,0.0036306733,0.00086167135,0.0008158739,0.001185547,0.0012941979,0.0014120552,0.003380665],"category_scores_gemma":[0.0012549339,0.0010460827,0.0019707829,0.00095427193,0.0019995645,0.0012819861,0.00044269615,0.004958315,0.0008006636],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.64500374,0.17635886,0.010262766,0.0007118249,0.0014236947,0.00046959546,0.00069505634,0.005380913,0.047794495,0.00075517665,0.0038580345,0.10728587],"study_design_scores_gemma":[0.26710266,0.71168244,0.012635404,0.000025874084,0.00045316626,0.00030211196,0.00011734764,0.0007393832,0.0037010873,0.00018910461,0.0030101105,0.00004128804],"about_ca_topic_score_codex":0.0027961682,"about_ca_topic_score_gemma":0.005413656,"teacher_disagreement_score":0.0036306733,"about_ca_system_score_codex":0.0012735873,"about_ca_system_score_gemma":0.0025980636,"threshold_uncertainty_score":0.011309445},"labels":[],"label_agreement":null},{"id":"W2073746430","doi":"10.1007/s002800000223","title":"Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity","year":2001,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Armand Frappier Museum; BioPhage Pharma (Canada)","funders":"","keywords":"Cytidine; Cytidine deaminase; In vivo; Leukemia; Nucleoside; Cytarabine; Cancer research; Chemistry; Biology; Pharmacology; Biochemistry; Immunology; Enzyme","score_opus":0.059812744456622755,"score_gpt":0.39303638163254234,"score_spread":0.3332236371759196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073746430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975926,0.0013520815,0.00015135482,0.00003998638,0.000032800428,0.000040130977,0.00011388268,0.000015127033,0.0006620741],"genre_scores_gemma":[0.99743646,0.0010064022,0.0003113502,0.000019546917,0.000028504217,0.000025076537,0.00025908512,0.0000101913765,0.00090342195],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998393,0.00005252537,0.000010831555,0.000030718114,0.000021593858,0.000044956003],"domain_scores_gemma":[0.99978024,0.00007468836,0.000030961048,0.000024764042,0.000019003193,0.00007035881],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034445577,0.00030195605,0.0007836261,0.0003220095,0.00023310185,0.00034355896,0.00035999858,0.00042999376,0.00150559],"category_scores_gemma":[0.00035948536,0.00020231376,0.000295252,0.0002840883,0.00037628654,0.0005160081,0.00009979709,0.0007093486,0.00023680566],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040536553,0.0037492143,0.00081961346,0.00024378054,0.00013314739,0.00018754172,0.00013618055,0.0014037902,0.933374,0.00044562336,0.0003155797,0.018655008],"study_design_scores_gemma":[0.00622299,0.19612125,0.009159515,0.000025703966,0.0003701288,0.00089528784,0.000115510935,0.0031172861,0.77901,0.00013085497,0.00479429,0.000037184385],"about_ca_topic_score_codex":0.0016256534,"about_ca_topic_score_gemma":0.0022397488,"teacher_disagreement_score":0.0016256534,"about_ca_system_score_codex":0.00038150826,"about_ca_system_score_gemma":0.00043827156,"threshold_uncertainty_score":0.005036652},"labels":[],"label_agreement":null},{"id":"W2074046269","doi":"10.1007/s00280-005-0098-0","title":"Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer","year":2005,"lang":"en","type":"review","venue":"Cancer Chemotherapy and Pharmacology","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Prostate cancer; Androgen; Androgen receptor; Medicine; Cancer research; Clusterin; Cancer; Internal medicine; Oncology; Biology; Hormone; Apoptosis; Genetics","score_opus":0.03139075232972255,"score_gpt":0.4092197528021406,"score_spread":0.3778290004724181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074046269","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026101194,0.9979724,0.00025865046,0.00041036258,0.00020283283,0.0000063140765,0.000009720853,0.0000100827,0.00086863036],"genre_scores_gemma":[0.0018972867,0.9961164,0.00038234977,0.0003273308,0.00021355023,0.000009464001,0.000026054004,0.0000022592662,0.0010252268],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998599,0.000026652437,0.0000130824255,0.000022502281,0.000059865193,0.00001794237],"domain_scores_gemma":[0.9998203,0.00007577537,0.00002742759,0.000007255697,0.000043387954,0.00002590996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065259135,0.0008077603,0.0017573201,0.0011860026,0.00030358435,0.0010128673,0.0011004206,0.0010489009,0.0017731055],"category_scores_gemma":[0.00039329974,0.00024427637,0.00037055457,0.0014198762,0.0008466778,0.0011251476,0.0006159472,0.0023785853,0.0013189293],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002821156,0.00015081174,0.00019357447,0.007016833,0.000118585805,0.0002529302,0.0000603253,0.0010091759,0.0042689485,0.006297489,0.04390015,0.9364491],"study_design_scores_gemma":[0.000111444046,0.0001914736,0.00085770665,0.0009990709,0.000102323975,0.0011052581,0.00004309247,0.00029350983,0.0012826844,0.0026879478,0.9923012,0.000024223154],"about_ca_topic_score_codex":0.0016421245,"about_ca_topic_score_gemma":0.0041249534,"teacher_disagreement_score":0.0017731055,"about_ca_system_score_codex":0.0011097509,"about_ca_system_score_gemma":0.0010469337,"threshold_uncertainty_score":0.008051813},"labels":[],"label_agreement":null},{"id":"W2074712302","doi":"10.1007/s00280-003-0699-4","title":"Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells","year":2003,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Armand Frappier Museum","funders":"","keywords":"Cytarabine; In vivo; Pharmacology; Nucleoside; In vitro; Chemistry; Leukemia; Biology; Biochemistry; Immunology","score_opus":0.014840424263793414,"score_gpt":0.297704482429017,"score_spread":0.2828640581652236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074712302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909813,0.004554887,0.00028015062,0.000075787495,0.000037746537,0.00003199083,0.00028341997,0.000020460428,0.003734184],"genre_scores_gemma":[0.99549854,0.0018136678,0.0007225585,0.00003660474,0.000013963022,0.000020043706,0.0003968953,0.000005287694,0.0014924012],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998733,0.000043754517,0.000010229983,0.000018486691,0.000031629672,0.000022664371],"domain_scores_gemma":[0.99989915,0.00003879346,0.000011524467,0.000018525081,0.00001543059,0.000016608783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017382303,0.00018995056,0.00039535444,0.00023931329,0.00020763568,0.00029440844,0.00015950989,0.00029282682,0.0027333575],"category_scores_gemma":[0.00021333275,0.00012828349,0.00017830037,0.00022466856,0.00016033303,0.00023658315,0.00013464117,0.00041768313,0.00023978605],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011370898,0.0002045298,0.00032012566,0.00016431657,0.000023860326,0.00015803435,0.00008733598,0.00059944397,0.9875507,0.00047254015,0.000290053,0.008991956],"study_design_scores_gemma":[0.00029974387,0.0051932354,0.0063436995,0.000042695312,0.000056011137,0.0008221002,0.00009894463,0.001181906,0.9771509,0.00009867964,0.008701147,0.000010946257],"about_ca_topic_score_codex":0.0014297828,"about_ca_topic_score_gemma":0.0035759995,"teacher_disagreement_score":0.0027333575,"about_ca_system_score_codex":0.00026745605,"about_ca_system_score_gemma":0.00028752902,"threshold_uncertainty_score":0.009143949},"labels":[],"label_agreement":null},{"id":"W2075096471","doi":"10.1007/s00280-011-1657-1","title":"A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202","year":2011,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute","keywords":"Capecitabine; Gemcitabine; Medicine; Internal medicine; Gallbladder cancer; Gallbladder; Gastroenterology; Regimen; Cancer; Oncology; Biliary tract cancer; Colorectal cancer","score_opus":0.05717419124661998,"score_gpt":0.355581271116952,"score_spread":0.298407079870332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075096471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924028,0.001953236,0.00026863083,0.00074649963,0.00021564518,0.0014155149,0.0012358208,0.000060459723,0.0017012798],"genre_scores_gemma":[0.98416984,0.0026301502,0.0013367587,0.0015569257,0.00034677595,0.0023277462,0.0035083252,0.00004111497,0.004082306],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9987447,0.00085116865,0.000052984476,0.0001455474,0.000049856735,0.00015562032],"domain_scores_gemma":[0.99816436,0.00036855674,0.00029496854,0.00018035399,0.00008782479,0.00090399757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029025865,0.0023309882,0.003529501,0.000698265,0.0006756378,0.0013599026,0.0012569202,0.0018379103,0.00641241],"category_scores_gemma":[0.0021045662,0.0010740064,0.003018991,0.00094185874,0.0014842453,0.0014276882,0.000659208,0.004248297,0.0010927551],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94689757,0.020975236,0.004179334,0.00039552347,0.0018125403,0.000121992394,0.00017506664,0.001006101,0.0052887737,0.0001422523,0.0021862409,0.016819442],"study_design_scores_gemma":[0.83182186,0.16059089,0.0051714834,0.000017770686,0.00051877246,0.00007144253,0.000064561544,0.0002802547,0.00039233518,0.00007666843,0.0009771725,0.000016705193],"about_ca_topic_score_codex":0.0031772146,"about_ca_topic_score_gemma":0.008760241,"teacher_disagreement_score":0.00641241,"about_ca_system_score_codex":0.0013577329,"about_ca_system_score_gemma":0.0025733295,"threshold_uncertainty_score":0.021451652},"labels":[],"label_agreement":null},{"id":"W2075881224","doi":"10.1007/s00280-007-0544-2","title":"Identification, characterization and potent antitumor activity of ECO-4601, a novel peripheral benzodiazepine receptor ligand","year":2007,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Synthesis and pharmacology of benzodiazepine derivatives","field":"Chemistry","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Pharmacology; In vivo; Glioma; Receptor; Cell culture; Chemistry; Biology; Cancer research; Biochemistry; Genetics","score_opus":0.016617771239689334,"score_gpt":0.3031539496841207,"score_spread":0.28653617844443136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075881224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875485,0.0039439993,0.005410743,0.0001823577,0.00001495231,0.00008036984,0.00046308592,0.00005057467,0.002305456],"genre_scores_gemma":[0.9866426,0.003631559,0.004421721,0.00009214234,0.0000136412755,0.000047542126,0.0018279688,0.000016042262,0.003306752],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999913,0.000018020663,0.000006370083,0.000014182266,0.000027059856,0.000021399943],"domain_scores_gemma":[0.9999299,0.000008792741,0.000018666713,0.000008186753,0.000011337211,0.000023061944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018472661,0.00029995674,0.00029796868,0.00021385412,0.0001261975,0.0002720602,0.00023880157,0.00018888227,0.0006304949],"category_scores_gemma":[0.00018240244,0.00013739498,0.00014248457,0.00016813894,0.00017304347,0.00018868048,0.00015191347,0.00037589844,0.0004740782],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021939138,0.00011059227,0.0004409345,0.000043040593,0.000006173538,0.00012030671,0.000027222462,0.00041669715,0.9904811,0.00015669313,0.00010619299,0.007871731],"study_design_scores_gemma":[0.00018103402,0.0026024694,0.0066342624,0.0000110327655,0.000044577235,0.0022496178,0.000042623116,0.0022645087,0.97417295,0.00009974867,0.0116777895,0.000019443583],"about_ca_topic_score_codex":0.0008157133,"about_ca_topic_score_gemma":0.0010335683,"teacher_disagreement_score":0.0008157133,"about_ca_system_score_codex":0.00027124383,"about_ca_system_score_gemma":0.00035888236,"threshold_uncertainty_score":0.0021092296},"labels":[],"label_agreement":null},{"id":"W2077355516","doi":"10.1007/s002800050033","title":"Modulation of Adriamycin cytotoxicity and transport in drug-sensitive and multidrug-resistant Chinese hamster ovary cells by hyperthermia and cyclosporin A","year":2000,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Drug Transport and Resistance Mechanisms","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal","funders":"National Cancer Institute","keywords":"Cytotoxicity; Hyperthermia; Pharmacology; Chinese hamster ovary cell; Doxorubicin; Membrane permeability; P-glycoprotein; Clonogenic assay; Multiple drug resistance; Intracellular; Cell culture; Biology; Chemistry; Chemotherapy; Drug resistance; Biochemistry; In vitro; Membrane","score_opus":0.0054470357018174,"score_gpt":0.2585138945395139,"score_spread":0.2530668588376965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077355516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980697,0.0005829019,0.0005483405,0.000048658956,0.000018213364,0.000011886173,0.00012053837,0.000023682953,0.0005760828],"genre_scores_gemma":[0.99864846,0.0002632212,0.0002681789,0.000012127139,0.0000061990063,0.000011352676,0.00013984399,0.000007669044,0.00064293155],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998209,0.000042684525,0.00002374103,0.000025036241,0.000039963947,0.000047821457],"domain_scores_gemma":[0.9998299,0.00005737346,0.000026290441,0.0000352273,0.000021727325,0.000029450242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020010637,0.00022554341,0.0003706593,0.00028971166,0.0003020839,0.00041164632,0.00019933835,0.00023407333,0.00079341413],"category_scores_gemma":[0.00018949487,0.00016908863,0.00031417605,0.00033322666,0.00031927146,0.00033243024,0.0001748335,0.0005249848,0.00014841303],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003761069,0.00004515405,0.0002784277,0.000020500653,0.000007176599,0.00004461054,0.000050653398,0.00012064391,0.99806565,0.00021781403,0.000024619207,0.000748668],"study_design_scores_gemma":[0.000030256499,0.0003645842,0.0050157714,0.0000019977156,0.000015192044,0.000099613375,0.000043717446,0.001205837,0.9925136,0.000035980578,0.00066714984,0.000006239436],"about_ca_topic_score_codex":0.0024363988,"about_ca_topic_score_gemma":0.0024558369,"teacher_disagreement_score":0.0024363988,"about_ca_system_score_codex":0.00058753433,"about_ca_system_score_gemma":0.00031035003,"threshold_uncertainty_score":0.004844427},"labels":[],"label_agreement":null},{"id":"W2082878515","doi":"10.1007/s00280-009-1110-x","title":"Differential roles of Trk and p75 neurotrophin receptors in tumorigenesis and chemoresistance ex vivo and in vivo","year":2009,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Nerve injury and regeneration","field":"Neuroscience","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"National Institute of Neurological Disorders and Stroke; National Cancer Institute; National Institutes of Health; Cancer Research Society","keywords":"Tropomyosin receptor kinase A; Trk receptor; Low-affinity nerve growth factor receptor; Tropomyosin receptor kinase C; Neurotrophin; Biology; Cancer research; Receptor; Platelet-derived growth factor receptor; Growth factor","score_opus":0.016339139668434796,"score_gpt":0.29725041431848087,"score_spread":0.28091127465004606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082878515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99266726,0.002303634,0.0026150886,0.00013844205,0.000037993617,0.0000138461655,0.00023065173,0.000058378373,0.0019347976],"genre_scores_gemma":[0.995187,0.0007166725,0.0009076454,0.000027929755,0.000011158746,0.000019037792,0.00017141401,0.000017234646,0.0029418776],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99975246,0.000048664268,0.000015920868,0.00004093337,0.00004871776,0.00009320626],"domain_scores_gemma":[0.99987626,0.000027600236,0.000025969968,0.000025713052,0.000014550434,0.00002985988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023086743,0.00029661926,0.00032449834,0.00041463022,0.0002533628,0.00054229895,0.00025546734,0.00028856215,0.0018104117],"category_scores_gemma":[0.0001937356,0.00026477678,0.00027862642,0.00022260369,0.00038444047,0.00083450123,0.0001587161,0.0009131839,0.00041707433],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005664279,0.00009179965,0.0002869356,0.000028176912,0.000010800546,0.00004934023,0.00003971615,0.00007770499,0.99589264,0.0004016523,0.00007463273,0.0024801749],"study_design_scores_gemma":[0.000035696467,0.00063873746,0.008173785,0.000005100889,0.000047523237,0.00039925735,0.00013687926,0.0011113378,0.98795635,0.00015284117,0.001334953,0.000007441283],"about_ca_topic_score_codex":0.0014498347,"about_ca_topic_score_gemma":0.0019535394,"teacher_disagreement_score":0.0018104117,"about_ca_system_score_codex":0.00045175786,"about_ca_system_score_gemma":0.0003205781,"threshold_uncertainty_score":0.0060563684},"labels":[],"label_agreement":null},{"id":"W2083324782","doi":"10.1007/s00280-006-0343-1","title":"Class III β-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site","year":2006,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Hospices Civils de Lyon","keywords":"Paclitaxel; Tubulin; Cancer research; Primary (astronomy); Oncology; Class (philosophy); Internal medicine; Medicine; Biology; Microtubule; Chemotherapy; Genetics; Computer science","score_opus":0.011221506565915439,"score_gpt":0.293799886724627,"score_spread":0.28257838015871156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083324782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958198,0.0010854284,0.00035791413,0.000060864986,0.000010148499,0.000008811461,0.00014433044,0.000036541547,0.0024762228],"genre_scores_gemma":[0.99851996,0.00032219026,0.00018485816,0.000018195671,0.000009273404,0.0000049770206,0.00018799322,0.000008331666,0.00074432825],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998603,0.000018894749,0.00001381485,0.000030739157,0.000039103663,0.000037118833],"domain_scores_gemma":[0.9995864,0.00010027809,0.00012093541,0.00003260176,0.000084801504,0.00007491039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019197125,0.00014594995,0.0002765178,0.0011468612,0.0003519402,0.0006243843,0.00018178519,0.00033776843,0.002311358],"category_scores_gemma":[0.00076972117,0.00018108921,0.00014192873,0.0006437687,0.00019674649,0.00024314821,0.00014073109,0.00029784543,0.00044357855],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017123596,0.00007427659,0.7033072,0.00008839198,0.00008459427,0.002141166,0.00016518618,0.00017686705,0.27372336,0.00013403657,0.0003798005,0.018012818],"study_design_scores_gemma":[0.000013487849,0.0003771053,0.94920844,0.000011355654,0.000121375706,0.008811453,0.00028200465,0.0008184435,0.03868271,0.00010563252,0.0015625729,0.000005522231],"about_ca_topic_score_codex":0.002194334,"about_ca_topic_score_gemma":0.0023114912,"teacher_disagreement_score":0.002311358,"about_ca_system_score_codex":0.00035914467,"about_ca_system_score_gemma":0.00016519833,"threshold_uncertainty_score":0.0077322125},"labels":[],"label_agreement":null},{"id":"W2088605318","doi":"10.1007/s00280-007-0579-4","title":"Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety","year":2007,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Pfizer","keywords":"Pharmacokinetics; Dosing; Medicine; Adverse effect; Toxicity; Internal medicine; Tyrosine-kinase inhibitor; Incidence (geometry); Pharmacology; Clinical trial; Gastroenterology; Oncology; Cancer","score_opus":0.018120891819779165,"score_gpt":0.380221315198652,"score_spread":0.3621004233788728,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088605318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968125,0.0013771493,0.0004858131,0.0001775494,0.0000214626,0.00003943505,0.00026901564,0.00005918361,0.00075785513],"genre_scores_gemma":[0.9984617,0.0004020992,0.00027460064,0.00009659736,0.00003823366,0.00002203724,0.00029536977,0.000018249402,0.0003911503],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9996331,0.00016824824,0.000022975182,0.00005480368,0.00006777491,0.000053084837],"domain_scores_gemma":[0.9990189,0.0003315704,0.00026621678,0.00005912964,0.00006205261,0.00026221797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000576673,0.00047519617,0.0013397876,0.00036784878,0.00028107522,0.0006493946,0.00028083497,0.00046998655,0.00095945393],"category_scores_gemma":[0.0026941448,0.00042388475,0.0005278871,0.0005138686,0.0002907019,0.00070750545,0.00015656871,0.0017507893,0.00026500484],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42337278,0.0061151744,0.19491026,0.0003226754,0.0020695212,0.0014532121,0.0005454633,0.013072213,0.13339521,0.0005599977,0.003601016,0.22058247],"study_design_scores_gemma":[0.02662511,0.16548423,0.7290282,0.000053871554,0.0021072316,0.005074981,0.00031042032,0.022690233,0.040458713,0.0006098747,0.0073786364,0.00017842591],"about_ca_topic_score_codex":0.0015101619,"about_ca_topic_score_gemma":0.0020052532,"teacher_disagreement_score":0.0015101619,"about_ca_system_score_codex":0.0008203549,"about_ca_system_score_gemma":0.00082323706,"threshold_uncertainty_score":0.00595212},"labels":[],"label_agreement":null},{"id":"W2091073184","doi":"10.1007/s00280-004-0941-8","title":"Pancratistatin causes early activation of caspase-3 and the flipping of phosphatidyl serine followed by rapid apoptosis specifically in human lymphoma cells","year":2005,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Chemical synthesis and alkaloids","field":"Chemistry","cited_by":112,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Windsor","funders":"University of Windsor","keywords":"Apoptosis; Cancer cell; DNA fragmentation; DNA damage; Programmed cell death; Biology; Caspase; Cell biology; DNA; Cancer research; Molecular biology; Cancer; Biochemistry; Genetics","score_opus":0.01018464371079852,"score_gpt":0.2613468441754455,"score_spread":0.251162200464647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091073184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928423,0.0018974892,0.001912768,0.00011802149,0.000047132595,0.00006215275,0.00060971046,0.00011186567,0.0023985216],"genre_scores_gemma":[0.99608886,0.0006977778,0.0007756422,0.00004656781,0.000013907452,0.00003167029,0.0005225952,0.000012007189,0.0018110739],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998683,0.00002200188,0.000010634261,0.000020194257,0.000030759344,0.00004810146],"domain_scores_gemma":[0.9999101,0.000018683511,0.000017577213,0.000020408695,0.000013909852,0.000019339082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010724051,0.00023712151,0.00025245664,0.00017719601,0.00012884852,0.00018505468,0.00012664884,0.00023997521,0.0012564851],"category_scores_gemma":[0.000105302075,0.00013674071,0.00022886883,0.00020538372,0.000112770176,0.00019712241,0.00012865529,0.00048458084,0.000475667],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029535106,0.00002982311,0.00012653752,0.000023301205,0.000004378484,0.00006191543,0.00001176961,0.000038070204,0.99846786,0.0000500547,0.00005200355,0.00083895144],"study_design_scores_gemma":[0.000035486202,0.0005602754,0.00318355,0.0000014921183,0.0000101208425,0.00037261625,0.000012884133,0.0003048485,0.9942298,0.000024226643,0.0012628975,0.0000018844269],"about_ca_topic_score_codex":0.00068572204,"about_ca_topic_score_gemma":0.0011690864,"teacher_disagreement_score":0.0012564851,"about_ca_system_score_codex":0.00032667082,"about_ca_system_score_gemma":0.0002036923,"threshold_uncertainty_score":0.004203379},"labels":[],"label_agreement":null},{"id":"W2091972238","doi":"10.1007/s002800100348","title":"The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity","year":2001,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Dexrazoxane; Cardiotoxicity; Medicine; Doxorubicin; Mitoxantrone; Cardioprotection; Pharmacology; Chemotherapy; Cumulative dose; Urology; Internal medicine; Myocardial infarction; Anthracycline; Cancer","score_opus":0.06302401746380445,"score_gpt":0.3387333388777059,"score_spread":0.2757093214139015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091972238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99574226,0.0014532777,0.001552273,0.000099734054,0.00008021801,0.0000608455,0.00013675012,0.000022208604,0.000852444],"genre_scores_gemma":[0.99620795,0.0005520397,0.002006955,0.0000751934,0.000028066923,0.00006996708,0.0002218997,0.0000045537236,0.0008333882],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997321,0.00010509814,0.000028572844,0.0000430273,0.000053983822,0.000037153597],"domain_scores_gemma":[0.99961346,0.00010176097,0.00009700418,0.000050191094,0.00004498294,0.00009264487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057111884,0.00047731624,0.00051262596,0.00027629826,0.00017923089,0.0003270114,0.0001456598,0.00040945702,0.00073230965],"category_scores_gemma":[0.0007407431,0.00012140255,0.0002519649,0.0002811307,0.00042748678,0.00036792314,0.00011260554,0.0008952505,0.00009079356],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015974455,0.0010082969,0.019082775,0.00012032372,0.00010611466,0.00014510295,0.000098773715,0.00023314798,0.94744503,0.00024394794,0.0000926808,0.015449203],"study_design_scores_gemma":[0.00066274113,0.042683613,0.087038286,0.0000147834435,0.0001989456,0.00090733735,0.00012760561,0.0019616408,0.8649263,0.00017498185,0.0012803953,0.000023214301],"about_ca_topic_score_codex":0.00040382036,"about_ca_topic_score_gemma":0.0006229108,"teacher_disagreement_score":0.00073230965,"about_ca_system_score_codex":0.0001893215,"about_ca_system_score_gemma":0.00028464626,"threshold_uncertainty_score":0.0030204058},"labels":[],"label_agreement":null},{"id":"W2092074789","doi":"10.1007/s00280-004-0984-x","title":"Human cells deficient in transcription-coupled repair show prolonged activation of the Jun N-terminal kinase and increased sensitivity following cisplatin treatment","year":2005,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Cancer Institute","keywords":"Xeroderma pigmentosum; Cockayne syndrome; Cisplatin; Nucleotide excision repair; DNA repair; DNA damage; Molecular biology; Kinase; Biology; c-jun; Programmed cell death; Cancer research; Cell biology; Chemistry; Transcription factor; DNA; Gene; Apoptosis; Biochemistry; Genetics; Chemotherapy","score_opus":0.011896685481671339,"score_gpt":0.28246559295964296,"score_spread":0.27056890747797163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092074789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99143046,0.0027502147,0.0031768412,0.00010104447,0.00006331884,0.000037551326,0.0009921675,0.00009304721,0.0013554108],"genre_scores_gemma":[0.9938923,0.0011271073,0.0010246275,0.000032240314,0.000008364108,0.00003323941,0.0017244832,0.000018746947,0.0021388505],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997962,0.000030140378,0.000025346491,0.000031539406,0.00005681469,0.000059895698],"domain_scores_gemma":[0.9998087,0.00004982881,0.000033416716,0.00004951101,0.000023900462,0.000034682103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018287367,0.00031042224,0.0006111032,0.00035498416,0.00021728115,0.0003931492,0.00018927979,0.00034968572,0.0030992636],"category_scores_gemma":[0.00026300902,0.00025039818,0.00035347868,0.00048520137,0.0002167932,0.00020351524,0.00020684135,0.0005756362,0.00092735136],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004616296,0.000047861824,0.00058910757,0.000032092605,0.000016824953,0.00013646792,0.000036571473,0.000080077756,0.99732935,0.00010789666,0.00009380153,0.0010681399],"study_design_scores_gemma":[0.000030181669,0.00057316566,0.013575219,0.000005095275,0.000035179193,0.0015506742,0.00005245951,0.0005934922,0.9810585,0.00006872602,0.002448892,0.000008442644],"about_ca_topic_score_codex":0.0010799,"about_ca_topic_score_gemma":0.00070616027,"teacher_disagreement_score":0.0030992636,"about_ca_system_score_codex":0.00023270393,"about_ca_system_score_gemma":0.0001774625,"threshold_uncertainty_score":0.010368049},"labels":[],"label_agreement":null},{"id":"W2094042165","doi":"10.1007/s00280-001-0385-3","title":"Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts","year":2002,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"National Cancer Institute","keywords":"Pharmacokinetics; Cmax; Pharmacology; Bioavailability; Doxorubicin; Chemistry; Anthracycline; Cancer; Breast cancer; Internal medicine; Medicine; Chemotherapy","score_opus":0.011592364575569109,"score_gpt":0.2842237320510442,"score_spread":0.27263136747547506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094042165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931672,0.0014822029,0.0015543222,0.00025382894,0.0001703048,0.00010159535,0.00083172915,0.00025790927,0.0021809714],"genre_scores_gemma":[0.9927021,0.0008560927,0.00096246484,0.00007660128,0.00009267164,0.000108204724,0.0005581912,0.00009707099,0.004546553],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997111,0.00008818648,0.000012035394,0.000050677136,0.00004203643,0.000095874995],"domain_scores_gemma":[0.99950993,0.0001545401,0.000101449674,0.000049945207,0.00002958058,0.00015468283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035963446,0.0005933614,0.00090334995,0.00051175326,0.000290274,0.00061475986,0.0004170199,0.00072106894,0.0017582304],"category_scores_gemma":[0.0006042715,0.0005223791,0.0003722017,0.0003845024,0.000522304,0.00081358134,0.00015437913,0.0015015654,0.0005208227],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04774092,0.0025611848,0.0014116083,0.00011418652,0.00009731299,0.00018758376,0.00020966833,0.0027664334,0.92607075,0.0005918548,0.0014066931,0.016841847],"study_design_scores_gemma":[0.002131411,0.04130136,0.009474122,0.000019363912,0.0002701653,0.0003603525,0.00012468529,0.011370795,0.9310062,0.00032241558,0.0035624313,0.00005666062],"about_ca_topic_score_codex":0.0026208363,"about_ca_topic_score_gemma":0.0034228228,"teacher_disagreement_score":0.0026208363,"about_ca_system_score_codex":0.00072552304,"about_ca_system_score_gemma":0.00085884985,"threshold_uncertainty_score":0.005881846},"labels":[],"label_agreement":null},{"id":"W2094118633","doi":"10.1007/s00280-004-0836-8","title":"Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies","year":2004,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Research Resources; National Cancer Institute; National Institute of Biomedical Imaging and Bioengineering; National Institute of Mental Health","keywords":"Pharmacokinetics; NONMEM; Population; Medicine; Population pharmacokinetics; Pharmacology; Internal medicine","score_opus":0.007054605613093194,"score_gpt":0.28416593735180146,"score_spread":0.2771113317387083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094118633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99853015,0.00015125512,0.00080026925,0.000030002644,0.0000033490783,0.000012408864,0.00017604245,0.000031823332,0.00026471925],"genre_scores_gemma":[0.99903935,0.00007203285,0.00032837022,0.000036626352,0.000009291147,0.000017030301,0.00025546853,0.000008459863,0.00023348107],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999608,0.0001598333,0.000019337629,0.00009297876,0.000077318655,0.000042539923],"domain_scores_gemma":[0.99927276,0.000311974,0.00015665403,0.00008035815,0.00006836853,0.00010984873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005195987,0.00024442803,0.00059367646,0.00020857959,0.00015548313,0.00041440382,0.00013584385,0.0003240788,0.00088230026],"category_scores_gemma":[0.0017216154,0.00020508647,0.00030962183,0.00028335906,0.00017385437,0.00032367924,0.00016315126,0.0006359905,0.00020109292],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02969325,0.00081617705,0.8682487,0.000061044484,0.0008521468,0.00053300103,0.00046273854,0.0058335606,0.039260082,0.0003631373,0.0010650607,0.05281116],"study_design_scores_gemma":[0.0005516608,0.01669024,0.95423824,0.000007217795,0.00049718906,0.0022449482,0.0002113247,0.013222163,0.009549619,0.00029473047,0.0024528932,0.000039770897],"about_ca_topic_score_codex":0.00090679293,"about_ca_topic_score_gemma":0.0006466789,"teacher_disagreement_score":0.00090679293,"about_ca_system_score_codex":0.00034011243,"about_ca_system_score_gemma":0.00035825712,"threshold_uncertainty_score":0.0029515624},"labels":[],"label_agreement":null},{"id":"W2094417916","doi":"10.1007/s00280-010-1379-9","title":"Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy","year":2010,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University of Calgary; McGill University; Dr. H. Bliss Murphy Cancer Centre; Saskatchewan Cancer Agency; Aptose Biosciences (Canada); Alberta Cancer Foundation","funders":"","keywords":"Medicine; Nimotuzumab; Chills; Rash; Toxicity; Internal medicine; Lung cancer; Regimen; Oncology; Gastroenterology; Radiation therapy; Phases of clinical research; Surgery; Cancer; Epidermal growth factor receptor","score_opus":0.030605001814380035,"score_gpt":0.4110274883242362,"score_spread":0.38042248650985616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094417916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935295,0.00097018987,0.00018933874,0.0006027609,0.00015978474,0.0018264574,0.0007588581,0.000048969567,0.001914248],"genre_scores_gemma":[0.99118114,0.001311517,0.001075469,0.0005403261,0.00015217578,0.0010706674,0.0017410829,0.00001976031,0.0029079202],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994677,0.00015204551,0.000014800917,0.00009390238,0.000060556973,0.00021111843],"domain_scores_gemma":[0.99925596,0.00004633951,0.00008804821,0.00003852871,0.000056137265,0.00051507965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013053232,0.0018080471,0.0021801393,0.00041275207,0.0011921643,0.0011146097,0.0017061537,0.0013510764,0.0035819667],"category_scores_gemma":[0.00095665565,0.0007256417,0.0014711644,0.00081928854,0.0017971463,0.0005878107,0.00058131735,0.0028060086,0.00069921155],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8786906,0.045079913,0.009917454,0.00027712804,0.00091616757,0.0002030945,0.00039726353,0.0020101697,0.014938542,0.0002661632,0.004178547,0.043125022],"study_design_scores_gemma":[0.55545646,0.39191362,0.042059977,0.000035896013,0.00083674915,0.0002580257,0.00020831531,0.001589824,0.0023794214,0.00020690057,0.0049958047,0.000058953923],"about_ca_topic_score_codex":0.19213496,"about_ca_topic_score_gemma":0.3913373,"teacher_disagreement_score":0.807865,"about_ca_system_score_codex":0.008837877,"about_ca_system_score_gemma":0.014633398,"threshold_uncertainty_score":0.38203323},"labels":[],"label_agreement":null},{"id":"W2094704437","doi":"10.1007/s00280-007-0442-7","title":"O6-benzylguanine and BCNU in multiple myeloma: a phase II trial","year":2007,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Center for Research Resources; National Cancer Institute","keywords":"Carmustine; Medicine; Multiple myeloma; Neutropenia; Internal medicine; Chemotherapy; Bone marrow; Toxicity; Oncology; Gastroenterology; Regimen; Pharmacology; Etoposide","score_opus":0.04729938861380173,"score_gpt":0.412195691664822,"score_spread":0.3648963030510203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094704437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9797417,0.010548367,0.00060867105,0.0020075834,0.00056485395,0.0019851907,0.001267905,0.00019518036,0.0030806835],"genre_scores_gemma":[0.9747269,0.010415767,0.0014401722,0.0022192867,0.0007796497,0.0027123129,0.0021683865,0.00008099006,0.0054564313],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999228,0.00034705072,0.0000336543,0.00014538955,0.00005868692,0.00018711487],"domain_scores_gemma":[0.99888355,0.00022368965,0.0001462086,0.00011244336,0.000042820688,0.0005912394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018507852,0.0025491065,0.0051717116,0.00085384876,0.00072183623,0.0014121656,0.0016266598,0.0031192757,0.0054358323],"category_scores_gemma":[0.0012380488,0.0008805651,0.0022719274,0.0011074814,0.0018782251,0.0016217745,0.0007524775,0.006615468,0.0011418604],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.859578,0.032319963,0.0014727826,0.0008504522,0.0016872892,0.00018477184,0.00019791673,0.001853594,0.013582636,0.00036223588,0.0037234616,0.08418686],"study_design_scores_gemma":[0.82840836,0.16481544,0.002086796,0.00003959835,0.00040437802,0.000112098256,0.000032778666,0.0003677212,0.0014318812,0.0001990442,0.0020822873,0.000019624284],"about_ca_topic_score_codex":0.002809779,"about_ca_topic_score_gemma":0.004964499,"teacher_disagreement_score":0.0054358323,"about_ca_system_score_codex":0.0014785794,"about_ca_system_score_gemma":0.0022925448,"threshold_uncertainty_score":0.018184662},"labels":[],"label_agreement":null},{"id":"W2095031513","doi":"10.1007/s00280-012-1889-8","title":"A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors","year":2012,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Institut national de la recherche scientifique; Amgen","keywords":"Everolimus; Bevacizumab; Panitumumab; Solid tumor; Medicine; Oncology; Internal medicine; Cancer research; Chemotherapy; Cancer; Colorectal cancer; KRAS","score_opus":0.017694038033376425,"score_gpt":0.3676464043998438,"score_spread":0.34995236636646737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095031513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913687,0.0027423515,0.00066879956,0.00063771155,0.00020349614,0.0016916265,0.000986354,0.00009032549,0.0016106761],"genre_scores_gemma":[0.98564535,0.0033075546,0.0021671925,0.0007642637,0.00019877833,0.0021303461,0.0025412354,0.00006265082,0.003182668],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994816,0.00021284928,0.000019899924,0.000096161544,0.000044877645,0.00014455865],"domain_scores_gemma":[0.99921846,0.00010366432,0.000092964874,0.00007946855,0.00004353799,0.00046192456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016475228,0.0016878702,0.0028892665,0.0007270739,0.0006490651,0.001205469,0.0011099423,0.0014821338,0.002635059],"category_scores_gemma":[0.0007603173,0.00091140845,0.0016101527,0.00071563025,0.0013082761,0.0010815761,0.00040225586,0.0039336113,0.0007066898],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6963559,0.119048044,0.0041621793,0.00068297854,0.0016742552,0.00032618913,0.00035681203,0.0049397647,0.07765629,0.00060029246,0.0053061103,0.088891186],"study_design_scores_gemma":[0.5244027,0.45600754,0.0066004964,0.000024534273,0.000605223,0.00027729812,0.00007373135,0.0010508677,0.0071257525,0.00026238465,0.0035316807,0.00003785532],"about_ca_topic_score_codex":0.0023174665,"about_ca_topic_score_gemma":0.0055168164,"teacher_disagreement_score":0.0028892665,"about_ca_system_score_codex":0.0011473912,"about_ca_system_score_gemma":0.0020519588,"threshold_uncertainty_score":0.008815169},"labels":[],"label_agreement":null},{"id":"W2100822088","doi":"10.1007/s00280-004-0813-2","title":"Inhibition of HUVEC tubulogenesis by hederacolchiside-A1 is associated with plasma membrane cholesterol sequestration and activation of the Ha-Ras/MEK/ERK cascade","year":2004,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Natural product bioactivities and synthesis","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Université du Québec à Montréal","funders":"Canadian Institutes of Health Research","keywords":"Matrigel; MAPK/ERK pathway; Angiogenesis; Cell biology; Endothelial stem cell; Chemistry; Biology; Cancer research; Biochemistry; Signal transduction; In vitro","score_opus":0.008358183458473594,"score_gpt":0.24970636205964786,"score_spread":0.24134817860117427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100822088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949013,0.001772356,0.0008420838,0.000108149674,0.000033694592,0.000022898681,0.00026699793,0.00006887471,0.00198376],"genre_scores_gemma":[0.99595827,0.0008261776,0.0005132212,0.000036326393,0.000009918883,0.000019055073,0.0003251621,0.000006654709,0.002305163],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99994004,0.00001042304,0.000004357211,0.000007432236,0.000010942573,0.0000267262],"domain_scores_gemma":[0.99995005,0.000011802031,0.000010371207,0.000007857364,0.000004114117,0.00001580166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008343077,0.0002339118,0.0002117137,0.00018051549,0.00016760352,0.00017386497,0.00010183025,0.00015903212,0.0016075784],"category_scores_gemma":[0.000060622027,0.000113789436,0.00021346683,0.00015440371,0.00018912087,0.00014215519,0.000119640106,0.0005066828,0.0002692023],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044719852,0.000058016063,0.000120667035,0.000032423584,0.000005324216,0.000079757185,0.000011264499,0.000059543472,0.9970155,0.00013746836,0.00006844411,0.0019643763],"study_design_scores_gemma":[0.000019729116,0.00018275525,0.0026520542,0.0000017612313,0.0000042465126,0.0000675662,0.000008672854,0.00018867596,0.9961784,0.000020662985,0.0006738477,0.0000015723296],"about_ca_topic_score_codex":0.0008381088,"about_ca_topic_score_gemma":0.0012684345,"teacher_disagreement_score":0.0016075784,"about_ca_system_score_codex":0.00034026828,"about_ca_system_score_gemma":0.0002570062,"threshold_uncertainty_score":0.005377829},"labels":[],"label_agreement":null},{"id":"W2103111313","doi":"10.1007/s00280-013-2275-x","title":"Physiologically based pharmacokinetic modelling of Busulfan: a new approach to describe and predict the pharmacokinetics in adults","year":2013,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Glutathione Transferases and Polymorphisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre","funders":"","keywords":"Physiologically based pharmacokinetic modelling; Busulfan; Pharmacokinetics; Volume of distribution; Pharmacology; Chemistry; Distribution (mathematics); Medicine; Mathematics; Internal medicine; Chemotherapy","score_opus":0.022343166664552657,"score_gpt":0.2629195736374368,"score_spread":0.24057640697288413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103111313","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.112161554,0.0011630491,0.8821086,0.00061995845,0.000059505022,0.00008034975,0.0004760858,0.00042970426,0.00290124],"genre_scores_gemma":[0.91580427,0.0020066807,0.07467154,0.00029146633,0.00008286543,0.00038197867,0.0005011155,0.00013809344,0.0061220713],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99987817,0.000051501513,0.000008482129,0.000024175273,0.000027203656,0.000010504651],"domain_scores_gemma":[0.99980706,0.000103056474,0.000039266633,0.000011823345,0.000026283673,0.000012575783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037469383,0.00056896405,0.00082808547,0.00023511722,0.00021458002,0.00082454307,0.0006704719,0.0009216079,0.00089759723],"category_scores_gemma":[0.0010199132,0.00031018557,0.0007412445,0.00024967967,0.00017624213,0.0005374802,0.00029092177,0.0009568393,0.00036090525],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000068907946,0.00005545343,0.0022477668,0.0000424313,0.00013019166,0.00009806168,0.000042569915,0.97736144,0.0042753005,0.0028135162,0.00044450496,0.012419891],"study_design_scores_gemma":[0.000009103084,0.000048150217,0.00046370464,0.0000041388885,0.00003210048,0.00006421612,0.0000050483304,0.99700063,0.000534374,0.0011017828,0.00072902296,0.000007638463],"about_ca_topic_score_codex":0.008183048,"about_ca_topic_score_gemma":0.0050357576,"teacher_disagreement_score":0.008183048,"about_ca_system_score_codex":0.000512411,"about_ca_system_score_gemma":0.0010324513,"threshold_uncertainty_score":0.016270876},"labels":[],"label_agreement":null},{"id":"W2106673894","doi":"10.1007/s00280-004-0914-y","title":"Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin","year":2005,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Drug Transport and Resistance Mechanisms","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Université du Québec à Montréal","funders":"Natural Sciences and Engineering Research Council of Canada; Institut National de la Santé et de la Recherche Médicale","keywords":"Rhodamine 123; P-glycoprotein; Vinca; Vinblastine; Pharmacology; ATP-binding cassette transporter; Multiple drug resistance; Cell culture; Cytotoxicity; Verapamil; In vitro; Biology; Vinca alkaloid; Umbelliferone; Doxorubicin; Chemistry; Vincristine; Biochemistry; Transporter; Coumarin; Chemotherapy","score_opus":0.007670302057908099,"score_gpt":0.2630383083437881,"score_spread":0.25536800628588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106673894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99536276,0.0005116844,0.0007210702,0.00014404683,0.000021842954,0.000042567048,0.00012552287,0.000058642778,0.0030118595],"genre_scores_gemma":[0.99743074,0.00025771157,0.000494097,0.00002662082,0.000005821088,0.00001903281,0.00020666826,0.000010906799,0.0015484015],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998404,0.00004198449,0.000010277748,0.0000124169355,0.000026576383,0.00006832273],"domain_scores_gemma":[0.99987125,0.00004033346,0.000020334353,0.000027237318,0.000012153202,0.000028614073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021894046,0.00024520274,0.0003656015,0.00022409906,0.00022810855,0.00031978232,0.0004175434,0.00029518752,0.001243072],"category_scores_gemma":[0.00035986936,0.0001600657,0.00015265039,0.00024300546,0.00035062857,0.0002289688,0.00023236491,0.00080401305,0.00022433914],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025985811,0.00039576855,0.00058794365,0.000082554856,0.000017053353,0.00041613652,0.00008857299,0.000732693,0.9823287,0.001870138,0.0004106546,0.010471103],"study_design_scores_gemma":[0.0002569513,0.0010385991,0.0040436913,0.000006459095,0.000012422822,0.00049409765,0.000031055144,0.0017010975,0.989513,0.00015951319,0.0027351829,0.000008087741],"about_ca_topic_score_codex":0.0030001625,"about_ca_topic_score_gemma":0.0026295672,"teacher_disagreement_score":0.0030001625,"about_ca_system_score_codex":0.0006533786,"about_ca_system_score_gemma":0.000674346,"threshold_uncertainty_score":0.0059654117},"labels":[],"label_agreement":null},{"id":"W2107882830","doi":"10.1007/s00280-008-0894-4","title":"The x c − cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine","year":2008,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Sulfur Compounds in Biology","field":"Biochemistry, Genetics and Molecular Biology","cited_by":131,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency","funders":"","keywords":"Sulfasalazine; Antiporter; Glutamate receptor; Cystine; Medicine; Lung cancer; Cancer research; Pharmacology; Chemistry; Oncology; Internal medicine; Biochemistry; Membrane; Enzyme; Cysteine","score_opus":0.021945319597095087,"score_gpt":0.3029447925616004,"score_spread":0.28099947296450534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107882830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96477556,0.026438741,0.0026251427,0.0025233715,0.00014769137,0.00005630024,0.000053809945,0.000081171136,0.0032982558],"genre_scores_gemma":[0.98783666,0.008663904,0.0015599658,0.00018829678,0.00004072844,0.000011855998,0.00003452236,0.000006072123,0.0016580272],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999517,0.000014770794,0.000004200781,0.0000063518582,0.0000089087225,0.00001402884],"domain_scores_gemma":[0.99995613,0.000007814719,0.000011337346,0.000004734486,0.000008401026,0.0000116621995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002938154,0.00016985639,0.00023998598,0.0001075865,0.00020080782,0.000352447,0.0002476632,0.00031153698,0.0006373737],"category_scores_gemma":[0.00008598786,0.00007098866,0.00025007396,0.00012593796,0.00029073766,0.0002472798,0.00014741026,0.00039798007,0.00009325729],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002536951,0.00020823262,0.0023681254,0.00023581405,0.000058483354,0.0006382893,0.00007396148,0.0007807793,0.9330031,0.0025732638,0.0009558178,0.056567103],"study_design_scores_gemma":[0.0006059563,0.00558656,0.0065477523,0.00003141626,0.00017801342,0.0020976039,0.00020440915,0.0036933972,0.95200175,0.0005610843,0.028467953,0.00002410147],"about_ca_topic_score_codex":0.002033132,"about_ca_topic_score_gemma":0.0047916137,"teacher_disagreement_score":0.002033132,"about_ca_system_score_codex":0.00045372624,"about_ca_system_score_gemma":0.0005765496,"threshold_uncertainty_score":0.004042566},"labels":[],"label_agreement":null},{"id":"W2113716960","doi":"10.1007/s00280-010-1283-3","title":"Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma","year":2010,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Pharmacokinetics; Pharmacodynamics; Bortezomib; Dosing; Medicine; Multiple myeloma; Pharmacology; Toxicity; Proteasome inhibitor; Internal medicine","score_opus":0.01165579831940681,"score_gpt":0.33695038874226746,"score_spread":0.32529459042286063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113716960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979426,0.00083433825,0.00027466865,0.00015857385,0.000039139777,0.00006424033,0.000145999,0.00004725672,0.000493071],"genre_scores_gemma":[0.9987841,0.00018916208,0.00021478336,0.0001723037,0.00008826679,0.0000515366,0.00018806162,0.000016749427,0.00029516974],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99913317,0.0003815562,0.00004263581,0.00015862744,0.0001625903,0.00012141746],"domain_scores_gemma":[0.99874,0.00044290966,0.00020036698,0.00014949129,0.000052886087,0.00041436113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079850166,0.0008518642,0.0024190329,0.0004195947,0.00055220176,0.0009062013,0.000536269,0.001058753,0.0012037634],"category_scores_gemma":[0.0034142907,0.00063655997,0.0009949603,0.0005149085,0.00077829073,0.0009860769,0.00032010901,0.0027324075,0.00041495246],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7008309,0.015245389,0.085812226,0.0002777343,0.001760036,0.0017208353,0.00084028294,0.005287283,0.1009964,0.000462014,0.0018125671,0.084954366],"study_design_scores_gemma":[0.09299559,0.3445221,0.5075659,0.000047725203,0.0019017281,0.0053915884,0.00049048505,0.013312567,0.026238916,0.00065957574,0.0066310717,0.00024277205],"about_ca_topic_score_codex":0.0012319864,"about_ca_topic_score_gemma":0.001104766,"teacher_disagreement_score":0.0024190329,"about_ca_system_score_codex":0.0010034225,"about_ca_system_score_gemma":0.0007453592,"threshold_uncertainty_score":0.0072804093},"labels":[],"label_agreement":null},{"id":"W2115126022","doi":"10.1007/s00280-004-0961-4","title":"Effect of NQO1 induction on the antitumor activity of RH1 in human tumors in vitro and in vivo","year":2005,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Genomics, phytochemicals, and oxidative stress","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"In vivo; In vitro; Pharmacology; Biology; Cancer research; Medicine; Chemistry; Biochemistry; Genetics","score_opus":0.009708236940939355,"score_gpt":0.3095653741582068,"score_spread":0.2998571372172674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115126022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99536645,0.0014149225,0.0009492839,0.0001552641,0.00004024133,0.000035533685,0.00037076348,0.00007812123,0.0015893882],"genre_scores_gemma":[0.9960575,0.00055888697,0.0005053415,0.00003512385,0.000016259226,0.000029092407,0.00055109506,0.00001375942,0.002232908],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999859,0.000049929924,0.00000841416,0.000027002661,0.000018715027,0.00003688075],"domain_scores_gemma":[0.99973637,0.0001227297,0.000028865974,0.000041749914,0.000021044289,0.000049163493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036767646,0.00030615376,0.0002996866,0.00023335447,0.00014335306,0.00014099234,0.00020335967,0.0002470644,0.0032667397],"category_scores_gemma":[0.0002484323,0.000118327276,0.0001911938,0.00013120122,0.00036975142,0.00020634985,0.00012715805,0.0007968943,0.00039608235],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002096569,0.00030902275,0.00031596393,0.00007343308,0.000011620553,0.000054016764,0.00005707522,0.00023668056,0.9922659,0.00028061785,0.00019678645,0.0041024014],"study_design_scores_gemma":[0.00006207912,0.0026911811,0.0021145341,0.000005288816,0.00002110386,0.0000891637,0.000022283231,0.00045027214,0.9932439,0.000054150296,0.0012411119,0.0000049782006],"about_ca_topic_score_codex":0.0011336284,"about_ca_topic_score_gemma":0.0010699247,"teacher_disagreement_score":0.0032667397,"about_ca_system_score_codex":0.00023303117,"about_ca_system_score_gemma":0.00027448998,"threshold_uncertainty_score":0.010928392},"labels":[],"label_agreement":null},{"id":"W2119247100","doi":"10.1007/s00280-013-2271-1","title":"Clinical evaluation of targeted arterial perfusion of verapamil and chemotherapeutic drugs in interventional therapy of advanced lung cancer","year":2013,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Natural Sciences; Canadian Cancer Society Research Institute; Foundation for the National Institutes of Health; Cancer Research Institute; National Cancer Institute; National Science Foundation","keywords":"Medicine; Lung cancer; Verapamil; Chemotherapy; Perfusion; Arterial perfusion; Cancer; Internal medicine; Lung; Oncology; Surgery","score_opus":0.03531797604947373,"score_gpt":0.4054754355285837,"score_spread":0.37015745947911,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119247100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996126,0.0024009987,0.00043443643,0.00003578032,0.000008269911,0.000048022903,0.000024804282,0.000014078504,0.0009076383],"genre_scores_gemma":[0.9990969,0.00043017007,0.00021934616,0.00003551642,0.000023982915,0.000025683603,0.000048608337,0.0000012730715,0.000118570104],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99978894,0.00008407319,0.000019906121,0.00003208899,0.00005075194,0.000024201256],"domain_scores_gemma":[0.9995426,0.000116823794,0.0001550879,0.000018402772,0.000071749295,0.0000953669],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031278905,0.00016641253,0.00033280186,0.0001655192,0.00011671983,0.00014874357,0.00010377898,0.0002041533,0.00041017387],"category_scores_gemma":[0.00091757043,0.00006309843,0.0001288704,0.00015020647,0.0001792273,0.00017587029,0.000102001686,0.000270308,0.00008717652],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022116771,0.0027436113,0.57514244,0.0006959959,0.00027263272,0.005386263,0.0004989504,0.0010809944,0.2069117,0.00012691278,0.0007288124,0.18429504],"study_design_scores_gemma":[0.0011459404,0.06535263,0.87926185,0.000040323273,0.00041234362,0.010530507,0.00017589501,0.0023055514,0.03719513,0.00009218714,0.0034568037,0.000030859926],"about_ca_topic_score_codex":0.00012039703,"about_ca_topic_score_gemma":0.00016819169,"teacher_disagreement_score":0.00041017387,"about_ca_system_score_codex":0.00012769329,"about_ca_system_score_gemma":0.00014034154,"threshold_uncertainty_score":0.0016542077},"labels":[],"label_agreement":null},{"id":"W2137086876","doi":"10.1007/s00280-006-0371-x","title":"A first-in-man phase I tolerability and pharmacokinetic study of the cyclin-dependent kinase-inhibitor AZD5438 in healthy male volunteers","year":2006,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Pharmacokinetics; Tolerability; Vomiting; Nausea; Pharmacology; Medicine; Pharmacodynamics; Internal medicine; Adverse effect","score_opus":0.014082082024975417,"score_gpt":0.3399569902318229,"score_spread":0.3258749082068475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137086876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949444,0.0010130754,0.0016200605,0.00012955336,0.000058263497,0.0007556504,0.0005669408,0.00010978036,0.0008023745],"genre_scores_gemma":[0.99385977,0.0006301906,0.0014982129,0.0005057976,0.00014184124,0.00047427503,0.0008283573,0.0000629257,0.0019986872],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99941266,0.00028308245,0.00001752028,0.00013767552,0.000057671466,0.00009143789],"domain_scores_gemma":[0.9992323,0.00015536627,0.00011473243,0.00012330106,0.00005740811,0.00031691423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012929924,0.0016495892,0.001835404,0.00038451268,0.0010552544,0.0006231893,0.00063478365,0.00085261423,0.0033800995],"category_scores_gemma":[0.0015747899,0.0009670671,0.000997083,0.0002704748,0.0010654827,0.0009449733,0.00033325524,0.0019697365,0.0008531655],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5318142,0.063128196,0.035286397,0.0006165278,0.0018570573,0.0010819581,0.0013876337,0.0019973912,0.23988482,0.0003770129,0.0039543957,0.11861439],"study_design_scores_gemma":[0.09004517,0.76635855,0.11042726,0.000028684608,0.0013228579,0.0015498644,0.00040271776,0.0020659666,0.02097977,0.00048378465,0.0062242434,0.00011118571],"about_ca_topic_score_codex":0.0018498703,"about_ca_topic_score_gemma":0.002422575,"teacher_disagreement_score":0.0033800995,"about_ca_system_score_codex":0.0006891346,"about_ca_system_score_gemma":0.00065212906,"threshold_uncertainty_score":0.011307538},"labels":[],"label_agreement":null},{"id":"W2138513351","doi":"10.1007/s00280-013-2094-0","title":"Therapeutic targeting malignant mesothelioma with a novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate via its selective uptake by the proton-coupled folate transporter","year":2013,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Folate and B Vitamins Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Canadian Institutes of Health Research; Barbara Ann Karmanos Cancer Institute; Mesothelioma Applied Research Foundation","keywords":"Antifolate; In vivo; Ribonucleotide; In vitro; Nucleoside; Cell culture; Biology; Purine metabolism; Chemistry; Biochemistry; Molecular biology; Antimetabolite; Nucleotide; Immunology; Enzyme","score_opus":0.02077438752416983,"score_gpt":0.30493655675241405,"score_spread":0.2841621692282442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138513351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829973,0.008966584,0.0045295404,0.0004407252,0.00011118853,0.000076443976,0.0001281417,0.000114129754,0.0026359847],"genre_scores_gemma":[0.9946372,0.0021939448,0.001737378,0.00006029914,0.000018778324,0.000017576018,0.00007580999,0.000006007972,0.0012531007],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999434,0.000012512773,0.000003706021,0.000011653091,0.00000938471,0.000019364863],"domain_scores_gemma":[0.99997485,0.0000048447077,0.000006353556,0.0000039873526,0.0000039733377,0.000006022354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014718834,0.00023139855,0.00029908208,0.00017139413,0.00020602864,0.00022217326,0.00030971423,0.0005003342,0.00069094275],"category_scores_gemma":[0.000097265445,0.0001395871,0.00023746675,0.0001321231,0.0001596409,0.00020071153,0.0001651426,0.00040125108,0.00018687555],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006370537,0.000081210565,0.0002946745,0.00016132451,0.000027932003,0.0003886848,0.00006389761,0.0003974831,0.9866615,0.00032193275,0.00021407235,0.010750294],"study_design_scores_gemma":[0.00030807298,0.003401189,0.0020833386,0.000017589538,0.00012541263,0.0012954868,0.000041514166,0.0026254107,0.9766402,0.00009420702,0.01335038,0.00001712154],"about_ca_topic_score_codex":0.0012715905,"about_ca_topic_score_gemma":0.002829801,"teacher_disagreement_score":0.0012715905,"about_ca_system_score_codex":0.00030841157,"about_ca_system_score_gemma":0.00021061821,"threshold_uncertainty_score":0.002528429},"labels":[],"label_agreement":null},{"id":"W2139011868","doi":"10.1007/s00280-005-0040-5","title":"Structure-activity study of the interaction of bioreductive benzoquinone alkylating agents with DNA topoisomerase II","year":2005,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"National Cancer Institute","keywords":"Topoisomerase; DNA; Chemistry; Benzoquinone; Carcinogen; Pharmacology; Stereochemistry; Cancer research; Biochemistry; Biology","score_opus":0.016196097049669407,"score_gpt":0.3171702543919485,"score_spread":0.3009741573422791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139011868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99741876,0.0010133416,0.0008225291,0.00004264139,0.000011106117,0.000012756149,0.00007611958,0.000017926543,0.00058486185],"genre_scores_gemma":[0.9983606,0.00036580442,0.00034509043,0.000012191353,0.000005871417,0.0000047681556,0.00014607032,0.0000035464618,0.0007560992],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984515,0.000036333266,0.0000058139817,0.00002196171,0.0000470588,0.000043570737],"domain_scores_gemma":[0.9998307,0.00006556873,0.00003802453,0.000010327876,0.00003248715,0.000022803591],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024166235,0.0002783219,0.00024364205,0.00014278092,0.00014206562,0.00019922186,0.00032142826,0.00021881025,0.0013675042],"category_scores_gemma":[0.0003464818,0.00015868447,0.00022296607,0.00015569615,0.00020611823,0.00014810641,0.000080700316,0.00040445258,0.00021442599],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004028118,0.000105841544,0.00031873528,0.000033190056,0.000014941011,0.000040129038,0.000029459494,0.00050382817,0.9974369,0.00013024469,0.00004021301,0.0009435466],"study_design_scores_gemma":[0.000038098195,0.0014657218,0.00291196,0.000003883937,0.000022934719,0.00009696943,0.000023102433,0.0015716346,0.9928322,0.000023626555,0.0010048202,0.000004982168],"about_ca_topic_score_codex":0.001895089,"about_ca_topic_score_gemma":0.0017426445,"teacher_disagreement_score":0.001895089,"about_ca_system_score_codex":0.00031334566,"about_ca_system_score_gemma":0.00018841709,"threshold_uncertainty_score":0.0045747757},"labels":[],"label_agreement":null},{"id":"W2140095109","doi":"10.1007/s00280-004-0949-0","title":"A novel phospholipid gemcitabine conjugate is able to bypass three drug-resistance mechanisms","year":2005,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Drug Transport and Resistance Mechanisms","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Vector Institute","keywords":"Gemcitabine; Conjugate; Deoxycytidine kinase; Nucleoside transporter; Pharmacology; Phospholipid; Nucleoside; Antimetabolite; Chemistry; Cancer research; Deoxycytidine; Biology; Chemotherapy; Biochemistry; Medicine; Internal medicine; Transporter","score_opus":0.013296316808104846,"score_gpt":0.2922853730567955,"score_spread":0.2789890562486907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140095109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98730403,0.0018113677,0.0060672965,0.00028483733,0.000077936165,0.00011383701,0.00009842916,0.0001469466,0.004095286],"genre_scores_gemma":[0.9928087,0.00087077677,0.0026140164,0.00007690905,0.000010606108,0.000030699215,0.00016296684,0.000019614472,0.0034057405],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999186,0.00002425796,0.000007300912,0.000014730761,0.000016770979,0.000018384815],"domain_scores_gemma":[0.9999422,0.000012455395,0.0000139792655,0.000008768917,0.0000066111006,0.000016124215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001429572,0.00033665306,0.0003309027,0.00014906617,0.000171547,0.00038155718,0.00021800934,0.00040814638,0.0010805567],"category_scores_gemma":[0.00020358084,0.00015097411,0.00016184985,0.00011231569,0.00018648963,0.00038473782,0.00032929392,0.0005287968,0.00039554934],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006848479,0.00011508273,0.0002651383,0.00009531735,0.00001730341,0.00025982544,0.000043952172,0.00043666858,0.9812011,0.0010778513,0.00022629721,0.015576588],"study_design_scores_gemma":[0.00008373454,0.00080226205,0.00040065867,0.000004619573,0.000023713903,0.00037493056,0.000008013735,0.0008068628,0.99226475,0.00007581144,0.0051468485,0.000007941329],"about_ca_topic_score_codex":0.00022095769,"about_ca_topic_score_gemma":0.00019877673,"teacher_disagreement_score":0.0010805567,"about_ca_system_score_codex":0.00026457035,"about_ca_system_score_gemma":0.00020972427,"threshold_uncertainty_score":0.0036147833},"labels":[],"label_agreement":null},{"id":"W2143746306","doi":"10.1007/s00280-003-0718-5","title":"Structure-activity study with bioreductive benzoquinone alkylating agents: effects on DT-diaphorase-mediated DNA crosslink and strand break formation in relation to mechanisms of cytotoxicity","year":2003,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Carcinogens and Genotoxicity Assessment","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Institute in Oncology and Hematology; University of Manitoba; CancerCare Manitoba","funders":"National Cancer Institute; Canadian Institutes of Health Research; Cancer Institute, University of Pittsburgh","keywords":"DNA; Chemistry; In vitro; DNA damage; Cytotoxicity; Agarose; Biochemistry; Molecular biology; Stereochemistry; Biology","score_opus":0.010184799143635301,"score_gpt":0.2974872117290596,"score_spread":0.2873024125854243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143746306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99496377,0.0021839137,0.0020731294,0.000038803475,0.000013252713,0.000030441515,0.00012027768,0.000042211206,0.0005342049],"genre_scores_gemma":[0.99732614,0.00095476356,0.00082114775,0.000012916287,0.000006162118,0.000011498867,0.00016979976,0.000007813478,0.00068970124],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998462,0.000040283132,0.000011328361,0.000022652523,0.000041409417,0.000038148144],"domain_scores_gemma":[0.99975127,0.0000883146,0.00004987401,0.000024568368,0.00005538981,0.000030566498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036663585,0.00036069748,0.00033766942,0.00024649783,0.00014953168,0.00017718942,0.00027637096,0.00031846587,0.0010170717],"category_scores_gemma":[0.00039214644,0.00018418736,0.0003030982,0.0002668137,0.00026766115,0.00026940132,0.00010470032,0.00037494197,0.00018773171],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027173274,0.00007782675,0.00016797196,0.00003107009,0.000006695697,0.000029139308,0.000024806033,0.00021316366,0.99821055,0.000059569375,0.000011653128,0.0008958492],"study_design_scores_gemma":[0.000015261054,0.0012987735,0.0013788635,0.0000018039894,0.000021041842,0.00008118913,0.00000960773,0.00041622127,0.9963576,0.000015930304,0.00040048608,0.0000032702249],"about_ca_topic_score_codex":0.0013120363,"about_ca_topic_score_gemma":0.0014768915,"teacher_disagreement_score":0.0013120363,"about_ca_system_score_codex":0.00025869612,"about_ca_system_score_gemma":0.0002191464,"threshold_uncertainty_score":0.003402412},"labels":[],"label_agreement":null},{"id":"W2145604692","doi":"10.1007/s00280-006-0353-z","title":"Irinotecan–cisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line","year":2006,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of British Columbia Hospital; BC Cancer Agency; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Irinotecan; Cisplatin; Cytotoxicity; Drug; Cell culture; DNA; Cancer research; SN-38; Chemistry; Camptothecin; DNA adduct; Pharmacology; Biology; In vitro; Chemotherapy; Medicine; Cancer; Internal medicine; Biochemistry; Genetics","score_opus":0.03020654306366584,"score_gpt":0.3436383977097108,"score_spread":0.31343185464604495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145604692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990306,0.0011870954,0.004990607,0.00011229997,0.00003668163,0.00015994445,0.0009808906,0.00014137694,0.0020851009],"genre_scores_gemma":[0.98490113,0.0011218152,0.0069641904,0.000066149296,0.00001156338,0.00021172398,0.0016787468,0.000032074677,0.0050125434],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989549,0.000381083,0.00012473544,0.00012830405,0.00032585193,0.000085145286],"domain_scores_gemma":[0.99943167,0.00017626458,0.000073990705,0.00010266099,0.00016313347,0.000052329393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063972955,0.0006665416,0.00085846084,0.00063590024,0.00058054336,0.0004984739,0.0004554407,0.00070412975,0.0022699425],"category_scores_gemma":[0.00047712313,0.0003974415,0.00039550598,0.00091825007,0.00032665776,0.00048483684,0.0003198479,0.0007304292,0.000764911],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026647534,0.00019907879,0.0008417633,0.000057552283,0.000031631862,0.00010111207,0.00008154312,0.0004012899,0.9962655,0.00005500871,0.00008727218,0.0016118409],"study_design_scores_gemma":[0.000014291314,0.0007644864,0.0039098184,0.000002597016,0.00003044261,0.00016146107,0.000036540954,0.00095509057,0.99363697,0.0000125136075,0.00046879466,0.0000069716825],"about_ca_topic_score_codex":0.0034202943,"about_ca_topic_score_gemma":0.0051397528,"teacher_disagreement_score":0.0034202943,"about_ca_system_score_codex":0.0005258662,"about_ca_system_score_gemma":0.000563258,"threshold_uncertainty_score":0.007593751},"labels":[],"label_agreement":null},{"id":"W2150807070","doi":"10.1007/s00280-007-0522-8","title":"Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo","year":2007,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"National Science Council","keywords":"In vivo; Apoptosis; Growth inhibition; In vitro; Cervical carcinoma; Cancer research; Hsp90; Biology; Pharmacology; Chemistry; Internal medicine; Medicine; Cervical cancer; Cancer; Heat shock protein; Gene; Biochemistry; Genetics","score_opus":0.016125795953849154,"score_gpt":0.3175938469495421,"score_spread":0.30146805099569296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150807070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890947,0.00366663,0.0022784162,0.00017067998,0.00010504585,0.00009700765,0.00064448826,0.00017389056,0.0037692646],"genre_scores_gemma":[0.9957617,0.0013065094,0.00051221123,0.000033159067,0.000025927655,0.000057856803,0.0005345022,0.000022101827,0.001746159],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99973565,0.000071773014,0.000018826187,0.000030636176,0.00005282171,0.00009026269],"domain_scores_gemma":[0.99973947,0.00008174331,0.000036629306,0.000058906477,0.000024610545,0.00005858652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041666802,0.00052238913,0.0006247176,0.0006676134,0.00032036516,0.00028325937,0.00041829096,0.00033479813,0.002132349],"category_scores_gemma":[0.00026020058,0.00025286447,0.00045293284,0.00041487577,0.00036435222,0.0003466169,0.00016661116,0.00114829,0.00033317425],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005230845,0.0016770669,0.000602716,0.00015200641,0.00011567546,0.00008994949,0.00010491429,0.0011777688,0.97493094,0.00070908584,0.00060797407,0.014601039],"study_design_scores_gemma":[0.00022475145,0.007481895,0.0035914036,0.00001164239,0.00009646308,0.00018924581,0.000033932072,0.0011661677,0.9853956,0.0001083968,0.0016894486,0.000011086734],"about_ca_topic_score_codex":0.0017107079,"about_ca_topic_score_gemma":0.0019627362,"teacher_disagreement_score":0.002132349,"about_ca_system_score_codex":0.00029893927,"about_ca_system_score_gemma":0.00056472264,"threshold_uncertainty_score":0.0071334243},"labels":[],"label_agreement":null},{"id":"W2151917263","doi":"10.1007/s00280-015-2777-9","title":"Development of a new equation to estimate creatinine clearance in cancer patients","year":2015,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Carboplatin; Dosing; Medicine; Renal function; Creatinine; Body surface area; Urology; Lung cancer; Cancer; Retrospective cohort study; Chemotherapy; Internal medicine; Surgery; Cisplatin","score_opus":0.13157277190601038,"score_gpt":0.4725437734992171,"score_spread":0.3409710015932067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151917263","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.088514455,0.004032382,0.8921388,0.002686494,0.0014257979,0.00069148943,0.0030846589,0.0024384458,0.004987582],"genre_scores_gemma":[0.31283167,0.0022884093,0.6718138,0.001060754,0.00047042556,0.0012191773,0.003339595,0.00032403893,0.006652132],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99732023,0.0006883497,0.00038054472,0.0005743427,0.0009402696,0.00009620741],"domain_scores_gemma":[0.9952834,0.0015069684,0.00042565097,0.00031574097,0.0023779075,0.00009023255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004324152,0.0008909675,0.0018145838,0.0018994577,0.0004811782,0.0019153749,0.0015587155,0.0011296484,0.0019832596],"category_scores_gemma":[0.012645948,0.00068434223,0.0018453362,0.0014495524,0.00021471019,0.0016914239,0.0012411665,0.0020305861,0.0012457358],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076233654,0.0006027784,0.27424487,0.00063455873,0.0020000387,0.00033259467,0.0003651751,0.029527253,0.00796707,0.008656895,0.026346326,0.64856017],"study_design_scores_gemma":[0.0005939511,0.0008854464,0.1454095,0.0004416196,0.0022221324,0.0022353318,0.00023682498,0.7577646,0.017797226,0.007224463,0.06493885,0.000250024],"about_ca_topic_score_codex":0.009799383,"about_ca_topic_score_gemma":0.010361348,"teacher_disagreement_score":0.009799383,"about_ca_system_score_codex":0.0013375806,"about_ca_system_score_gemma":0.0024768903,"threshold_uncertainty_score":0.022868574},"labels":[],"label_agreement":null},{"id":"W2157706519","doi":"10.1007/s00280-011-1798-2","title":"Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children’s Oncology Group study","year":2011,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Center for Research Resources; National Cancer Institute; Frank A. Campini Foundation","keywords":"Sunitinib; Medicine; Pharmacokinetics; Neutropenia; Dosing; Tolerability; Refractory (planetary science); Internal medicine; Tyrosine-kinase inhibitor; Pharmacology; Gastroenterology; Urology; Adverse effect; Toxicity; Cancer","score_opus":0.03107978894315848,"score_gpt":0.350450297542223,"score_spread":0.3193705085990645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157706519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99929583,0.00022636565,0.00007124073,0.000034428645,0.0000053896565,0.00005296136,0.00015256238,0.0000067611754,0.00015433748],"genre_scores_gemma":[0.998601,0.00034580333,0.00023009199,0.00006655745,0.00002647975,0.00006714764,0.0003884634,0.000009909292,0.0002646656],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99972457,0.000097167,0.000018838624,0.000052606516,0.000054810476,0.000052042447],"domain_scores_gemma":[0.9993773,0.00012168469,0.00019900591,0.000057130885,0.00004330715,0.0002015604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005331582,0.00056709134,0.0012757636,0.000249061,0.0003259553,0.00046547834,0.00034210682,0.00042785855,0.001063867],"category_scores_gemma":[0.0008261663,0.00026737293,0.0008906162,0.00040004664,0.0005484222,0.00067312346,0.00016131415,0.0015373182,0.0002466511],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42722812,0.036330894,0.22761829,0.0007186762,0.0031181348,0.0020496377,0.0017273017,0.0060012834,0.1291055,0.0004828036,0.0038017482,0.16181757],"study_design_scores_gemma":[0.05412961,0.48125103,0.42936692,0.000036674122,0.0017425176,0.0026649232,0.00067340565,0.0034227397,0.021604735,0.00012687074,0.00488672,0.00009387984],"about_ca_topic_score_codex":0.0018562585,"about_ca_topic_score_gemma":0.0020418689,"teacher_disagreement_score":0.0018562585,"about_ca_system_score_codex":0.0009608723,"about_ca_system_score_gemma":0.00077056116,"threshold_uncertainty_score":0.0069716573},"labels":[],"label_agreement":null},{"id":"W2292096944","doi":"10.1007/s00280-015-2929-y","title":"Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human","year":2015,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cellular transport and secretion","field":"Biochemistry, Genetics and Molecular Biology","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Nuclear Laboratories","funders":"","keywords":"Metabolite; Pharmacokinetics; Metabolism; Hydroxylation; Pharmacology; Chemistry; Feces; Internal medicine; Biology; Endocrinology; Biochemistry; Medicine","score_opus":0.012525230348863457,"score_gpt":0.28500653046982105,"score_spread":0.2724813001209576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2292096944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99308723,0.002577276,0.00083417824,0.000076180106,0.000030974716,0.000014208088,0.0010505272,0.00006659861,0.0022627844],"genre_scores_gemma":[0.991691,0.0013790505,0.0005630514,0.000042818006,0.000014258077,0.00001718903,0.0010771774,0.000027491184,0.0051878816],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992156,0.000015623049,0.0000054434686,0.000028462828,0.000007759436,0.000021090342],"domain_scores_gemma":[0.99987745,0.000033537654,0.000024622886,0.0000253999,0.00000931116,0.000029581357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015665413,0.00018614127,0.00027539147,0.0003717184,0.00019444643,0.00039414875,0.00015028885,0.00025670032,0.0021514886],"category_scores_gemma":[0.00022518604,0.00024437511,0.00025833774,0.00026186905,0.0004409012,0.00039382704,0.00010830641,0.00046681607,0.0006058906],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.091355905,0.00086327357,0.013738439,0.00029821417,0.00019025864,0.0014091943,0.0006129699,0.0015371767,0.83173764,0.0023282715,0.0018306499,0.054098044],"study_design_scores_gemma":[0.0003310243,0.012016184,0.063738644,0.000016928825,0.00038377123,0.0023657838,0.0005092093,0.0045143273,0.9039309,0.0003813116,0.011751146,0.00006079542],"about_ca_topic_score_codex":0.0036675713,"about_ca_topic_score_gemma":0.0033419111,"teacher_disagreement_score":0.0036675713,"about_ca_system_score_codex":0.00042849165,"about_ca_system_score_gemma":0.0003380389,"threshold_uncertainty_score":0.0072924495},"labels":[],"label_agreement":null},{"id":"W2323158095","doi":"10.1007/s00280-016-3018-6","title":"Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice","year":2016,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Drug Transport and Resistance Mechanisms","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"National Cancer Institute; U.S. Public Health Service; American Lebanese Syrian Associated Charities","keywords":"Physiologically based pharmacokinetic modelling; Sorafenib; Multidrug resistance-associated protein 2; Pharmacology; Pharmacokinetics; Transporter; Efflux; Chemistry; CYP3A4; Metabolite; Organic anion-transporting polypeptide; Glucuronide; Abcg2; In vivo; ATP-binding cassette transporter; Cytochrome P450; Biology; Metabolism; Biochemistry; Cancer research; Hepatocellular carcinoma","score_opus":0.0252176359212309,"score_gpt":0.31581283572286145,"score_spread":0.29059519980163057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2323158095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9653674,0.00062525703,0.027978566,0.0005147066,0.00004600055,0.00004714004,0.0008201216,0.00013764172,0.004463172],"genre_scores_gemma":[0.98622143,0.0008491828,0.008503554,0.00016592698,0.000018740293,0.00012582098,0.00050032645,0.00006451626,0.0035506333],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9999014,0.000024298804,0.0000063700277,0.000023743802,0.00001808593,0.000026068637],"domain_scores_gemma":[0.9996178,0.00022250702,0.000076430064,0.000017370585,0.00003275984,0.000033136297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027756297,0.0005787158,0.0010235143,0.00043881396,0.00028017545,0.00086937944,0.0009810845,0.0016349552,0.0011985416],"category_scores_gemma":[0.000620435,0.00041814803,0.0013998809,0.00040820322,0.00050566474,0.0005908754,0.00040347115,0.0010425737,0.00021178619],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037664807,0.00015401463,0.0021928954,0.000057916823,0.000059987167,0.00013462456,0.000038529037,0.9861037,0.007364028,0.0016733658,0.00018163303,0.0016626483],"study_design_scores_gemma":[0.00006508597,0.00012598584,0.0006447206,0.0000059030835,0.0000493068,0.000038190432,0.000023631821,0.99581414,0.0024060418,0.00047910816,0.00033389468,0.000013932101],"about_ca_topic_score_codex":0.016705463,"about_ca_topic_score_gemma":0.00604993,"teacher_disagreement_score":0.016705463,"about_ca_system_score_codex":0.0008439449,"about_ca_system_score_gemma":0.0014301607,"threshold_uncertainty_score":0.033216417},"labels":[],"label_agreement":null},{"id":"W2339737660","doi":"10.1007/s00280-016-3026-6","title":"The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer","year":2016,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Gemcitabine; Erlotinib; Medicine; Pancreatic cancer; Internal medicine; Interstitial lung disease; Gastroenterology; Lung cancer; Oncology; Incidence (geometry); Cancer; Lung; Epidermal growth factor receptor","score_opus":0.008902987812251021,"score_gpt":0.2873161042179896,"score_spread":0.27841311640573857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339737660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993173,0.0003782531,0.000084442116,0.000025490132,0.0000036139522,0.000003217082,0.000029846604,0.0000020349198,0.00015596635],"genre_scores_gemma":[0.99977845,0.00006547183,0.0000626851,0.000013406795,0.000006368145,0.0000016282181,0.00003840959,6.6165745e-7,0.000032976703],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995989,0.00013671821,0.00006330465,0.0000882115,0.000063243824,0.000049665363],"domain_scores_gemma":[0.99884903,0.00016772682,0.0006363767,0.00005563759,0.00008255397,0.00020870456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042343707,0.00023779664,0.00031226344,0.00032655345,0.00028136076,0.00033645556,0.00019232705,0.00032874907,0.0013484944],"category_scores_gemma":[0.0008996959,0.00016018342,0.00030459414,0.00056912244,0.00026208634,0.00019749643,0.00024751402,0.0005144167,0.00015104424],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002973488,0.000026444037,0.99688333,0.000011107219,0.00006164092,0.00012352575,0.000014865553,0.000033336833,0.00115552,0.000005350297,0.00003514952,0.0013523712],"study_design_scores_gemma":[0.000030639985,0.0003383914,0.9964444,0.000005534225,0.00008735664,0.0021421982,0.00006486484,0.00024210743,0.00038194368,0.000017843244,0.00024157789,0.0000030866206],"about_ca_topic_score_codex":0.00073581294,"about_ca_topic_score_gemma":0.00091012806,"teacher_disagreement_score":0.0013484944,"about_ca_system_score_codex":0.00018186598,"about_ca_system_score_gemma":0.00018882987,"threshold_uncertainty_score":0.0045111775},"labels":[],"label_agreement":null},{"id":"W2470744532","doi":"10.1007/s00280-016-3102-y","title":"A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer","year":2016,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of British Columbia; BC Cancer Agency","funders":"Novartis","keywords":"Refractory (planetary science); Pancreatic cancer; Chemotherapy; Medicine; Hsp90 inhibitor; Cancer; Oncology; Internal medicine; Hsp90; Chemistry; Materials science; Metallurgy","score_opus":0.01799644560490742,"score_gpt":0.36780365554293126,"score_spread":0.34980720993802383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2470744532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99153894,0.0022887227,0.0008704949,0.0004947935,0.00016244363,0.002049777,0.00084747537,0.0001299197,0.0016174181],"genre_scores_gemma":[0.9865129,0.0036714862,0.0017177355,0.00056160527,0.00018070318,0.0022560288,0.0019991798,0.000064289794,0.00303605],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996055,0.00016841697,0.00001778898,0.00006994273,0.00003103823,0.00010743628],"domain_scores_gemma":[0.999561,0.000056953206,0.000057312318,0.0000620148,0.00002145673,0.00024127177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010696205,0.0015958035,0.0031944714,0.0006099615,0.0006064522,0.0010567638,0.0011597743,0.0011812409,0.0035907917],"category_scores_gemma":[0.0005364318,0.0007117426,0.0013575378,0.0007328832,0.0012690992,0.0011348347,0.00049435295,0.004133815,0.00086620176],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5470642,0.13876365,0.0037069728,0.0015814161,0.0019234659,0.00058158825,0.0004978527,0.008550762,0.15530504,0.00074011483,0.0056646923,0.13562031],"study_design_scores_gemma":[0.32917586,0.6445571,0.0055645714,0.00003839177,0.0005717262,0.00038533486,0.00013023587,0.0016843355,0.013786577,0.00025736858,0.003801177,0.000047279365],"about_ca_topic_score_codex":0.0016933082,"about_ca_topic_score_gemma":0.0033795773,"teacher_disagreement_score":0.0035907917,"about_ca_system_score_codex":0.0007684727,"about_ca_system_score_gemma":0.0014163528,"threshold_uncertainty_score":0.012012422},"labels":[],"label_agreement":null},{"id":"W2576527888","doi":"10.1007/s00280-016-3226-0","title":"Single-center comparison of multiple chemotherapy regimens for concurrent chemoradiotherapy in unresectable stage III non-small-cell lung cancer","year":2017,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Carboplatin; Regimen; Lung cancer; Hazard ratio; Chemotherapy; Chemoradiotherapy; Oncology; Vinblastine; Proportional hazards model; Chemotherapy regimen; Etoposide; Gastroenterology; Cisplatin; Surgery","score_opus":0.04700574394080015,"score_gpt":0.39529307686205317,"score_spread":0.348287332921253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2576527888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99801034,0.0011761003,0.00012799082,0.00004730533,0.00006784427,0.0001546692,0.0000897778,0.000010033049,0.0003159862],"genre_scores_gemma":[0.99873525,0.00040013305,0.0002559223,0.00006396684,0.00005600927,0.00010508801,0.0001590674,0.0000060036896,0.00021857297],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99886036,0.0005565475,0.000096571435,0.00020132455,0.00012837783,0.00015689299],"domain_scores_gemma":[0.99858236,0.00041215372,0.00035296063,0.00015620056,0.00013784022,0.0003585321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013309491,0.00058576406,0.002038174,0.00043270903,0.0004197531,0.000940136,0.000693504,0.0006702033,0.0021481027],"category_scores_gemma":[0.0021814052,0.00038099632,0.0016190213,0.0005075925,0.0005257449,0.00077606924,0.00044991056,0.0011229214,0.00023933793],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90416074,0.017439043,0.009440264,0.00032104377,0.0024263626,0.00004181292,0.00012279203,0.0021885675,0.0060350364,0.00008443568,0.00046054705,0.057279345],"study_design_scores_gemma":[0.1716714,0.7103482,0.10412574,0.000090251946,0.0044502793,0.00013369702,0.0003475591,0.003619831,0.0037908596,0.0001773319,0.001175682,0.000069163856],"about_ca_topic_score_codex":0.0022441924,"about_ca_topic_score_gemma":0.00590696,"teacher_disagreement_score":0.0022441924,"about_ca_system_score_codex":0.001464262,"about_ca_system_score_gemma":0.0013899648,"threshold_uncertainty_score":0.0106239915},"labels":[],"label_agreement":null},{"id":"W2595403257","doi":"10.1007/s00280-017-3260-6","title":"A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma","year":2017,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":94,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"Oncolytics Biotech","keywords":"Chills; Medicine; Carboplatin; Internal medicine; Melanoma; Nausea; Oncology; Adverse effect; Paclitaxel; Phases of clinical research; Chemotherapy; Immunotherapy; Gastroenterology; myalgia; Cancer; Immunology; Cisplatin; Cancer research","score_opus":0.014822680131463905,"score_gpt":0.3479693058060301,"score_spread":0.33314662567456615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595403257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917926,0.0019785762,0.00091858127,0.0005187038,0.0001687482,0.0019028509,0.00080949825,0.0001422183,0.0017682315],"genre_scores_gemma":[0.98762983,0.0025817417,0.0017018147,0.00060863595,0.00018870833,0.0018628914,0.0016435398,0.000059397724,0.003723426],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999582,0.00017601222,0.0000150490305,0.00008328006,0.000033049364,0.00011074834],"domain_scores_gemma":[0.99955136,0.000074931995,0.0000711674,0.000051894618,0.000022687063,0.00022804884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010798912,0.0015257965,0.0021662484,0.00061257737,0.0004209372,0.0010594048,0.0010964851,0.0012848116,0.0039049736],"category_scores_gemma":[0.0005697349,0.00069107703,0.0016028571,0.00054111367,0.0010005564,0.001002854,0.0003492839,0.0039065634,0.0008845533],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6230727,0.12763907,0.004170198,0.0011234634,0.0022095519,0.00036708682,0.00045854528,0.004782658,0.09533265,0.0006490318,0.004478507,0.13571656],"study_design_scores_gemma":[0.39157826,0.5885758,0.0065877317,0.000028672004,0.00058949273,0.0002537515,0.00008345155,0.001219164,0.00737275,0.00016140075,0.003516472,0.0000331011],"about_ca_topic_score_codex":0.0020340462,"about_ca_topic_score_gemma":0.0040290533,"teacher_disagreement_score":0.0039049736,"about_ca_system_score_codex":0.0009543456,"about_ca_system_score_gemma":0.0015843939,"threshold_uncertainty_score":0.013063431},"labels":[],"label_agreement":null},{"id":"W2604986769","doi":"10.1007/s00280-017-3298-5","title":"Up-regulation of autophagy is a mechanism of resistance to chemotherapy and can be inhibited by pantoprazole to increase drug sensitivity","year":2017,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Autophagy in Disease and Therapy","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Prostate Cancer Canada","keywords":"Autophagy; Pantoprazole; Drug resistance; Pharmacology; Cancer research; Chemotherapy; Programmed cell death; Biology; Apoptosis; Chemistry; Biochemistry","score_opus":0.013776681150835128,"score_gpt":0.3230400342287358,"score_spread":0.30926335307790065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604986769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97765154,0.011881184,0.002227104,0.0012167479,0.00016908256,0.00008196832,0.00038687736,0.0002873477,0.006098082],"genre_scores_gemma":[0.9935963,0.0027216787,0.0010746886,0.00015431928,0.000018239953,0.000036343106,0.00028039876,0.000015787997,0.0021021536],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996737,0.00006525573,0.00003172942,0.000036638812,0.000100227,0.00009252683],"domain_scores_gemma":[0.999877,0.000022292741,0.00003831116,0.000018994777,0.000026745625,0.00001676918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017372477,0.00027452453,0.0005147328,0.0004895721,0.00035010668,0.0004118846,0.00017328371,0.00048754615,0.0019125546],"category_scores_gemma":[0.00025523166,0.00018041927,0.0005049331,0.0004895964,0.00028180238,0.00026568814,0.00034369624,0.0006882331,0.00040980495],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006318911,0.00023631925,0.00193447,0.0002886569,0.000044179033,0.00045316148,0.000042005875,0.00024543382,0.9755137,0.00043646953,0.0010295912,0.01914406],"study_design_scores_gemma":[0.00012633081,0.0022437829,0.04210787,0.00006150111,0.000081574006,0.0027346264,0.0001352313,0.0020480019,0.9328528,0.0004890423,0.017086554,0.000032638767],"about_ca_topic_score_codex":0.0011305021,"about_ca_topic_score_gemma":0.0024072852,"teacher_disagreement_score":0.0019125546,"about_ca_system_score_codex":0.00054089737,"about_ca_system_score_gemma":0.00032993057,"threshold_uncertainty_score":0.0063981414},"labels":[],"label_agreement":null},{"id":"W2607270289","doi":"10.1007/s00280-017-3287-8","title":"Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study","year":2017,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"Amgen","keywords":"Carfilzomib; Medicine; Multiple myeloma; Pharmacokinetics; End stage renal disease; Stage (stratigraphy); Oncology; Disease; Internal medicine; Intensive care medicine; Proteasome inhibitor","score_opus":0.05407738287008189,"score_gpt":0.3948468544672407,"score_spread":0.3407694715971588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607270289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986958,0.0004715707,0.00019271228,0.00009047658,0.000015301026,0.00015983054,0.0001281397,0.000027664544,0.00021845597],"genre_scores_gemma":[0.9980204,0.00030832764,0.0004543225,0.00024150881,0.00006321584,0.0001939688,0.00035633883,0.000007828348,0.00035401114],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996146,0.00015808106,0.000021387357,0.00006792391,0.000072207054,0.00006578691],"domain_scores_gemma":[0.99930024,0.00010968143,0.00016261253,0.000058108602,0.000034695917,0.00033472502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008984379,0.0007832686,0.0018732866,0.00021114603,0.0003274822,0.00060983625,0.00042686472,0.00082680926,0.00089626136],"category_scores_gemma":[0.0010818379,0.0004350415,0.000798232,0.00025887252,0.0006308688,0.0006066045,0.00021050018,0.0020612462,0.00036537868],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50518006,0.08089615,0.09276111,0.00070338545,0.0016439621,0.001608207,0.0012131421,0.0042586736,0.17765692,0.00021500482,0.0030894745,0.13077392],"study_design_scores_gemma":[0.14333425,0.6500889,0.18720233,0.00003199051,0.0006796113,0.0018798138,0.00014177797,0.0038891926,0.008891595,0.00015670763,0.0036307985,0.00007296114],"about_ca_topic_score_codex":0.00046008214,"about_ca_topic_score_gemma":0.0007975883,"teacher_disagreement_score":0.0018732866,"about_ca_system_score_codex":0.0005849294,"about_ca_system_score_gemma":0.0007446344,"threshold_uncertainty_score":0.004751444},"labels":[],"label_agreement":null},{"id":"W2617943271","doi":"10.1007/s00280-008-0848-x","title":"Identification, characterization and potent antitumor activity of ECO-4601, a novel peripheral benzodiazepine receptor ligand","year":2008,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Synthesis and pharmacology of benzodiazepine derivatives","field":"Chemistry","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Identification (biology); Benzodiazepine; Ligand (biochemistry); Peripheral; Pharmacology; Chemistry; GABAA receptor; Receptor; Biology; Medicine; Biochemistry; Internal medicine; Botany","score_opus":0.022173343416873204,"score_gpt":0.289562908502084,"score_spread":0.2673895650852108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2617943271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98716134,0.004031877,0.005538283,0.00018597176,0.000015516567,0.00008182839,0.00046840406,0.000050387483,0.002466369],"genre_scores_gemma":[0.9862364,0.0038394227,0.004517735,0.00009292387,0.000013792972,0.00004700394,0.0017705164,0.000015617072,0.0034665938],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991655,0.000016938353,0.000006132138,0.000013699722,0.000026398144,0.000020330695],"domain_scores_gemma":[0.9999341,0.000007927342,0.000017795572,0.000007701329,0.000011057745,0.000021466294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018083694,0.00029183936,0.00028745556,0.0002076846,0.00012213323,0.00026657188,0.00023845826,0.00018289337,0.0006334486],"category_scores_gemma":[0.00017430916,0.0001321052,0.00013996987,0.00016793578,0.0001660665,0.00018880986,0.00015090921,0.00037412308,0.00047187618],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020991258,0.00011082397,0.0004404409,0.000044731903,0.0000062034337,0.000119520104,0.000027412498,0.00043412411,0.9902322,0.00016674165,0.00011016222,0.0080975685],"study_design_scores_gemma":[0.00017870095,0.002634132,0.0066440026,0.0000115443445,0.000045308592,0.0022241415,0.00004371282,0.002402225,0.9731727,0.00010401986,0.012519269,0.000020275029],"about_ca_topic_score_codex":0.0007945294,"about_ca_topic_score_gemma":0.0010425881,"teacher_disagreement_score":0.0007945294,"about_ca_system_score_codex":0.00026499145,"about_ca_system_score_gemma":0.0003584891,"threshold_uncertainty_score":0.002119124},"labels":[],"label_agreement":null},{"id":"W2743564890","doi":"10.1007/s00280-017-3412-8","title":"Absence of cardiotoxicity with prolonged treatment and large accumulating doses of pegylated liposomal doxorubicin","year":2017,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Cardiotoxicity; Doxorubicin; Medicine; Pharmacology; Liposome; Chemotherapy; Internal medicine; Chemistry","score_opus":0.029199937636791344,"score_gpt":0.35614252414482866,"score_spread":0.3269425865080373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2743564890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99711967,0.00077049475,0.0010377993,0.00006484297,0.00002736945,0.000026671234,0.00010762026,0.000033355584,0.0008122624],"genre_scores_gemma":[0.99875,0.000121039506,0.00036030266,0.000022917371,0.000008245023,0.0000140731545,0.00013176244,0.000006906347,0.0005848362],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998387,0.000040626583,0.000014263066,0.00003157162,0.000032175714,0.00004253283],"domain_scores_gemma":[0.99965715,0.00007720155,0.000084864136,0.00008002558,0.000029457795,0.00007129374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025213455,0.0002801383,0.00030612078,0.00011112699,0.00010813418,0.00019461318,0.000121479075,0.00028650506,0.0014406658],"category_scores_gemma":[0.0004550293,0.00012910791,0.0001751739,0.00011291941,0.00038336412,0.00034228564,0.00018950933,0.0006525799,0.00016880671],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021238397,0.00014281982,0.00093523884,0.00003167495,0.00001535979,0.0000992462,0.000025705838,0.0001647005,0.9933617,0.00009491277,0.00007202234,0.0029327276],"study_design_scores_gemma":[0.00008295315,0.0051783537,0.021806141,0.000008467832,0.00004326094,0.0008562499,0.000039289815,0.001488118,0.96910703,0.00012720944,0.0012507635,0.00001226895],"about_ca_topic_score_codex":0.00028158538,"about_ca_topic_score_gemma":0.00035032604,"teacher_disagreement_score":0.0014406658,"about_ca_system_score_codex":0.0001548704,"about_ca_system_score_gemma":0.00029362802,"threshold_uncertainty_score":0.0048195124},"labels":[],"label_agreement":null},{"id":"W2769776705","doi":"10.1007/s00280-017-3477-4","title":"Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma","year":2017,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Amino Acid Enzymes and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Public Health Agency of Canada","keywords":"Medicine; Chemotherapy; Immunohistochemistry; Oncology; Internal medicine; Metastasis; Pancreatic ductal adenocarcinoma; Cancer research; Cancer; Pancreatic cancer","score_opus":0.024717676985180934,"score_gpt":0.3291384125174103,"score_spread":0.3044207355322293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769776705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99913114,0.000366845,0.000053209693,0.00004262019,0.0000024076883,0.0000013280752,0.000051441057,0.0000045902243,0.00034641166],"genre_scores_gemma":[0.99947625,0.00008873092,0.000036239657,0.00001250967,0.0000044840717,0.0000026159103,0.000076813725,0.0000017557367,0.00030057903],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998952,0.000030872437,0.000013014172,0.000017506569,0.000018269555,0.0000251838],"domain_scores_gemma":[0.999335,0.00020108416,0.0002804586,0.000031794472,0.00006219075,0.00008953417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021953309,0.00010152396,0.00020311822,0.00045339655,0.00018358105,0.00044915077,0.00012786862,0.00026811348,0.0014240838],"category_scores_gemma":[0.00076289306,0.00013582222,0.00015078839,0.0004940399,0.00023970172,0.0002547865,0.00016700657,0.0003927145,0.00020783118],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006969742,0.00014443802,0.89537835,0.000060605355,0.000119375836,0.00081378256,0.00018699816,0.00042640054,0.08469761,0.00015916649,0.00030320743,0.010740358],"study_design_scores_gemma":[0.000028233917,0.0005618619,0.98407364,0.000008469108,0.000083270046,0.001464246,0.00031214015,0.0013158747,0.010890878,0.00013565145,0.0011166226,0.000009091618],"about_ca_topic_score_codex":0.00044100295,"about_ca_topic_score_gemma":0.0005635115,"teacher_disagreement_score":0.0014240838,"about_ca_system_score_codex":0.00032574718,"about_ca_system_score_gemma":0.000103132996,"threshold_uncertainty_score":0.0047640204},"labels":[],"label_agreement":null},{"id":"W2773849850","doi":"10.1007/s00280-017-3494-3","title":"Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors","year":2017,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Mirati Therapeutics","keywords":"Gemcitabine; Medicine; Pancreatic cancer; Internal medicine; Adverse effect; Cancer; Clinical endpoint; Phases of clinical research; Gastroenterology; Maximum tolerated dose; Oncology; Clinical trial","score_opus":0.012006969423434283,"score_gpt":0.36023163951508524,"score_spread":0.348224670091651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2773849850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883158,0.00291143,0.0007253474,0.0009485274,0.0002827315,0.0028933391,0.001483477,0.00013475298,0.002304581],"genre_scores_gemma":[0.9832131,0.0039685974,0.0021216308,0.0010232287,0.0002241737,0.0028392002,0.0028266145,0.000074631454,0.0037086788],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99962175,0.00014739379,0.000017744842,0.00008101376,0.00002211958,0.000109858585],"domain_scores_gemma":[0.99947435,0.000059869504,0.000068505484,0.000048970847,0.000024232668,0.0003241145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010484798,0.0017430659,0.0034092388,0.0007664874,0.00061001733,0.0014915208,0.001101269,0.001318032,0.0044985334],"category_scores_gemma":[0.00067239546,0.0009913131,0.0019533508,0.000827643,0.0013099381,0.0013030749,0.0004987695,0.0046899975,0.000977553],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78746086,0.081804566,0.0052086855,0.0008942731,0.002134035,0.00025063808,0.00032128594,0.0043467516,0.03173314,0.00052515685,0.0049152696,0.080405354],"study_design_scores_gemma":[0.6567361,0.32822382,0.0062986133,0.000041790245,0.0007042372,0.00016900759,0.00009286119,0.0011240084,0.0029253892,0.00023218873,0.0034176812,0.000034373425],"about_ca_topic_score_codex":0.0021246893,"about_ca_topic_score_gemma":0.00634482,"teacher_disagreement_score":0.0044985334,"about_ca_system_score_codex":0.0013059165,"about_ca_system_score_gemma":0.0023735836,"threshold_uncertainty_score":0.0150491},"labels":[],"label_agreement":null},{"id":"W2774981435","doi":"10.1007/s00280-017-3486-3","title":"Model based analysis of the heterogeneity in the tumour size dynamics differentiates vemurafenib, dabrafenib and trametinib in metastatic melanoma","year":2017,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CBC (Canada)","funders":"","keywords":"Dabrafenib; Vemurafenib; Trametinib; Tumour heterogeneity; Melanoma; Medicine; Oncology; Cancer research; Metastatic melanoma; Pathology; Internal medicine; Biology; Cancer; MAPK/ERK pathway; Kinase","score_opus":0.024330399213969414,"score_gpt":0.3176762638160448,"score_spread":0.2933458646020754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2774981435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9676142,0.00017761166,0.03146482,0.00011865544,0.0000044039657,0.000020810194,0.00021261183,0.00005927549,0.0003277019],"genre_scores_gemma":[0.9978726,0.000045612003,0.0017302405,0.0000063763746,0.0000024966052,0.000013912361,0.00015817456,0.0000048942356,0.0001656546],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9997851,0.000079827565,0.000012950961,0.000066562505,0.000027882214,0.000027592905],"domain_scores_gemma":[0.9984353,0.0011417955,0.00024969532,0.00006616854,0.00006442257,0.000042658725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013520103,0.00031577633,0.00048359038,0.00049004745,0.0001079366,0.00053627125,0.00030869132,0.00037648372,0.00028888282],"category_scores_gemma":[0.0037048196,0.000175557,0.000596772,0.00027235603,0.00026704045,0.0003466483,0.00024044885,0.0003675526,0.00005482634],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022365077,0.00007079015,0.03180881,0.00005116906,0.00013697089,0.00011194046,0.000056582026,0.9480092,0.009281341,0.0012661843,0.00013945147,0.008843987],"study_design_scores_gemma":[0.0000047149715,0.00005965984,0.01177359,0.0000020859602,0.000014134109,0.000048996233,0.000012077224,0.9865464,0.0008556769,0.0006046905,0.00007133657,0.0000066604284],"about_ca_topic_score_codex":0.005960108,"about_ca_topic_score_gemma":0.0039650053,"teacher_disagreement_score":0.005960108,"about_ca_system_score_codex":0.0007908462,"about_ca_system_score_gemma":0.00051445473,"threshold_uncertainty_score":0.011850834},"labels":[],"label_agreement":null},{"id":"W2790931628","doi":"10.1007/s00280-018-3521-z","title":"Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors","year":2018,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McGill University; Jewish General Hospital","funders":"","keywords":"Cmax; Pharmacokinetics; Pharmacology; Posaconazole; Bioavailability; Dosing; Medicine; Pharmacodynamics; Crossover study; Itraconazole","score_opus":0.008819464249852981,"score_gpt":0.2969617970561452,"score_spread":0.28814233280629226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790931628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99770665,0.0013603694,0.00005885912,0.00017824688,0.000039185226,0.000023831843,0.000122030484,0.000014979183,0.0004958265],"genre_scores_gemma":[0.998054,0.0006326534,0.00017778919,0.00014936195,0.00006167213,0.00001856325,0.00019683954,0.000007710946,0.0007013264],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997048,0.00014394482,0.000021418598,0.00005208526,0.000028848412,0.000048856127],"domain_scores_gemma":[0.9992274,0.0003426777,0.00014355319,0.000053354102,0.000037530852,0.0001955131],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045198548,0.0003441758,0.0009562388,0.00019765655,0.00025988126,0.00052749075,0.00017191478,0.0004534906,0.001432918],"category_scores_gemma":[0.0018102385,0.00021100353,0.0007111317,0.0002632717,0.00038384684,0.0006957286,0.00019152349,0.0015961028,0.00018044062],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6782971,0.008899064,0.050073344,0.00033416186,0.0015185397,0.0007531083,0.00047796688,0.0019475224,0.045599945,0.0002552416,0.00256896,0.20927499],"study_design_scores_gemma":[0.05925968,0.45986822,0.43005836,0.00008100068,0.00328876,0.00201398,0.00083840196,0.006717371,0.02535298,0.00059056655,0.011744715,0.00018592663],"about_ca_topic_score_codex":0.0009034106,"about_ca_topic_score_gemma":0.0021726326,"teacher_disagreement_score":0.001432918,"about_ca_system_score_codex":0.0005226832,"about_ca_system_score_gemma":0.0004518942,"threshold_uncertainty_score":0.0047935843},"labels":[],"label_agreement":null},{"id":"W2807339691","doi":"10.1007/s00280-018-3614-8","title":"Interactions of lean soft-tissue and chemotherapy toxicities in patients receiving anti-cancer treatments","year":2018,"lang":"en","type":"review","venue":"Cancer Chemotherapy and Pharmacology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Alberta Hospital","funders":"","keywords":"Chemotherapy; Soft tissue; Lean body mass; Dosing; Lean tissue; Medicine; Cancer; Body surface area; Oncology; Internal medicine; Pathology; Adipose tissue; Body weight","score_opus":0.07627704170520572,"score_gpt":0.4638383095801216,"score_spread":0.3875612678749159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807339691","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003977795,0.9989221,0.000047729645,0.000185509,0.000058043537,0.0000034840305,0.000017195869,0.0000019101035,0.00036626947],"genre_scores_gemma":[0.004073223,0.99496585,0.00019535699,0.00030285833,0.00016554011,0.000007848403,0.00002789004,7.315142e-7,0.00026062346],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99978834,0.00006301617,0.000044494052,0.000027468779,0.00006215776,0.000014525088],"domain_scores_gemma":[0.99954706,0.00025044035,0.00012356123,0.0000056171693,0.000058636277,0.000014718633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004314546,0.00045672126,0.0010613216,0.0010164285,0.000132128,0.0006380268,0.00036676382,0.00053285895,0.0019469777],"category_scores_gemma":[0.0012103664,0.00016464699,0.00070383726,0.0011147206,0.00021987203,0.00045887506,0.0004769592,0.00095906405,0.00021418631],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023862564,0.000106992986,0.0029030826,0.033349056,0.00091086305,0.00014988153,0.000085755106,0.00030441035,0.00053791376,0.0012538774,0.010303123,0.9498566],"study_design_scores_gemma":[0.00023659473,0.0007241263,0.033410225,0.04102762,0.006714961,0.0033285085,0.00036388895,0.0004965862,0.00095994194,0.0038373847,0.9088103,0.00008985237],"about_ca_topic_score_codex":0.0013017452,"about_ca_topic_score_gemma":0.004304063,"teacher_disagreement_score":0.0019469777,"about_ca_system_score_codex":0.00030536405,"about_ca_system_score_gemma":0.0007757399,"threshold_uncertainty_score":0.0065132976},"labels":[],"label_agreement":null},{"id":"W2881471750","doi":"10.1007/s00280-018-3632-6","title":"An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer","year":2018,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development; Cancer Research UK","keywords":"Prostate cancer; Medicine; Repolarization; Ventricular Repolarization; Internal medicine; Pharmacokinetics; Prostate; Cancer; Oncology; Electrophysiology","score_opus":0.03939307538328744,"score_gpt":0.4318884542488405,"score_spread":0.392495378865553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2881471750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956943,0.0012822666,0.0004707726,0.00010491541,0.000040212377,0.0014295048,0.00037177908,0.00005164726,0.0005546991],"genre_scores_gemma":[0.9957391,0.0006810561,0.0008825221,0.00030723293,0.00008627393,0.0010067988,0.0005590551,0.000015706615,0.0007222019],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996055,0.00019572553,0.000026515716,0.00007100718,0.000045268247,0.00005595749],"domain_scores_gemma":[0.999253,0.000105592466,0.00021618675,0.00006568263,0.000057169284,0.00030231482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086243724,0.0008074655,0.0013107792,0.00025102135,0.00028144606,0.0005884511,0.0008118636,0.00076390646,0.002396389],"category_scores_gemma":[0.00084076513,0.00039806333,0.0006696657,0.00030332486,0.00061175384,0.0005683665,0.00021379825,0.001921269,0.0005006865],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6748986,0.09356555,0.011403503,0.0011944195,0.0020927142,0.0002461453,0.00034526814,0.0022541825,0.10473283,0.00014647584,0.0017690606,0.10735123],"study_design_scores_gemma":[0.30081043,0.6723049,0.01973173,0.000029388948,0.00033822714,0.00024884046,0.000059217862,0.00074635557,0.004248763,0.0000828791,0.0013755866,0.000023692937],"about_ca_topic_score_codex":0.0008101692,"about_ca_topic_score_gemma":0.0017694252,"teacher_disagreement_score":0.002396389,"about_ca_system_score_codex":0.0004632286,"about_ca_system_score_gemma":0.000896481,"threshold_uncertainty_score":0.008016646},"labels":[],"label_agreement":null},{"id":"W2885544802","doi":"10.1007/s00280-018-3654-0","title":"A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc™) in patients with locally advanced or metastatic cancer","year":2018,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Curcumin's Biomedical Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":132,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nucro Technics","funders":"Paracelsus Medizinische Privatuniversität","keywords":"Tolerability; Curcumin; Medicine; Pharmacokinetics; Hemolysis; Pharmacology; Toxicity; Adverse effect; Cancer; Pharmacodynamics; Phases of clinical research; Gastroenterology; Internal medicine","score_opus":0.01766075689360954,"score_gpt":0.35294913302099534,"score_spread":0.3352883761273858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885544802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99785703,0.0004490069,0.00042600872,0.00011157129,0.000024257452,0.0007126759,0.00012456745,0.000034589022,0.00026026717],"genre_scores_gemma":[0.9949944,0.0006067976,0.0018286203,0.0002630338,0.00006501082,0.00095554197,0.00037496258,0.000019710327,0.0008918769],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996407,0.00019291061,0.0000147784,0.000057381752,0.00003841342,0.000055863275],"domain_scores_gemma":[0.99935097,0.00015584462,0.00014402939,0.00007239843,0.000036103007,0.00024061842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011558661,0.0011193431,0.00183325,0.0003417753,0.00036823825,0.00040121473,0.00045683776,0.0006488424,0.0016300512],"category_scores_gemma":[0.0010291125,0.00049900176,0.00064842333,0.00023261739,0.0008286621,0.0005569944,0.0002445089,0.0021841044,0.00036646848],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37140876,0.118865155,0.0105581,0.0011560473,0.00091693253,0.0007539167,0.0009337511,0.006005766,0.35624182,0.00027074118,0.0029861976,0.12990284],"study_design_scores_gemma":[0.13818488,0.82849044,0.014957507,0.00002040334,0.00025701695,0.0003783863,0.000052082927,0.001518518,0.014260934,0.00015743347,0.0016822837,0.000040260653],"about_ca_topic_score_codex":0.00031483214,"about_ca_topic_score_gemma":0.00081285875,"teacher_disagreement_score":0.00183325,"about_ca_system_score_codex":0.0005491247,"about_ca_system_score_gemma":0.00079298596,"threshold_uncertainty_score":0.0061128736},"labels":[],"label_agreement":null},{"id":"W2897175439","doi":"10.1007/s00280-018-3689-2","title":"Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer","year":2018,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Medicine; Afatinib; Internal medicine; Rash; Trastuzumab; Diarrhea; Metastatic breast cancer; Cancer; Adverse effect; Oncology; Gastroenterology; Breast cancer; Surgery; Epidermal growth factor receptor; Erlotinib","score_opus":0.028446106103640956,"score_gpt":0.4090134797091505,"score_spread":0.3805673736055095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897175439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99179006,0.0020126514,0.000503612,0.0007960611,0.00019134687,0.0025563077,0.00059783895,0.00008518453,0.001466985],"genre_scores_gemma":[0.98988426,0.0011222189,0.0019068354,0.0011235747,0.00018168836,0.0027546452,0.0014018363,0.00002789807,0.0015968966],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994742,0.000226953,0.00003409365,0.00009238001,0.000048672722,0.00012371258],"domain_scores_gemma":[0.9989448,0.00013949303,0.00019922204,0.00008214446,0.000061734005,0.00057263306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018924744,0.0015800889,0.002260442,0.00040291,0.0005268518,0.001129167,0.0011854052,0.0017145037,0.0028335345],"category_scores_gemma":[0.0013924643,0.0007147317,0.001588889,0.000521111,0.001142874,0.00093970797,0.0004176871,0.0037395537,0.0007239611],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81550545,0.06587776,0.0046526752,0.0007598073,0.0016830539,0.00033050904,0.0003785662,0.0035023023,0.025968328,0.00036899475,0.0048602605,0.07611228],"study_design_scores_gemma":[0.7824784,0.20970653,0.0044410727,0.000021071828,0.0001715805,0.0001977026,0.00002289595,0.00080962706,0.0009822791,0.0001447335,0.0010040031,0.000020087176],"about_ca_topic_score_codex":0.0012893836,"about_ca_topic_score_gemma":0.0031616734,"teacher_disagreement_score":0.0028335345,"about_ca_system_score_codex":0.0015361608,"about_ca_system_score_gemma":0.00250645,"threshold_uncertainty_score":0.011145651},"labels":[],"label_agreement":null},{"id":"W2898091448","doi":"10.1007/s00280-018-3706-5","title":"Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103)","year":2018,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Apotex (Canada)","funders":"National Health and Medical Research Council","keywords":"Carboplatin; Gemcitabine; Ovarian cancer; Medicine; Platinum; Internal medicine; Oncology; Chemotherapy; Phases of clinical research; Cancer; Cisplatin; Chemistry","score_opus":0.027892984069719035,"score_gpt":0.3651652371962587,"score_spread":0.3372722531265397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898091448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98940605,0.0022594256,0.0004657029,0.00067316246,0.00018865943,0.0024665797,0.0019697563,0.00016721552,0.002403377],"genre_scores_gemma":[0.9798148,0.0031069966,0.0017209958,0.0014161427,0.00017262582,0.0030009288,0.0061670267,0.00009591274,0.004504537],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99958414,0.00015325645,0.000016596252,0.000078326666,0.000026096452,0.00014162973],"domain_scores_gemma":[0.9993462,0.000055794375,0.00006585197,0.000066437344,0.000024850888,0.00044076858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012336763,0.001518965,0.0036070356,0.0006990506,0.00061128405,0.0012427233,0.0013830885,0.0016546809,0.005229725],"category_scores_gemma":[0.000637399,0.0009248485,0.0022338065,0.0007725588,0.0011841034,0.0008704988,0.0005983579,0.005053509,0.0013669097],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.70050734,0.1099774,0.008493366,0.0009302108,0.0022722813,0.00043643155,0.0005486545,0.0043820804,0.048162334,0.0005618209,0.009857425,0.11387061],"study_design_scores_gemma":[0.50624484,0.46922353,0.014432502,0.00004244659,0.00067452004,0.00035251922,0.00010947156,0.0010329697,0.0035702207,0.00024317644,0.0040330025,0.0000408173],"about_ca_topic_score_codex":0.0037780954,"about_ca_topic_score_gemma":0.009574304,"teacher_disagreement_score":0.005229725,"about_ca_system_score_codex":0.0012888089,"about_ca_system_score_gemma":0.0029780397,"threshold_uncertainty_score":0.017495155},"labels":[],"label_agreement":null},{"id":"W2901231185","doi":"10.1007/s00280-018-3726-1","title":"6-MOMIPP, a novel brain-penetrant anti-mitotic indolyl-chalcone, inhibits glioblastoma growth and viability","year":2018,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Synthesis and biological activity","field":"Chemistry","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; National Cancer Institute; University of Toledo Foundation; McMaster University","keywords":"Viability assay; Cyclin-dependent kinase 1; Programmed cell death; Tubulin; Apoptosis; Cancer research; Mitosis; Mitotic catastrophe; Cell cycle; Flow cytometry; Biology; Cell growth; Microtubule; Cell biology; Chemistry; Molecular biology; Biochemistry","score_opus":0.018193188634112643,"score_gpt":0.28785041135742856,"score_spread":0.26965722272331594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901231185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9584955,0.009272557,0.006833178,0.00063017575,0.00012324753,0.00019111467,0.0012478356,0.00093948,0.022266788],"genre_scores_gemma":[0.9836962,0.00560456,0.0021525552,0.00011919318,0.00004562612,0.000067211215,0.0012768509,0.00003144723,0.007006348],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999685,0.0000037432335,0.000001834572,0.000004060747,0.0000058231676,0.000016052189],"domain_scores_gemma":[0.9999808,0.0000018804916,0.00000434021,0.000001551106,0.0000022406184,0.000009262886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000049324288,0.00035554843,0.00023231728,0.00035252483,0.00017205991,0.00019639732,0.0003721082,0.00022029529,0.0020932406],"category_scores_gemma":[0.000055716933,0.000073516356,0.00012613289,0.00021605178,0.0001244002,0.00021330774,0.00017202333,0.0004066417,0.0006717693],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011901943,0.000379637,0.00048464382,0.00035071129,0.000017107981,0.0007961423,0.00003850023,0.0004905632,0.9264945,0.00087633805,0.0019773422,0.066904314],"study_design_scores_gemma":[0.00025330062,0.003551442,0.0050767083,0.000023291579,0.000039937604,0.0014942065,0.000048670507,0.0010706707,0.967855,0.00023639007,0.020328877,0.000021522523],"about_ca_topic_score_codex":0.0007305754,"about_ca_topic_score_gemma":0.0016823186,"teacher_disagreement_score":0.0020932406,"about_ca_system_score_codex":0.00022662466,"about_ca_system_score_gemma":0.0002914706,"threshold_uncertainty_score":0.0070025325},"labels":[],"label_agreement":null},{"id":"W2901454723","doi":"10.1007/s00280-018-3730-5","title":"Pharmacokinetics of liposomal curcumin (Lipocurc™) infusion: effect of co-medication in cancer patients and comparison with healthy individuals","year":2018,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Curcumin's Biomedical Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nucro Technics","funders":"","keywords":"Curcumin; Pharmacokinetics; Pharmacology; Medicine; Volume of distribution; Cancer; Ramipril; Internal medicine; Blood pressure","score_opus":0.010417947066418243,"score_gpt":0.3572506904396505,"score_spread":0.3468327433732323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901454723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991598,0.00041486154,0.00008185134,0.000016795502,0.000007380487,0.000008582803,0.00008065569,0.000008933559,0.00022123227],"genre_scores_gemma":[0.99921274,0.00016450303,0.000115745424,0.00002455181,0.000015623025,0.000013464319,0.00012631399,0.000003824974,0.00032333296],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99983025,0.000042557054,0.000012917427,0.00006215337,0.000024192335,0.000027998318],"domain_scores_gemma":[0.9996314,0.00011266403,0.00009450086,0.000030015173,0.00002946288,0.000101945996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019427242,0.00021299822,0.0005217303,0.000171351,0.00015180849,0.00031585008,0.00010212519,0.00032878137,0.0012952165],"category_scores_gemma":[0.00084707607,0.0001424555,0.00022781815,0.00019873561,0.00017383033,0.00033004823,0.00016936602,0.0003883768,0.0002611485],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30524853,0.0041250563,0.46795985,0.00035859025,0.0009895901,0.0013699546,0.0008650526,0.0012176996,0.12063837,0.00021340042,0.0010589319,0.09595497],"study_design_scores_gemma":[0.0017413865,0.043874018,0.93278766,0.00001782417,0.0007432544,0.0019629225,0.00039744083,0.0030641446,0.013009946,0.00012004124,0.0022207028,0.00006057077],"about_ca_topic_score_codex":0.00055329996,"about_ca_topic_score_gemma":0.00045036536,"teacher_disagreement_score":0.0012952165,"about_ca_system_score_codex":0.0002204081,"about_ca_system_score_gemma":0.00018513534,"threshold_uncertainty_score":0.0043329},"labels":[],"label_agreement":null},{"id":"W2904569076","doi":"10.1007/s00280-018-3738-x","title":"A phase II trial of the effect of perindopril on hand–foot skin reaction (HFSR) incidence and severity in patients receiving regorafenib for refractory mCRC","year":2018,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Regorafenib; Perindopril; Medicine; Refractory (planetary science); Incidence (geometry); Foot (prosody); Skin reaction; Internal medicine; Oncology; Surgery; Dermatology; Colorectal cancer; Biology","score_opus":0.0164618740842383,"score_gpt":0.355211686871391,"score_spread":0.33874981278715266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904569076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940871,0.0015851732,0.00027859045,0.00033551618,0.00015207447,0.0019047719,0.0005184681,0.000050499475,0.0010878984],"genre_scores_gemma":[0.9938876,0.0008727383,0.0009539431,0.00046435773,0.0001821782,0.0016968146,0.0007602394,0.000011789807,0.0011703799],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99954396,0.00023641212,0.000024569155,0.00007817844,0.000035715533,0.00008117473],"domain_scores_gemma":[0.9989918,0.000201844,0.00022034638,0.00009238968,0.00006013505,0.0004335488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017234948,0.0013855518,0.0018139197,0.00030506958,0.00037858268,0.0007231575,0.00071344513,0.0010803337,0.0035835532],"category_scores_gemma":[0.001450093,0.0005192655,0.0015791932,0.0002649975,0.000877572,0.0008401978,0.00031072987,0.0031767902,0.00059381145],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9033199,0.042727087,0.0035498522,0.000720608,0.0009827401,0.000097757504,0.00012467286,0.0014245944,0.012275205,0.00011517134,0.0015298309,0.03313249],"study_design_scores_gemma":[0.7553091,0.23638561,0.005438855,0.000021558928,0.00030320178,0.000098718134,0.000028010601,0.00075023994,0.0009797458,0.00010099856,0.0005654128,0.000018547704],"about_ca_topic_score_codex":0.0006345768,"about_ca_topic_score_gemma":0.0020717985,"teacher_disagreement_score":0.0035835532,"about_ca_system_score_codex":0.0007678592,"about_ca_system_score_gemma":0.0012434989,"threshold_uncertainty_score":0.011988163},"labels":[],"label_agreement":null},{"id":"W2955507595","doi":"10.1007/s00280-019-03899-y","title":"Population pharmacokinetics of trabectedin in adolescent patients with cancer","year":2019,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; SickKids Foundation; University of Toronto","funders":"Janssen Research and Development; National Cancer Institute","keywords":"Trabectedin; Pharmacokinetics; Medicine; Population pharmacokinetics; Population; Cancer; Oncology; Pharmacology; Internal medicine; Sarcoma; Pathology; Soft tissue sarcoma","score_opus":0.020476247915726567,"score_gpt":0.35171804403402446,"score_spread":0.3312417961182979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955507595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99833316,0.00048987666,0.0004432772,0.00008829839,0.000005758838,0.000009571021,0.000153862,0.00001392323,0.00046221982],"genre_scores_gemma":[0.9991334,0.00022670215,0.00024376788,0.00004453425,0.000009758054,0.000008748982,0.0001403113,0.000006498319,0.00018630021],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99980205,0.0000915311,0.0000085034635,0.00003781691,0.00003577747,0.000024430105],"domain_scores_gemma":[0.9993337,0.0003306806,0.0001619281,0.00004040222,0.000050387796,0.000082870414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031996498,0.00012407111,0.0003903872,0.000113006674,0.00012432218,0.0003499123,0.000091362526,0.00022722462,0.00087076606],"category_scores_gemma":[0.00204631,0.00014622282,0.00021367292,0.00018562107,0.00013017449,0.0003225807,0.00013375745,0.00064333325,0.00012885037],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074941656,0.0003909718,0.94275814,0.000056143243,0.00041889524,0.00048089164,0.00043077543,0.0021427032,0.008383537,0.00060299516,0.001349032,0.035491794],"study_design_scores_gemma":[0.00019662558,0.004043318,0.9831708,0.000015273305,0.00018292788,0.0019054199,0.00028191894,0.0057232175,0.0020717774,0.0002927372,0.0021009028,0.00001517148],"about_ca_topic_score_codex":0.0015042323,"about_ca_topic_score_gemma":0.0016943178,"teacher_disagreement_score":0.0015042323,"about_ca_system_score_codex":0.00031896084,"about_ca_system_score_gemma":0.00032496304,"threshold_uncertainty_score":0.002990961},"labels":[],"label_agreement":null},{"id":"W2973076369","doi":"10.1007/s00280-019-03956-6","title":"Skin platinum deposition in colorectal cancer patients following oxaliplatin-based therapy","year":2019,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Fluidigm (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Oxaliplatin; FOLFOX; Medicine; Peripheral neuropathy; Cumulative dose; Colorectal cancer; Internal medicine; Neurotoxicity; Gastroenterology; Chemotherapy; Cancer; Oncology; Toxicity; Endocrinology","score_opus":0.012279270525962987,"score_gpt":0.3243970405063564,"score_spread":0.3121177699803934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2973076369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970204,0.00046875956,0.00006599442,0.00004410685,0.000010704521,0.000011473679,0.000067047935,0.000005407793,0.0023061342],"genre_scores_gemma":[0.99941707,0.00013991774,0.000032095748,0.000027878754,0.000009428882,0.0000017707663,0.000041936662,0.0000022699735,0.0003277174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99978524,0.00004611917,0.000022862412,0.000034160315,0.00006030151,0.000051273564],"domain_scores_gemma":[0.9992329,0.00017865752,0.00031782754,0.000032773438,0.000100978374,0.00013682374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018716443,0.00013475934,0.00035048905,0.0006439022,0.00039294653,0.0004940496,0.00014078102,0.00034120103,0.0023174733],"category_scores_gemma":[0.0011539755,0.0001868335,0.00040440957,0.0005766884,0.00018477469,0.00030848038,0.00024947716,0.00044933576,0.00024305876],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021745896,0.0001938612,0.9657634,0.000081689665,0.00013203124,0.011962353,0.00026744758,0.00016422984,0.0064370492,0.000033338918,0.00024630647,0.012543894],"study_design_scores_gemma":[0.000014342208,0.00051063404,0.98736703,0.000008141148,0.00008142177,0.010292657,0.000260137,0.0001987918,0.0008385649,0.00003156458,0.00038972002,0.000006968661],"about_ca_topic_score_codex":0.0019368108,"about_ca_topic_score_gemma":0.0027586704,"teacher_disagreement_score":0.0023174733,"about_ca_system_score_codex":0.00034987295,"about_ca_system_score_gemma":0.000185835,"threshold_uncertainty_score":0.007752657},"labels":[],"label_agreement":null},{"id":"W2986277146","doi":"10.1007/s00280-019-03989-x","title":"Characterization and outcomes of patients enrolled to multiple phase I cancer trials","year":2019,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Clinical trial; Internal medicine; Adverse effect; Cancer; Demographics; Phases of clinical research; Demography","score_opus":0.2538180196436872,"score_gpt":0.5874401460463614,"score_spread":0.3336221264026742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986277146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863653,0.0024280273,0.0015479663,0.0012909806,0.00004876546,0.0003821399,0.0019735675,0.000020318797,0.0059429295],"genre_scores_gemma":[0.9950799,0.0004443696,0.0004927094,0.00060004747,0.00008509703,0.0003291848,0.0021026677,0.000018610359,0.00084761274],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99408287,0.0022755312,0.0010248887,0.00076200615,0.00093446946,0.0009201832],"domain_scores_gemma":[0.98190445,0.003984381,0.009126099,0.0012281847,0.0016704467,0.002086487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057091736,0.00021753342,0.0008507177,0.0009976346,0.0008064221,0.0018985638,0.0004973187,0.00056839385,0.0024663648],"category_scores_gemma":[0.019244479,0.00014286181,0.0009046221,0.0014537673,0.00047772858,0.0013192338,0.0011447399,0.0013985817,0.00041820807],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075390306,0.0004556892,0.94702655,0.00011072778,0.0004561917,0.00026197007,0.00047415102,0.00048494755,0.00137846,0.0009508123,0.0015732888,0.039288066],"study_design_scores_gemma":[0.00038314873,0.0044891,0.98085016,0.000096915275,0.00032954224,0.0012536,0.0006226115,0.0011680954,0.00087422034,0.0018996112,0.0079954155,0.00003756317],"about_ca_topic_score_codex":0.0005902357,"about_ca_topic_score_gemma":0.0009974622,"teacher_disagreement_score":0.0057091736,"about_ca_system_score_codex":0.0011721713,"about_ca_system_score_gemma":0.0016071888,"threshold_uncertainty_score":0.030193329},"labels":[],"label_agreement":null},{"id":"W3006140059","doi":"10.1007/s00280-020-04038-8","title":"Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors","year":2020,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nexen (Canada)","funders":"Novartis Pharmaceuticals Corporation","keywords":"Tolerability; Trametinib; Dosing; Medicine; Rash; Adverse effect; Internal medicine; Mucositis; Oncology; Pharmacology; Toxicity; MAPK/ERK pathway","score_opus":0.014149507990633454,"score_gpt":0.2872376165837309,"score_spread":0.27308810859309746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006140059","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972365,0.0006350664,0.0002268285,0.00014565102,0.000038563066,0.0008923645,0.00020554784,0.000038521386,0.0005809776],"genre_scores_gemma":[0.99576926,0.00050128973,0.0010513486,0.00028171044,0.00006687113,0.00074256037,0.0006798885,0.000010565103,0.0008965803],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995333,0.00022158085,0.00003117803,0.00008144145,0.00005174286,0.00008081631],"domain_scores_gemma":[0.9993874,0.00010867432,0.00017570262,0.00006546271,0.00003742716,0.00022528949],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015157394,0.0012156647,0.0017400301,0.00032332243,0.00035217142,0.0006372929,0.0007331678,0.00069779163,0.0022561497],"category_scores_gemma":[0.00083408423,0.00049411715,0.0010662946,0.0003841591,0.0006116585,0.0006789824,0.00033034792,0.0035460806,0.0004901198],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.62886864,0.107568644,0.011627974,0.0010159868,0.0016499202,0.00040809406,0.00051843177,0.0052635064,0.068903126,0.00021200826,0.0033102627,0.17065342],"study_design_scores_gemma":[0.45759752,0.51219493,0.017822245,0.000041559022,0.0005349897,0.00039604062,0.000059388218,0.002273317,0.0070454334,0.00014849426,0.0018561042,0.000030029682],"about_ca_topic_score_codex":0.000534242,"about_ca_topic_score_gemma":0.002201883,"teacher_disagreement_score":0.0022561497,"about_ca_system_score_codex":0.00097549264,"about_ca_system_score_gemma":0.0013008583,"threshold_uncertainty_score":0.0080161095},"labels":[],"label_agreement":null},{"id":"W3014539959","doi":"10.1007/s00280-020-04063-7","title":"Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancer","year":2020,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Internal medicine; Oncology; Univariate analysis; Proportional hazards model; Cancer; Discontinuation; Prostate-specific antigen; Chemotherapy; Retrospective cohort study; Urology; Multivariate analysis","score_opus":0.02855337228452725,"score_gpt":0.34417924829541136,"score_spread":0.3156258760108841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014539959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995276,0.0029658892,0.000068406,0.000111805966,0.000024258752,0.000013169998,0.00017741862,0.000010560927,0.0013525479],"genre_scores_gemma":[0.99851686,0.0005716262,0.000046607744,0.00005683389,0.000022785616,0.000004731163,0.00018652683,0.0000024161695,0.00059158687],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9999018,0.000036607315,0.0000060214716,0.000012666687,0.000015385665,0.00002754422],"domain_scores_gemma":[0.999754,0.00007853124,0.000057667512,0.0000170393,0.0000112578855,0.00008149907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023529504,0.00021943766,0.0003593942,0.00013158396,0.00011534124,0.000254743,0.00016226165,0.00016028213,0.00090007787],"category_scores_gemma":[0.0007563388,0.00008888068,0.00042996157,0.00020206565,0.0001509282,0.00015595931,0.00011515266,0.00047078647,0.000081609316],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32472095,0.00536247,0.2970173,0.0006130824,0.0028242283,0.00071012496,0.0005201533,0.0126118325,0.04192543,0.000690017,0.004035777,0.3089686],"study_design_scores_gemma":[0.0035996186,0.050681945,0.9379723,0.00003868434,0.0010245073,0.00046260766,0.00009735051,0.0017254654,0.0015866525,0.00021592448,0.002566847,0.000028067576],"about_ca_topic_score_codex":0.002454871,"about_ca_topic_score_gemma":0.00870856,"teacher_disagreement_score":0.002454871,"about_ca_system_score_codex":0.00039268626,"about_ca_system_score_gemma":0.00033528268,"threshold_uncertainty_score":0.004881203},"labels":[],"label_agreement":null},{"id":"W3033856706","doi":"10.1007/s00280-020-04086-0","title":"Validation of an online tool for early prediction of the failure-risk in gestational trophoblastic neoplasia patients treated with methotrexate","year":2020,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Gestational Trophoblastic Disease Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Methotrexate; Medicine; Gestational trophoblastic neoplasia; Internal medicine; Antimetabolite; Human chorionic gonadotropin; Oncology; Biomarker; Antifolate; Hormone","score_opus":0.021258261742797727,"score_gpt":0.2921693911466551,"score_spread":0.27091112940385736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033856706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9505848,0.0022382177,0.018397963,0.0011986512,0.00031716086,0.0013740808,0.01594771,0.0019014858,0.008039819],"genre_scores_gemma":[0.95996743,0.0005737972,0.028726315,0.00037771696,0.00017369272,0.0014079808,0.006303333,0.00007612086,0.0023937146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970901,0.0013172831,0.0005862358,0.0003113558,0.00054148206,0.00015349289],"domain_scores_gemma":[0.9764499,0.016482752,0.0032988982,0.00072053465,0.0023171932,0.0007306554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042264108,0.00067598815,0.0009906782,0.0033164269,0.00030223225,0.0014809064,0.0006937403,0.00084122876,0.00488041],"category_scores_gemma":[0.019802835,0.0002695033,0.0008573475,0.0011786962,0.00016588908,0.0008033238,0.0008108067,0.0006355791,0.0011787366],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036115667,0.00094128936,0.84178084,0.00052717567,0.0004320969,0.00025645,0.0002939384,0.0020407864,0.0011739553,0.0004963734,0.007491045,0.14095443],"study_design_scores_gemma":[0.00083696446,0.0030089184,0.908828,0.00073043053,0.0011544524,0.0017664363,0.0006745695,0.055123813,0.0067374893,0.0013257504,0.019680971,0.00013224488],"about_ca_topic_score_codex":0.001389268,"about_ca_topic_score_gemma":0.0018642029,"teacher_disagreement_score":0.00488041,"about_ca_system_score_codex":0.00043670076,"about_ca_system_score_gemma":0.0009641622,"threshold_uncertainty_score":0.022351682},"labels":[],"label_agreement":null},{"id":"W3120367735","doi":"10.1007/s00280-020-04213-x","title":"Enhancing the activity of platinum-based drugs by improved inhibitors of ERCC1–XPF-mediated DNA repair","year":2021,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Northern Alberta Institute of Technology; University of British Columbia; University of Alberta","funders":"Novartis Pharmaceuticals Canada; Alberta Cancer Foundation; Alberta Innovates; Olav Raagholt og Gerd Meidel Raagholts stiftelse","keywords":"ERCC1; Pharmacology; DNA repair; DNA damage; Nucleotide excision repair; Medicine; DNA; Cancer research; Chemistry; Biology; Genetics","score_opus":0.005931140161619798,"score_gpt":0.26636515229225377,"score_spread":0.260434012130634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120367735","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97917044,0.008777062,0.006926423,0.00035877974,0.0001000261,0.00010415919,0.00033862542,0.0002987464,0.003925772],"genre_scores_gemma":[0.9932406,0.0026979153,0.0022105903,0.00006385179,0.000015110273,0.00002408139,0.00021932807,0.000032168027,0.0014963467],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998635,0.000019454199,0.000014616338,0.000028836625,0.00003683905,0.00003664014],"domain_scores_gemma":[0.99992335,0.000015829684,0.000022661443,0.000012140744,0.0000127505755,0.000013230132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021521887,0.00038069137,0.00049981324,0.00029798658,0.00011788411,0.0004368942,0.00035806643,0.00031296385,0.0018103058],"category_scores_gemma":[0.00025735635,0.00015886342,0.00018636948,0.00022287766,0.00016659098,0.0003413331,0.00016835328,0.0007293594,0.00032996738],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048316686,0.00016497908,0.00025677335,0.000117774194,0.0000363143,0.000070093505,0.000013368869,0.001008266,0.9822121,0.0006095587,0.00022806424,0.014799592],"study_design_scores_gemma":[0.00006123436,0.00049508625,0.0011580269,0.0000069813186,0.00003164493,0.00022017024,0.0000040834448,0.0013250147,0.9921061,0.00006338164,0.0045208046,0.000007400872],"about_ca_topic_score_codex":0.00046957904,"about_ca_topic_score_gemma":0.0007333303,"teacher_disagreement_score":0.0018103058,"about_ca_system_score_codex":0.0004446647,"about_ca_system_score_gemma":0.0002382251,"threshold_uncertainty_score":0.0060560703},"labels":[],"label_agreement":null},{"id":"W3137618571","doi":"10.1007/s00280-021-04249-7","title":"Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)","year":2021,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Janssen Research and Development","keywords":"Medicine; Prostate cancer; Abiraterone acetate; Internal medicine; Prednisone; Enzalutamide; Adverse effect; Oncology; Pharmacokinetics; Urology; Discontinuation; Androgen receptor; Cancer; Androgen deprivation therapy","score_opus":0.025117111216251545,"score_gpt":0.34287421252309486,"score_spread":0.3177571013068433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137618571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99560297,0.0027547434,0.0002866446,0.00014662814,0.000028503558,0.00032314833,0.00032615368,0.000029680563,0.0005015469],"genre_scores_gemma":[0.9945703,0.0014790623,0.0010936907,0.00043998944,0.00008340798,0.00032769068,0.0013939983,0.000019376621,0.00059251784],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9989385,0.0006239448,0.000057229343,0.0001379591,0.00016058786,0.00008161903],"domain_scores_gemma":[0.9991067,0.00016668529,0.00026653538,0.00009818426,0.000081104794,0.0002807571],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025244446,0.00083801296,0.0014258737,0.0002564002,0.00024244333,0.0008425404,0.00065283023,0.00056360336,0.0012179752],"category_scores_gemma":[0.0013952439,0.0004397245,0.000974995,0.00032642612,0.00053332717,0.0005494059,0.0003418853,0.0017661025,0.00032952506],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4319949,0.093175694,0.04278852,0.0018808222,0.004437837,0.00061068026,0.00069687853,0.0050953543,0.12099553,0.00027591747,0.0041797403,0.2938682],"study_design_scores_gemma":[0.34304374,0.548168,0.088191055,0.000094081144,0.0010701526,0.0016504009,0.000096835254,0.0029947523,0.00900317,0.00021558299,0.005391814,0.000080387035],"about_ca_topic_score_codex":0.00052423147,"about_ca_topic_score_gemma":0.0014144077,"teacher_disagreement_score":0.0025244446,"about_ca_system_score_codex":0.0006172007,"about_ca_system_score_gemma":0.0010003805,"threshold_uncertainty_score":0.013350725},"labels":[],"label_agreement":null},{"id":"W3183250534","doi":"10.1007/s00280-021-04339-6","title":"Repurposing proscillaridin A in combination with decitabine against embryonal rhabdomyosarcoma RD cells","year":2021,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"Fonds de Recherche du Québec - Santé; Cancer Research Society","keywords":"Decitabine; Cancer research; Azacitidine; Clonogenic assay; Rhabdomyosarcoma; Cell cycle; Demethylating agent; Biology; Paclitaxel; Chromatin immunoprecipitation; Chromatin; Epigenetics; DNA methylation; Cancer; Cell; Sarcoma; Gene expression; Medicine; Pathology; Gene; Biochemistry","score_opus":0.00957550685859864,"score_gpt":0.29500060313102366,"score_spread":0.285425096272425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3183250534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930098,0.001822817,0.0005670333,0.00018426178,0.000117880074,0.000077682336,0.00051022874,0.00009302946,0.0036173032],"genre_scores_gemma":[0.9947472,0.0011571584,0.0006165934,0.000053301163,0.00001348675,0.000050218623,0.0005791072,0.00000757044,0.0027753229],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999088,0.000018576513,0.000009788116,0.000011603894,0.00001725297,0.00003391082],"domain_scores_gemma":[0.99995375,0.000009555714,0.00000624377,0.000007787538,0.000004842965,0.000017774943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015516173,0.00039790227,0.00040917232,0.0003664407,0.00019814585,0.0002580593,0.0003475873,0.00027178408,0.0026562838],"category_scores_gemma":[0.000109526445,0.000117056115,0.00027806728,0.00022949469,0.00018348568,0.00018014322,0.00018460299,0.00074823364,0.00041522156],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035527612,0.0006800503,0.00039609167,0.00021336722,0.00005690875,0.00024757028,0.00006709455,0.0010623811,0.97439903,0.00032583304,0.000946078,0.01805287],"study_design_scores_gemma":[0.00062080455,0.0052684485,0.0054774345,0.000018968041,0.00010024137,0.0003344191,0.000112267044,0.0014851324,0.9779854,0.000080426384,0.008503339,0.000013109916],"about_ca_topic_score_codex":0.0020279845,"about_ca_topic_score_gemma":0.004578178,"teacher_disagreement_score":0.0026562838,"about_ca_system_score_codex":0.00031890156,"about_ca_system_score_gemma":0.00053699815,"threshold_uncertainty_score":0.0088861585},"labels":[],"label_agreement":null},{"id":"W3214003785","doi":"10.1007/s00280-021-04369-0","title":"A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer","year":2021,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sierra Wireless (Canada)","funders":"Gilead Sciences","keywords":"Erlotinib; Medicine; Tyrosine-kinase inhibitor; Internal medicine; Lung cancer; Pharmacology; Clinical endpoint; Oncology; Epidermal growth factor receptor; Cancer; Clinical trial","score_opus":0.02987213903771854,"score_gpt":0.3992001376410065,"score_spread":0.36932799860328797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214003785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911214,0.0019032568,0.0005367402,0.0004631983,0.000098768476,0.003343615,0.0008919967,0.0000717372,0.0015693156],"genre_scores_gemma":[0.9852938,0.0020809362,0.0018603577,0.00089726335,0.00015120527,0.004033015,0.0023894836,0.000029709045,0.0032643133],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995173,0.00021815747,0.00002945154,0.00008088395,0.00005755003,0.000096626005],"domain_scores_gemma":[0.9993937,0.000085603555,0.00011714364,0.000042917596,0.00004373866,0.00031698024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019877052,0.0015285552,0.0018691452,0.00049050915,0.0004963093,0.0008906581,0.0010658675,0.0015305541,0.00423531],"category_scores_gemma":[0.00083327,0.00078023586,0.0011957205,0.00043080753,0.0008098234,0.00091748615,0.0003443256,0.003172959,0.0009818316],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.699963,0.13843724,0.0065898625,0.0011012985,0.0015172055,0.00040505425,0.00036511564,0.00250132,0.068645775,0.00035549977,0.0039610504,0.07615757],"study_design_scores_gemma":[0.60829395,0.3768215,0.0077260067,0.000028693923,0.0003089124,0.00023050905,0.000040236377,0.00081824366,0.0035774913,0.00013290261,0.0019962552,0.000025358184],"about_ca_topic_score_codex":0.0009469814,"about_ca_topic_score_gemma":0.003059963,"teacher_disagreement_score":0.00423531,"about_ca_system_score_codex":0.0009378863,"about_ca_system_score_gemma":0.0019505426,"threshold_uncertainty_score":0.014168501},"labels":[],"label_agreement":null},{"id":"W4225259757","doi":"10.1007/s00280-022-04427-1","title":"Efficacy and safety exposure–response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study","year":2022,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Prostate Cancer Canada","funders":"Janssen Research and Development","keywords":"Placebo; Prostate cancer; Medicine; Internal medicine; Rash; Pharmacokinetics; Adverse effect; Antiandrogen; Oncology; Population; Pharmacology; Cancer; Pathology","score_opus":0.036061982547969766,"score_gpt":0.3577691898577706,"score_spread":0.32170720730980085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225259757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99725133,0.0012489326,0.00022427112,0.000119419776,0.000015180724,0.00011324296,0.00038373974,0.000026115322,0.0006178515],"genre_scores_gemma":[0.9982133,0.0004505957,0.00017800299,0.00014072926,0.00003753025,0.000052376774,0.00050553173,0.000015105383,0.00040696166],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989562,0.00062898605,0.000049402603,0.00010010083,0.00016276147,0.000102507685],"domain_scores_gemma":[0.9981275,0.00062082446,0.0006589117,0.00018089477,0.00011568943,0.00029620304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024255672,0.0006526853,0.0012415767,0.00033945323,0.00020479297,0.00066057936,0.00045577425,0.00044180936,0.0011125145],"category_scores_gemma":[0.002330508,0.00022628697,0.00136015,0.00046463253,0.0005191532,0.0006895636,0.00025172933,0.0015199229,0.0001915803],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6688631,0.015510574,0.080060825,0.00079500495,0.0069283,0.00021355946,0.0005077951,0.006602873,0.05000997,0.0003120055,0.0024304355,0.16776554],"study_design_scores_gemma":[0.092639044,0.4036733,0.47992468,0.00004225814,0.0036459884,0.00064728066,0.00024361635,0.004775172,0.009408351,0.0005294208,0.004361193,0.00010970036],"about_ca_topic_score_codex":0.0012564403,"about_ca_topic_score_gemma":0.0026595602,"teacher_disagreement_score":0.0024255672,"about_ca_system_score_codex":0.0007464678,"about_ca_system_score_gemma":0.0007046178,"threshold_uncertainty_score":0.012827754},"labels":[],"label_agreement":null},{"id":"W4242644534","doi":"10.1007/bf02665359","title":"Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent","year":2004,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Etoposide; Pharmacokinetics; Dexrazoxane; Pharmacology; Medicine; Toxicity; Chemotherapy; Cancer; Internal medicine; Breast cancer","score_opus":0.018015198205579865,"score_gpt":0.35429900040109963,"score_spread":0.3362838021955198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242644534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99745136,0.0011723523,0.000316792,0.000100426805,0.00002697363,0.00004165695,0.00015628249,0.000045247998,0.0006888389],"genre_scores_gemma":[0.9986072,0.0002290327,0.00030651063,0.00006305642,0.000036178462,0.00002623356,0.00024828094,0.000019938265,0.00046362387],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99941695,0.0003552555,0.000027381902,0.00006590557,0.00006797631,0.00006646411],"domain_scores_gemma":[0.9989575,0.00037375683,0.00019942017,0.00013390926,0.00005361745,0.000281773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007022862,0.0004256352,0.0012678282,0.00031273806,0.00031039264,0.000705339,0.00037954445,0.00060763216,0.0015037075],"category_scores_gemma":[0.0026092143,0.0004936398,0.00056066347,0.00034328052,0.0005716929,0.0010715139,0.00018810567,0.001471514,0.00040864572],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.58235383,0.004648498,0.07183614,0.00023200944,0.0012845617,0.0019679724,0.0010510291,0.00945303,0.25257483,0.00082408224,0.0032103185,0.07056371],"study_design_scores_gemma":[0.032713354,0.24605694,0.53365225,0.00006616684,0.0015940452,0.0073547526,0.0009917895,0.026369503,0.13954115,0.0008718219,0.010550953,0.00023730056],"about_ca_topic_score_codex":0.0012387353,"about_ca_topic_score_gemma":0.0011857626,"teacher_disagreement_score":0.0015037075,"about_ca_system_score_codex":0.00061880896,"about_ca_system_score_gemma":0.0005659547,"threshold_uncertainty_score":0.0050303936},"labels":[],"label_agreement":null},{"id":"W4295679167","doi":"10.1007/s00280-022-04471-x","title":"Population pharmacokinetics of zanidatamab, an anti-HER2 biparatopic antibody, in patients with advanced or metastatic cancer","year":2022,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Dosing; Pharmacokinetics; Medicine; Population; Body surface area; Cancer; Internal medicine; Pharmacology; Oncology","score_opus":0.035151670659454175,"score_gpt":0.43091332078514066,"score_spread":0.3957616501256865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295679167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99700016,0.0009852501,0.0007184296,0.00012316096,0.000015681204,0.000029110248,0.0002420605,0.00005265237,0.000833513],"genre_scores_gemma":[0.99834573,0.0003435867,0.00031800117,0.00012062529,0.00002608558,0.000025676483,0.0003818107,0.000018831954,0.0004196479],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995902,0.0001518753,0.000020687676,0.000097507036,0.00007707779,0.00006257697],"domain_scores_gemma":[0.9995883,0.00013079029,0.000112697315,0.000052045623,0.000033748503,0.000082414015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006204803,0.00030666438,0.0009031111,0.00022077658,0.00019082044,0.0006917155,0.00019141487,0.0004088152,0.000932548],"category_scores_gemma":[0.0019722474,0.0003701139,0.00045112378,0.00028991752,0.00022421873,0.0006796437,0.00023279978,0.0012523493,0.00019883418],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17894642,0.0027500812,0.577362,0.00023064298,0.0039861933,0.0007055852,0.00086501974,0.010884364,0.06167889,0.0009229794,0.004190916,0.15747693],"study_design_scores_gemma":[0.0046695704,0.029445373,0.93688345,0.000026435106,0.001623983,0.0015101234,0.0002782188,0.012135785,0.0055778073,0.0008566604,0.0069007827,0.000091831025],"about_ca_topic_score_codex":0.0010600307,"about_ca_topic_score_gemma":0.0013031699,"teacher_disagreement_score":0.0010600307,"about_ca_system_score_codex":0.00056461495,"about_ca_system_score_gemma":0.0005033008,"threshold_uncertainty_score":0.0040966272},"labels":[],"label_agreement":null},{"id":"W4308775132","doi":"10.1007/s00280-022-04491-7","title":"Fluoropyrimidine-associated toxicity and DPYD variants c.85T>C, c.496A>G, and c.1236G>A: impact of haplotype","year":2022,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; London Health Sciences Centre; Western University","funders":"Ontario Ministry of Research and Innovation; Canadian Institutes of Health Research; Ontario Institute for Cancer Research","keywords":"DPYD; Dihydropyrimidine dehydrogenase; Capecitabine; Toxicity; Haplotype; Internal medicine; Medicine; Pharmacogenetics; Linkage disequilibrium; Dosing; Fluorouracil; Genotyping; Pharmacology; Genotype; Thymidylate synthase; Oncology; Chemotherapy; Biology; Cancer; Genetics; Colorectal cancer","score_opus":0.02145409028837106,"score_gpt":0.3395445616480425,"score_spread":0.3180904713596714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308775132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965771,0.001159187,0.00013710959,0.00013868717,0.000021493783,0.000004536401,0.0005014539,0.0000048294437,0.0014555847],"genre_scores_gemma":[0.9993261,0.000082855164,0.000027864391,0.000030251065,0.000012099844,0.000001249106,0.00015301348,0.0000027792266,0.00036383022],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99968946,0.00008030798,0.00003681413,0.00009357311,0.000041867843,0.00005798512],"domain_scores_gemma":[0.9994061,0.00020264322,0.00018505257,0.000052062944,0.000039738232,0.00011444234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033732242,0.00024536665,0.00024573048,0.00019066986,0.0002498254,0.0004019306,0.00021236936,0.00047947135,0.004691071],"category_scores_gemma":[0.0013692342,0.00011039705,0.0004905407,0.00042166092,0.0002011683,0.0002797473,0.00020839371,0.0005030574,0.0002067879],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0095095765,0.0001902647,0.96071774,0.000075446864,0.0010223977,0.001680477,0.00018613502,0.0004514178,0.009281862,0.00039242438,0.0009513577,0.015540844],"study_design_scores_gemma":[0.00007277575,0.0007721945,0.99410087,0.000028548984,0.00046483136,0.0018897019,0.00012284615,0.00046796357,0.0005781931,0.00029904916,0.0011906691,0.000012246639],"about_ca_topic_score_codex":0.0040834383,"about_ca_topic_score_gemma":0.0042859586,"teacher_disagreement_score":0.004691071,"about_ca_system_score_codex":0.00022499698,"about_ca_system_score_gemma":0.00020928858,"threshold_uncertainty_score":0.015693188},"labels":[],"label_agreement":null},{"id":"W432292542","doi":"10.1007/s00280-015-2776-x","title":"Effect of bendamustine in combination with rituximab on QT interval duration in patients with advanced de novo indolent non-Hodgkin or mantle cell lymphoma","year":2015,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; University of Ottawa; Ottawa Hospital","funders":"Teva Pharmaceutical Industries","keywords":"Bendamustine; Medicine; Mantle cell lymphoma; Rituximab; Internal medicine; Regimen; Clinical endpoint; Population; QT interval; Lymphoma; Gastroenterology; Clinical trial","score_opus":0.010804804229402656,"score_gpt":0.32865101746843267,"score_spread":0.31784621323903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W432292542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99242544,0.005939848,0.00015202197,0.0002839234,0.00009918566,0.000038536084,0.00013338706,0.000021730364,0.0009059808],"genre_scores_gemma":[0.9982338,0.0010142156,0.00014770082,0.00013081275,0.00007401141,0.000020764486,0.00015784118,0.000004757907,0.00021602002],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9997079,0.00012540686,0.000037106878,0.000050851308,0.00002768487,0.00005109953],"domain_scores_gemma":[0.9994116,0.00024032457,0.000095520336,0.000028006405,0.000023964492,0.00020064019],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004470015,0.00051580596,0.0018525594,0.00018252301,0.00021953518,0.00035796998,0.00032190728,0.00047322505,0.0012310551],"category_scores_gemma":[0.0016671863,0.00021891187,0.0006747684,0.00028628905,0.000253416,0.0005325705,0.0002558271,0.0016922414,0.00018269451],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.707693,0.0050675627,0.052938305,0.0009032855,0.0037314405,0.0012921378,0.00041791884,0.0030294375,0.057648253,0.00021872796,0.0014220009,0.1656381],"study_design_scores_gemma":[0.15160738,0.31307772,0.4989883,0.00029005733,0.00661331,0.003185567,0.00054730143,0.0055821254,0.010324559,0.00054480333,0.009097327,0.00014155624],"about_ca_topic_score_codex":0.00068989815,"about_ca_topic_score_gemma":0.0019265888,"teacher_disagreement_score":0.0018525594,"about_ca_system_score_codex":0.00039824157,"about_ca_system_score_gemma":0.0003264853,"threshold_uncertainty_score":0.0041182637},"labels":[],"label_agreement":null},{"id":"W4323652772","doi":"10.1007/s00280-023-04516-9","title":"A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia","year":2023,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Pfizer","keywords":"Gemtuzumab ozogamicin; Medicine; Dosing; Calicheamicin; Refractory (planetary science); Pharmacokinetics; CD33; Myeloid leukemia; Internal medicine; Oncology; Pharmacology; CD34; Stem cell","score_opus":0.024792431537484075,"score_gpt":0.386802173481273,"score_spread":0.36200974194378893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323652772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99852943,0.0004362909,0.00023407338,0.000045928595,0.000011227167,0.000372462,0.00010576283,0.000019028736,0.00024576037],"genre_scores_gemma":[0.99773717,0.00028501297,0.00066376955,0.00013015971,0.00003303033,0.00045047808,0.00031944911,0.00000772233,0.0003731157],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997187,0.00014147924,0.000013216229,0.000051512605,0.000027681788,0.000047343397],"domain_scores_gemma":[0.9995121,0.000078540324,0.00013898754,0.00005877419,0.000024933832,0.00018672876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007578243,0.00080022577,0.0011961967,0.0002290828,0.00022239324,0.00042605595,0.00044912935,0.000533584,0.0012823915],"category_scores_gemma":[0.000734932,0.00028508354,0.00057616923,0.00022565633,0.0005897665,0.00040449324,0.000207249,0.0015556322,0.00026921387],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6012199,0.05884443,0.020739403,0.0006524427,0.0015496023,0.00026078898,0.0004371513,0.004136644,0.13093431,0.00024030243,0.0017558675,0.1792292],"study_design_scores_gemma":[0.23583023,0.71330565,0.038971327,0.000023277784,0.0004220126,0.00030726922,0.000049393446,0.0017089229,0.0073167,0.0001431597,0.0018991817,0.000022759097],"about_ca_topic_score_codex":0.00048826117,"about_ca_topic_score_gemma":0.0009889299,"teacher_disagreement_score":0.0012823915,"about_ca_system_score_codex":0.00057869236,"about_ca_system_score_gemma":0.0006791309,"threshold_uncertainty_score":0.0042900443},"labels":[],"label_agreement":null},{"id":"W4385968528","doi":"10.1007/s00280-023-04575-y","title":"Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations","year":2023,"lang":"en","type":"review","venue":"Cancer Chemotherapy and Pharmacology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"College of Physicians and Surgeons of Ontario; Hospital for Sick Children","funders":"","keywords":"Medicine; Ovarian cancer; Oncology; Internal medicine; Fallopian tube; Cancer; Chemotherapy; Carboplatin; Monoclonal antibody; Pharmacology; Gynecology; Antibody; Cisplatin; Immunology","score_opus":0.20744257282584447,"score_gpt":0.48335285051586097,"score_spread":0.2759102776900165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385968528","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009432823,0.9963296,0.00012472672,0.0016409465,0.00055838324,0.00000629911,0.000025325371,0.0000072775797,0.0012131002],"genre_scores_gemma":[0.0006909011,0.9963899,0.00019356253,0.001280633,0.0004894219,0.000010019282,0.000045901532,0.0000015059533,0.0008982324],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999803,0.000046754958,0.000024349833,0.000029577659,0.00007448307,0.000021897584],"domain_scores_gemma":[0.9997404,0.00011792767,0.000033839537,0.0000052512737,0.000083251005,0.000019222802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006353744,0.0005215731,0.0009948153,0.0009697483,0.00016430291,0.00095376757,0.00078543567,0.001255714,0.0043252422],"category_scores_gemma":[0.0006931267,0.00016834203,0.00067005545,0.00090514455,0.00030401794,0.0011431185,0.00051123765,0.0021731744,0.001836608],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000103588085,0.000067337176,0.00009140161,0.01818436,0.00013454785,0.00021515206,0.000059118935,0.00038856966,0.0013455907,0.0052473294,0.08622027,0.88794273],"study_design_scores_gemma":[0.000048394133,0.00008048919,0.00028810106,0.0048736827,0.00012282176,0.00057217106,0.000027075288,0.0001189341,0.0001957439,0.0017376075,0.9919224,0.000012736405],"about_ca_topic_score_codex":0.00096379756,"about_ca_topic_score_gemma":0.0024456065,"teacher_disagreement_score":0.0043252422,"about_ca_system_score_codex":0.00058355153,"about_ca_system_score_gemma":0.0008469034,"threshold_uncertainty_score":0.014469385},"labels":[],"label_agreement":null},{"id":"W4386727291","doi":"10.1007/s00280-023-04583-y","title":"Pharmacokinetics and pharmacodynamics of Rh2 and aPPD ginsenosides in prostate cancer: a drug interaction perspective","year":2023,"lang":"en","type":"review","venue":"Cancer Chemotherapy and Pharmacology","topic":"Ginseng Biological Effects and Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Prostate cancer; Pharmacology; Pharmacokinetics; Pharmacodynamics; Drug; Cancer; Chemistry; Medicine; Internal medicine","score_opus":0.03110023869443257,"score_gpt":0.41201521549504094,"score_spread":0.3809149768006084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386727291","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005321624,0.99798644,0.00029175458,0.00028641184,0.00010057099,0.00000622725,0.000044311564,0.000012820515,0.0007393894],"genre_scores_gemma":[0.0027004434,0.99551564,0.00039296853,0.0002781038,0.00016121438,0.000010676803,0.000062410865,0.0000029581727,0.0008756314],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998841,0.000026837468,0.000017111626,0.000021786998,0.00003796,0.000012166486],"domain_scores_gemma":[0.99981934,0.000097993114,0.00003182524,0.0000064627307,0.000032938824,0.000011494986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055138103,0.0007961956,0.0017058557,0.00094780646,0.000100024794,0.0008198262,0.00050380937,0.00066309667,0.002519729],"category_scores_gemma":[0.0005591585,0.0002511116,0.00073689397,0.0012241504,0.00023073649,0.00056159485,0.0003339378,0.0015237704,0.0010674639],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047657662,0.00014248003,0.00035365182,0.008876717,0.00037025157,0.0002623282,0.000027077787,0.0009991303,0.006893845,0.0019531907,0.013558057,0.9660867],"study_design_scores_gemma":[0.00027937125,0.001128225,0.0039268276,0.0030993803,0.0013747746,0.002591648,0.000069363625,0.0008847507,0.0049610073,0.003223957,0.9783997,0.000061004903],"about_ca_topic_score_codex":0.0009848366,"about_ca_topic_score_gemma":0.0021507097,"teacher_disagreement_score":0.002519729,"about_ca_system_score_codex":0.00040662155,"about_ca_system_score_gemma":0.00059551344,"threshold_uncertainty_score":0.0084293485},"labels":[],"label_agreement":null},{"id":"W4391033120","doi":"10.1007/s00280-023-04636-2","title":"Correction to: Up-regulation of autophagy is a mechanism of resistance to chemotherapy and can be inhibited by pantoprazole to increase drug sensitivity","year":2024,"lang":"en","type":"erratum","venue":"Cancer Chemotherapy and Pharmacology","topic":"Autophagy in Disease and Therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Pantoprazole; Mechanism (biology); Pharmacology; Autophagy; Drug; Drug resistance; Chemotherapy; Sensitivity (control systems); Medicine; Chemistry; Biology; Internal medicine; Biochemistry; Genetics","score_opus":0.00926900909796378,"score_gpt":0.30537013380570016,"score_spread":0.29610112470773636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391033120","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000052427295,0.0007015828,0.0002497374,0.024987906,0.9727203,0.000012488204,0.00026794217,0.00010317705,0.00090441137],"genre_scores_gemma":[0.0053551574,0.007597365,0.0035479818,0.08619224,0.7030038,0.00017033884,0.0012650308,0.0010116781,0.19185637],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968167,0.00046137272,0.00051784044,0.00044268472,0.0014271855,0.00033426654],"domain_scores_gemma":[0.9816466,0.0038313763,0.0009210974,0.000794836,0.01119176,0.0016143362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031513583,0.0029149766,0.0026623064,0.0037972003,0.0029387232,0.0039995806,0.0034614888,0.009155311,0.05377448],"category_scores_gemma":[0.033093844,0.0012893816,0.002371076,0.0018367426,0.0022133188,0.002050086,0.0019584014,0.01446103,0.03299296],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028841529,0.0000058188994,0.000032845524,0.00009419393,0.000011104765,0.00028464725,0.0000087351855,0.00003179838,0.000038684728,0.00019016721,0.99621934,0.00305371],"study_design_scores_gemma":[0.00006955091,0.000021440408,0.00045246573,0.00024637886,0.00005203105,0.00090195553,0.000042568805,0.00026097952,0.00025910445,0.00067961175,0.9969829,0.00003103531],"about_ca_topic_score_codex":0.015062508,"about_ca_topic_score_gemma":0.023003358,"teacher_disagreement_score":0.05377448,"about_ca_system_score_codex":0.0046625836,"about_ca_system_score_gemma":0.00473761,"threshold_uncertainty_score":0.17989355},"labels":[],"label_agreement":null},{"id":"W4400076077","doi":"10.1007/s00280-024-04690-4","title":"Quantitative characterization of the effects of fulvestrant alone or in combination with taselisib (PI3Kinase inhibitor) on longitudinal tumor growth in patients with estrogen receptor-positive, HER2-negative, PIK3CA-mutant, advanced or metastatic breast cancer","year":2024,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Fulvestrant; Metastatic breast cancer; Medicine; Estrogen; Oncology; Internal medicine; Estrogen receptor; Cancer; Cancer research; Endocrinology; Breast cancer","score_opus":0.006909258984809279,"score_gpt":0.27614848791007296,"score_spread":0.2692392289252637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400076077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983265,0.0008983026,0.00023660882,0.00004282873,0.000020678433,0.0000162823,0.00012828107,0.000014313017,0.00031620113],"genre_scores_gemma":[0.99906605,0.00020024095,0.00015331966,0.000021153079,0.000017607907,0.000016016273,0.00018448925,0.000003388203,0.00033770897],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998721,0.0000470558,0.000007531262,0.000024974493,0.000019260586,0.000029030465],"domain_scores_gemma":[0.9997471,0.00010410783,0.00004001286,0.000024794746,0.000014618734,0.00006930291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003310873,0.0002968337,0.00041431177,0.00018958886,0.00010656576,0.00018558762,0.00012981353,0.00020012449,0.0008739654],"category_scores_gemma":[0.00063699204,0.000112521935,0.00032021708,0.00018280446,0.00018406079,0.00019998314,0.00009806265,0.0005641607,0.00012347673],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14652957,0.00446933,0.055329517,0.000160751,0.0003600214,0.00037207975,0.00021482489,0.002184391,0.70403427,0.00017488672,0.00059714454,0.08557318],"study_design_scores_gemma":[0.0038082392,0.17748292,0.5080625,0.000016928994,0.0008515847,0.0012924806,0.00020671703,0.0067112064,0.29706615,0.00016949131,0.0042887926,0.00004306235],"about_ca_topic_score_codex":0.00043453233,"about_ca_topic_score_gemma":0.0007432831,"teacher_disagreement_score":0.0008739654,"about_ca_system_score_codex":0.00017218891,"about_ca_system_score_gemma":0.00021348536,"threshold_uncertainty_score":0.0029236674},"labels":[],"label_agreement":null},{"id":"W4417035889","doi":"10.1007/s00280-025-04839-9","title":"Potential clinical relevance of rare dihydropyrimidine dehydrogenase genetic variants identified using whole-exome NextGen sequencing in cancer patients with severe fluoropyrimidine toxicity","year":2025,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"Ontario Institute for Cancer Research","keywords":"DPYD; Dihydropyrimidine dehydrogenase; Genetic variants; Clinical significance; Toxicity; Pharmacogenetics; Cancer; Malignancy","score_opus":0.03134569304228882,"score_gpt":0.3589229152347624,"score_spread":0.32757722219247354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417035889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99653256,0.001084765,0.00039531634,0.00042340913,0.000025095562,0.00000920265,0.0005334107,0.000008938563,0.0009872551],"genre_scores_gemma":[0.99931276,0.000119999306,0.00015621631,0.00012141451,0.000017231558,0.0000020099244,0.00018779616,0.0000028882635,0.00007958489],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99943,0.00015916469,0.00009778686,0.00013810031,0.00009733867,0.00007755211],"domain_scores_gemma":[0.9986707,0.0006804271,0.00034764785,0.000052927422,0.00012400736,0.00012424364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045921505,0.0002715784,0.0003452461,0.0004857981,0.00043149802,0.0007427984,0.00030113154,0.00057029346,0.0019469684],"category_scores_gemma":[0.0035993918,0.000115973846,0.00054958,0.0007397484,0.00032822517,0.00028162,0.0003136559,0.0004919035,0.00014777645],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011559725,0.000053504868,0.9641318,0.00010707705,0.00036355667,0.007086121,0.0002405712,0.0007659575,0.008335163,0.00046087737,0.00069282623,0.016606497],"study_design_scores_gemma":[0.00008604313,0.00039442233,0.96760845,0.00009062347,0.00062280725,0.020580063,0.00058764574,0.0023369964,0.0026763456,0.0018676973,0.0031112027,0.00003760108],"about_ca_topic_score_codex":0.0018563855,"about_ca_topic_score_gemma":0.0026261043,"teacher_disagreement_score":0.0019469684,"about_ca_system_score_codex":0.00024529675,"about_ca_system_score_gemma":0.00031283943,"threshold_uncertainty_score":0.006513238},"labels":[],"label_agreement":null}]}